diff --git "a/deduped/dedup_0272.jsonl" "b/deduped/dedup_0272.jsonl" new file mode 100644--- /dev/null +++ "b/deduped/dedup_0272.jsonl" @@ -0,0 +1,47 @@ +{"text": "Allermatch\u2122 A query amino acid sequence is compared with all known allergenic proteins retrieved from the protein databases using a sliding window approach. This identifies stretches of 80 amino acids with more than 35% similarity or small identical stretches of at least six amino acids. The outcome of the analysis is presented in a concise format. The predictive performance of the FAO/WHO criteria is evaluated by screening sets of allergens and non-allergens against the Allermatch databases. Besides correct predictions, both methods are shown to generate false positive and false negative hits and the outcomes should therefore be combined with other methods of allergenicity assessment, as advised by the FAO/WHO.Allermatch\u2122 provides an accessible, efficient, and useful webtool for analysis of potential allergenicity of proteins introduced in genetically modified food prior to market release that complies with current FAO/WHO guidelines. A step-by-step procedure to assess allergenicity is described by the Codex alimentarius and the FAO/WHO consultation group [The safety of genetically engineered foods must be assessed before authorities in most nations will consider granting market approval. An important issue in current food safety assessment is the evaluation of the potential allergenicity of food derived from biotechnology. Since many food allergens are proteins, introduction of a new (\"foreign\") protein in food by genetic engineering can in theory cause allergic reactions. Therefore the allergenicity of novel proteins needs to be assessed. Potential allergenicity of a protein is a complex issue and various tests can be used for prediction, including bioinformatics, on group ,2. An imon group to estab(1) Obtain the amino acids sequences of known allergens in protein databases in FASTA format .(2) Prepare the complete set of 80-amino acid length sequences derived from the query protein .3) Compare each of the sequences of (2) with all sequences of (1), using the program FASTA [ Compare According to the Codex alimentarius , potenti(a) More than 35 % similarity over a window of 80 amino acids of the query protein with a known allergen.(b) A stretch of identity of 6 to 8 contiguous amino acids.This procedure is described in more detail by the expert consultation and the Codex Alimentarius. Potential allergenicity requires further testing of the protein with panels of patient sera and possibly animal exposure tests ,2.. Leader sequences were, if annotated, trimmed from the sequence. The SwissProt allergen list contains 334 mature protein sequences, while the WHO-IUIS allergen list contains 632 sequences . These two databases contain 236 duplicate entries. The non-redundant combined database contains 730 sequences windows using a sliding window with steps of a single residue. Each of these windows is compared with all sequences in the allergen database of choice. All database entries showing a similarity higher than a configurable threshold percentage (default is 35%) to any of the 80 aa query sequence windows are flagged. Upon completion of the analysis, a table is shown with all flagged database entries. Per entry, the highest similarity score is given, as well as the number of windows having a similarity above the cut-off percentage. For each allergen database entry identified, more detailed information on the similarity between the allergen and query sequence can be retrieved, such as those areas of both proteins within all 80 aa windows scoring above the cut-off percentage. The similarity score calculated by FASTA can apply to stretches smaller than 80 aa, Allermatch\u2122 converts such a similarity score to an 80 aa window. For example, 40% similarity on a stretch of 40 aa converts to 20% similarity on an 80 aa window.This method looks for short sub-sequences (words), which have a perfect identity with a database entry. The wordsize is configurable (default is 6 aa). The output given is similar to the output given by Mode 1. All database entries with at least one hit are listed and for each of these, more detailed information can be retrieved upon request.The Allermatch\u2122 webtool also offers a full alignment of the query sequence with either of the allergen databases using FASTA. Although this full alignment is currently not required by the FAO/WHO guidelines, the full alignment of protein sequences helps positioning of regions of potential allergenicity in the whole primary structure of the protein. The FASTA output is parsed and information from the allergen database is added and presented.To examine the predictive performance of the FAO/WHO criteria for potential allergenicity, we have performed two tests. The first test determines the percentage of false negative and the second test assesses the amount of false positives. Both tests are performed with standard settings; for the sliding window approach an 80 amino acid window with a 35% similarity cutoff is used and for the wordmatch approach 6, 7 and 8 aa word sizes are tested.The false negative error-rate is estimated by a leave-one-out method, testing all sequences in each Allermatch\u2122 database against that database with the tested sequence excluded. Each sequence not resulting in a hit is considered a false negative. The results of each method/database combination are summarized in Table i.e. T1 (related to Bet v 1), human serum albumin , and human heat shock protein 70 . A selection of unrelated, non-allergenic proteins is therefore likely to give a lower false positive rate. Caution should be taken in interpreting these false hit rates. The used methods might perform differently with other sets of proteins. For example, a member of a completely novel group of valid allergens is likely to generate a false negative result.In the second test, we assess the odds of a false positive by testing 12 protein sequences known to be non allergenic. This is based on non-reactivity of these proteins towards IgE-sera of allergy patients or on the inability to cause IgE-responses in experimental animals and confirm results, before arriving at conclusions. To prevent false positives as much as possible, one should choose for the well-annotated SwissProt database. To prevent false negatives, the combination of the larger WHO-IUIS database with that of SwissProt is more appropriate. Updates to the SwissProt and WHO-IUIS allergen lists will be incorporated in the Allermatch\u2122 databases on a regular basis.The prediction of potential allergenicity by primary sequence comparison depends on the quality of the data used for comparison. Addition of a non-allergenic or poorly annotated protein to any of the Allermatch\u2122 allergen databases would obviously result in undesired false positives and should be prevented. A workable strategy could be to use multiple databases, Several other websites in the public domain offer sequence alignment facilities that support the prediction of potential allergenicity, such as SDAP ,11, AlleAllermatch\u2122 is an efficient and comprehensive webtool that combines all bioinformatics approaches required to assess the allergenicity of protein sequences according to the current guidelines in the Codex. The application will be kept up to date with the FAO/WHO criteria and the SwissProt and WHO-IUIS allergen lists. It will be extended with other, supplementary methods to support and refine the prediction of allergenicity..Allermatch\u2122 is platform independent and accessible using any Netscape 4+ compatible webbrowser at MF developed and implemented the Allermatch\u2122 webtool. HN provided the domain name registration and advised in the web site development. GK and AP provided the scientific background and constructed the sequence databases. JPN and RvH provided time, resources and ample discussion. All authors have read and approved the final manuscript."} +{"text": "Based on a large, representative unscreened cohort from Malm\u00f6, Sweden, we have recently reported that a single prostate-specific antigen (PSA) measurement at or before age 50 is a strong predictor of prostate cancer occurring up to 25 years subsequently. We aimed to determine whether this association holds for advanced cancers, defined as clinical stage T3 or higher, or skeletal metastasis at the time of the cancer diagnosis.In 1974\u20131986 blood samples were obtained from a cohort of 21,277 men aged up to 50. Through 1999, 498 men were diagnosed with prostate cancer, and of these 161 had locally advanced or metastatic prostate cancers. Three controls, matched for age and date of venipuncture, were selected for each case. Conditional logistic regression was used to test associations between molecular markers and advanced cancer.p < 0.0005). Two-thirds of the advanced cancer cases occurred in men with the top 20% of PSA levels (0.9 ng/ml or higher).Median time from venipuncture to diagnosis was 17 years. Levels of all PSA forms and hK2 were associated with case status. Total PSA was a strong and statistically significant predictor of subsequent advanced cancer (area under the curve 0.791; A single PSA test taken at or before age 50 is a very strong predictor of advanced prostate cancer diagnosed up to 25 years later. This suggests the possibility of using an early PSA test to risk-stratify patients so that men at highest risk are the focus of the most intensive screening efforts. We have previously shown that a single prostate-specific antigen (PSA) measurement taken at age 50 or younger is a strong predictor of prostate cancer diagnosed up to 25 years subsequently . Our stuOur finding has several implications, most notably that a single PSA test at age 45\u201350 could risk-stratify the population for the intensity of subsequent screening. However, as is well known, more men die with prostate cancer than from prostate cancer, and many prostate cancers affect neither the length nor the quality of a man's life. For example, autopsy studies of men who die from causes other than prostate cancer have found cancer in the prostates of approximately 20% of men at age 60 and approximately 40% at age 70 ,4; this Accordingly, we decided to reanalyze our data to focus on an endpoint of unquestionable clinical significance: locally advanced or metastatic disease at the time of prostate cancer diagnosis. Skeletal metastases cause symptoms, such as pain, and most men with metastases die of their disease ,7; as reSubjects, matching and analytical methods of the Malm\u00f6 Preventive Medicine study have been thoroughly described in previous reports . The MalWe used a case-control study design nested within the Malm\u00f6 Preventive Project cohort. Participants without a prostate cancer diagnosis at the study close date were matched with cases for age and date of baseline venipuncture (\u00b1 3 months for both factors for ~95% of controls). Controls were then randomly selected from matches. The present investigation included only those cases with advanced prostate cancer and their respective controls. Advanced prostate cancer was defined as metastases verified by bone scan or clinical stage at least T3 at the time of prostate cancer diagnosis.There were 161 cases in the study. Although three controls were initially matched for each case, we later found that 47 controls were not followed until diagnosis of the matched case, usually because of early death, leaving 436 controls. Most cases had either two (24%) or three (73%) matched controls; four cases (3%) had one control. Almost all cases were ages 40\u201350 at venipuncture. The remaining nine cases were aged less than 40: the ages of each of these patients at venipuncture and at diagnosis were 33/49, 35/53, 35/54, 36/51, 37/57, 37/57, 39/53, 39/59 and 39/59. As age was a matching criterion, the age distribution in controls was very similar.PSA was assayed in anticoagulated plasma stored at -20\u00b0C for 17\u201328 years. Although PSA forms, particularly free PSA, in serum are labile in some storage conditions, we previously showed that the levels of both total PSA and free PSA in anticoagulated plasma are unaffected by long-term storage at -20\u00b0C . The levFor our main analysis we defined an event as metastases or clinical stage at least T3 at the time of prostate cancer diagnosis. We conducted conditional logistic regression based on matching for age and date of venipuncture to determine associations between molecular markers and the event. To calculate predicted probability of the event among Swedish men for a given PSA level, we entered PSA in a logistic model using restricted cubic splines with knots at the tertiles. Owing to the 3:1 matched case-control design, the incidence of advanced cancer in our study was close to 25%. To correct the incidence to the expected probability at age 75, we adjusted the probabilities by adding a constant (a Bayes factor) to the linear prediction. The expected probability of advanced cancer at age 75 was derived by taking the estimated probability of prostate cancer by age 75 in Swedish men (10%) , and mulThere were 161 patients matching the criteria for advanced prostate cancer for our main analysis, 62 with skeletal metastases and 149 with clinical stage at least T3 at the time of prostate cancer diagnosis. Fifty patients had both metastases and clinical stage at least T3. The median time from baseline venipuncture to diagnosis was 17 years , with median age at diagnosis 64 years . Eighteen patients (11%) had WHO grade I disease, 73 patients (45%) grade II and 69 patients (43%) grade III, with WHO grade missing for one patient. Five (3%) patients were clinically judged to have stage T1 disease, 7 patients (4%) T2 and 149 patients (93%) T3\u2013T4. Twelve (7%) patients had lymph node metastases, 57 (35%) patients did not and 92 patients were not evaluated for nodal status.Prostate-specific kallikrein measurements are reported in Table p < 0.0005). An increase of 1 ng/ml in total PSA was associated with an odds ratio for advanced cancer of 4.29 2.98, 6.18). Odds ratios from the multivariable model are not presented here because of high collinearity between the markers: for example, the correlation between free and total PSA was 0.963. To assess whether markers other than total PSA could aid in discrimination of advanced cancer from no cancer diagnosis, we calculated the area under the curve (AUC) for all markers alone using ten-fold cross-validation. Total PSA (AUC 0.791) and complexed PSA (AUC 0.793) discriminated advanced cancer from no cancer most strongly. We then fitted a multivariable model consisting of total PSA, free PSA, free-to-total PSA ratio and hK2; the AUC for this model was 0.785. Hence, there was no evidence that the additional markers added discriminative accuracy above that of total PSA alone. We therefore focused on total PSA for the remaining analyses.Table p < 0.0005). There was an apparent increase in odds ratio for diagnosis after 20 years. We believe that this is a chance finding related to chance differences in controls; the mean total PSA in controls for patients diagnosed more than 20 years following venipuncture was 0.56 ng/ml compared with 0.69 ng/ml in controls for patients diagnosed less than 20 years after venipuncture. Hence, although our data support the hypothesis that total PSA can predict advanced prostate cancer at the time of diagnosis up to 25 years later, we do not believe they can be used to suggest that total PSA predicts later cancers more effectively than earlier cancers.Small increases in total PSA markedly increased the risk of a subsequent diagnosis of advanced prostate cancer Table . For exap = 0.06) remained statistically significant predictors of advanced prostate cancer among men diagnosed at least 20 years after venipuncture.Similar results were found for the other kallikreins: all but hK2 and 382 controls who were ages 44\u201350 at baseline venipuncture . To check whether our results were sensitive to the definition of advanced cancer used, we performed additional analyses with two different definitions. The first was more inclusive, defining advanced prostate cancer as any of skeletal metastasis, clinical stage at least T3, lymph node involvement or WHO grade III at the time of prostate cancer diagnosis. The second was less inclusive and considered only presence of skeletal metastasis at diagnosis. This did not have a major effect on any of the results: some key statistics are shown in Table The Malm\u00f6 Preventive Medicine cohort was enrolled before the PSA era, and there was no subsequent recommendation for prostate cancer screening in this region. The rate of PSA testing has accordingly remained very low up to our current study endpoint . FurtherOur results describe the relationship between prostate kallikreins in blood plasma obtained at a single occasion at age 50 or below and the diagnosis of advanced prostate cancer up to 25 years later. We found that prostate-specific kallikreins were significantly increased decades before the clinical manifestation of advanced disease. The predictive accuracy of total PSA was very high (AUC 0.791). Modestly increased levels of total PSA in the ranges of 1.01\u20132 ng/ml and 2.01\u20133 ng/ml were associated with 7- and 22-fold elevated odds of advanced prostate cancer, respectively. The majority of advanced cancers (66%) occurred in the 20% of the population with the highest PSA levels. It is also noteworthy that our study of archived blood samples is taken from a highly representative, population-based sample. There was no selection based on test results . As such, we can be confident that our reported test characteristics reflect those of the population to which we would like to apply our results.These results confirm our previous finding of an association between PSA levels and subsequent prostate cancer, and suggest that this association is not restricted to cancers unlikely to affect a man's survival or quality of life. Indeed, we found total PSA to be more strongly predictive of subsequent advanced prostate cancer (AUC 0.791) than of any prostate cancer (AUC 0.762). This illustrates the rule of thumb that it is easier to predict more extreme medical events. Free-to-total PSA ratio and hK2, two markers associated more specifically with malignancy, were far less predictive than total PSA, a marker associated with both benign and malignant prostate conditions. This suggests that PSA elevations in cases below or at age 50 may be related to a premalignant state, or to a carcinogenic process, rather than the presence of malignant cells in the prostate.A possible limitation of our study is that any definition of clinically significant prostate cancer is open to question. However, we repeated our analysis altering our definition of advanced cancer to be more restrictive or more inclusive and found no important differences in our results. It might also be argued that death from prostate cancer would be the most appropriate endpoint, but owing to a small number of events in our current study cohort, statistical analysis would have been underpowered. Future studies will address the relationship between kallikreins and death from prostate cancer as the cohort matures.Previously, both our group and other investigators have studied the association between PSA level in the blood and the long-term risk of being diagnosed with any stage of prostate cancer, but did not specifically address whether these findings were applicable to diagnosis of advanced tumors ,14-16. OCurrent US prostate screening guidelines recommend that all men over age 50 who have a life expectancy of at least 10 years should have an annual digital examination and PSA test. Results from ongoing screening trials show that these recommendations result in over-diagnosis and over-treatment. For example, the Rotterdam section of the European Randomized Screening Study for Prostate Cancer have shown that almost 50% of screen-detected cancers are indolent and thus unlikely to affect a man's survival or quality of life . Over-trThis study is based on a previously published case-control study in which we attempted to predict the occurrence of prostate cancer at any stage. We did not re-match for this study and hence patients with a prostate cancer diagnosis were not included in the sample from which controls were selected. We note that kallikrein levels of these 301 participants are likely to be higher than those of Malm\u00f6 Preventive Medicine participants not diagnosed with prostate cancer, thus inflating differences between cases and controls in our current analysis. However, the original Malm\u00f6 Preventive Medicine cohort contains approximately 21,270 participants who could act as controls, from whom 436 controls were randomly chosen to be included in our current analysis. As there were 462 prostate cancer cases, we would expect prostate cancer patients to comprise approximately 2% of the control group. Therefore, we conclude that our failure to sample from non-advanced prostate cancer cases is unlikely to have any major effect on the current results.A PSA level measured at a single occasion in blood drawn at age up to 50 is a very strong predictor of being diagnosed with advanced prostate cancer up to 25 years later. This raises the possibility that screening for prostate cancer could be risk-stratified so that men at highest risk are the focus of the most intensive screening efforts.AUC, area under the receiver operating characteristic curve; EDTA, ethylenediamine tetraacetic acid; PSA, prostate-specific antigen; WHO, World Health OrganizationDr Hans Lilja holds patents for free PSA and hK2 assays.HL is the principal investigator and was responsible for the study design had full access to all data and data analyses, and had final responsibility for the decision to submit the manuscript. GB was mainly responsible for the study cohort, the case-control design nested within the study cohort. DU, CB and HL were responsible for measuring PSA forms and hK2. DU and TB were responsible for reviewing the patient medical records. AMC and AJV were responsible for all biostatistical analyses and workup. MFO, JAE and PTS actively contributed to all elements of the study. All authors read and approved the final manuscript.The pre-publication history for this paper can be accessed here:"} +{"text": "PSA gene. Studies of a single nucleotide polymorphism in ARE1 of the PSA gene have been conflicting for risk of prostate cancer and effect on plasma PSA levels. In this nested case\u2013control analysis of 500 white cases and 676 age- and smoking-matched white controls in the Physicians' Health Study we evaluated the association of rs266882 with risk and survival of prostate cancer and prediagnostic total and free PSA plasma levels, alone or in combination with AR CAG repeats. We used conditional logistic regression, linear regression and Cox regression, and found no significant associations between rs266882 and overall prostate cancer risk : 0.88\u20131.67) or prostate cancer-specific survival . Similarly, no associations were found among high grade or advanced stage tumours, or by calendar year of diagnosis. There was no significant association between rs266882 and baseline total or free PSA levels or the AR CAG repeats, nor any interaction associated with prostate cancer risk. Meta-analysis of 12 studies of rs266882 and overall prostate cancer risk was null.Prostate-specific antigen (PSA) is a protease produced in the prostate that cleaves insulin-like growth factor binding protein-3 and other proteins. Production is mediated by the androgen receptor (AR) binding to the androgen response elements (ARE) in the promoter region of the PSA gene (Prostate-specific antigen (PSA) is a protease produced primarily in the prostate and has widely been used as a diagnostic marker of prostate cancer since the early 1990s (PSA \u2212158 G/A) of the PSA gene (rs266882), identified in 1999 to evaluate the rs266882 polymorphism in prostate cancer. We examined associations with risk, survival and prediagnostic baseline plasma PSA levels, alone and in combination with \u03b2-carotene among 22\u2009071 US male physicians, aged 40\u201384 years in 1982; none had a cancer diagnosis at baseline on age and smoking status to controls selected at random from among men free from diagnosed prostate cancer at the time the case was diagnosed. A total of 676 controls were included. All men provided informed consent, and the protocol was approved by the Institutional Review Board at Partners Healthcare.PSA gene were amplified and the three possible genotypes were distinguished by cutting with the NheI restriction enzyme. The AR gene CAG repeat length was determined by running the PCR-amplified fragments on a denaturing polyacrylamide gel with automated fluorescence detection of the fragments and sizing by Genescan using conditional logistic regression, matched on age and smoking status, to evaluate the association between the rs266882 polymorphism and prostate cancer risk. We stratified the analysis further according to tumour grade , stage (T1/T2 or T3/T4) and calendar year of diagnosis (1982\u20131992 or 1992\u20131995). The following number of cases and matched controls for each subgroup: low grade , moderate grade , high grade , localized: T1/T2 , or advanced: T3/T4 tumour stage, diagnosed 1982\u20131992 and diagnosed 1992\u20131995 .To limit the potential for population stratification, we restricted the analysis to white men (94% of PHS cohort is white). Hardy\u2013Weinberg equilibrium of allelic frequency was tested by a goodness of fit \u22121, \u2a7e4\u2009ng\u2009ml\u22121; free PSA: <15%, 15\u201324%, \u2a7e25%) or number of AR CAG repeats using likelihood ratio tests.Additionally, we assessed whether the association of rs266882 genotype and prostate cancer risk differed according to categorical pre-diagnostic PSA levels . We used Cox proportional hazard models to calculate hazard ratios and 95% CI, adjusted for aggressive disease , age at diagnosis and date of diagnosis (pre/post 1992).AR CAG repeats was evaluated to determine if the effect of rs266882 genotype differed according to AR CAG repeat length. The SAS Statistical Software (Version 9.1) was used for these analyses.Linear regression was used to estimate the association among PSA levels with rs266882 genotype, separately for cases and controls. An interaction with vs AA genotypes and GA vs AA genotypes. Inverse variance weighting with a random effects model was used to create a summary estimate using the statistical package Stata and 31% were advanced tumour stage at diagnosis (8% missing) . The majP=0.18). Controlling for matching factors, there was no evidence of an association between PSA genotype and total prostate cancer risk. Moreover, we found no association between the rs266882 genotype and cancer risk when we stratified within tumour grade or stage, or among those diagnosed pre/post PSA era was similar to other studies of white men ( PSA era .P for interaction \u223c0.41) or free PSA level (P for interaction \u223c0.70).As shown earlier in AR. Shorter AR CAG repeats, which are associated with greater transactivation of the AR, were associated with higher risk of advanced prostate cancer compared with longer AR CAG repeats and free PSA levels .An earlier study within the PHS cohort examined a trinucleotide CAG repeat polymorphism in Among the 500 men with prostate cancer, 111 men died of their disease. The median survival time between diagnosis and prostate cancer-specific death was 13.5 years (range: <1\u201324.3 years). We found no association between the rs266882 genotype and prostate cancer survival .PSA \u2212158 G/A) polymorphism (rs266882 genotype) and prostate cancer risk, survival and pre-diagnostic plasma PSA levels. We found no association between the PSA polymorphism and cancer risk, overall or by grade, stage or calendar year of diagnosis. Similarly, the rs266882 genotype was not associated with cancer-specific survival. Finally, there was no association between the rs266882 genotype and PSA plasma levels among cases or controls. There were no significant interactions of the rs266882 genotype with PSA plasma level or AR CAG repeat length for any of the outcomes examined.In this large prospective study, we comprehensively assessed the relation of the ARE1 (\u03b22 (TGF-\u03b22) reported a positive association of the GG allele of rs266882 with a three-fold risk of advanced cancer , higher serum PSA levels were statistically significantly associated with AA genotype when all ethnic groups were combined, but not for any of the ethnic groups individually, suggesting population stratification may be a possibility for this finding (\u22121, men with the AA genotype had a 28% higher level of PSA than men with the GG genotype (\u22121 (\u22121 (It has been hypothesised that the rs266882 polymorphism may be associated with serum levels of PSA through higher binding affinity of the ARE1 with either the A or G allele. Results of such studies also have been contradictory. Among healthy controls (PSA levels <4\u2009ng\u2009mlAR regulates PSA expression by binding androgen response elements. Some studies of AR, including ours, found shorter CAG repeats associated with increased expression of AR and with higher risk of advanced prostate cancer compared with longer CAG repeats (AR is of interest. PSA gene. Models were adjusted for age and ethnicity, however residual confounding by ethnicity in this very diverse cohort could account for this borderline significant finding. Four additional studies, as well as the present, found no interaction between rs266882 genotype and AR CAG length in relation to plasma PSA levels (The results of this large study with long-term and prospective follow-up, taken together with earlier findings and the results of the meta-analysis, add further support for the conclusion that the rs266882 polymorphism is unrelated to prostate cancer risk, survival or to plasma PSA levels."} +{"text": "We used a nested case\u2013control design on data from men in four prospective studies with available stored serum samples to determine whether there was an advantage in measuring both free prostate-specific antigen (PSA) and total PSA as a potential screening test for prostate cancer. Of these men, 247 were verified through national vital statistics offices as having died of prostate cancer, or having developed the disease, and 953 men who did not develop prostate cancer (controls) were selected, matched to cases for age, study centre and sample storage duration. Fixing the false-positive rate at 1%, the prostate cancer detection rate (sensitivity) over the 3 years following serum collection (based on 14 cancers) increased from an estimated 95% using total PSA to 97% using free and bound PSA . Over a 6-year period (based on 41 cancers) a similar difference occurred (52% and 56% detection rates respectively). We conclude that there is no material advantage in adding free to total PSA in prostate cancer screening trials. \u00a9 2000 Cancer Research Campaign"} +{"text": "Objective(s): Since each unit of Intravenous Immunoglobulin (IVIG) is obtained from different blood donors, blood-borne viral diseases is of high importance. We aimed at investigating the prevalence of various viral infections: Human T-cell Lymphotropic Virus Type 1 (HTLV-I), Hepatitis B (HBV), Hepatitis C (HCV), and Human Immunodeficiency Virus (HIV) among patients referred for IVIG therapy section in Mashhad University of Medical Sciences, Mashhad, Iran.Materials and Methods: A prospective study was conducted on 130 IVIG recipients admitted to different wards of our Medical Centre: Immunology, Hematology, and Neurology, in 2010. After filling the informed consent form, a 5 cc blood sample was initially taken from each patient. Viral infections including HTLV-I Ab, HIV-Ab, HBsAg, HBc-Ab, and HBV-Ab were assessed using the ELISA technique before and after six three months treatment. Results: Test results for HTLV-I Ab, HBsAg, HBc Ab, HIV Ab, and HCV Ab were negative in all cases before IVIG therapy. After receiving IVIG, two female cases with CIDP showed positive results for HBV Ab (0.8%) and HBS Ag (0.8%) with ELISA and only one patient confirmed with PCR. There was not any significant relation between HBV Ag (P=0.14) and HBC Ab with type of disorder (P=0.66).Conclusion: This study showed that HTLV-I viral replication and the other investigated viral transmissions do not occur in plasma; therefore, the IVIG products are safe. Human T-Cell Lymphotropic virus type 1 (HTLV-I) is a member of Retroviridae family which has been associated with two main diseases: myelopathy/tropical spastic paraparesis (HAM/TSP) and adult T cell leukemia (ATL) .et al , Hepatitis C (HCV), Human Immunodeficiency virus (HIV) and Human T-Cell Lymphotropic Viruses (HTLV-I).During the past two decades the studies reported HCV transmission in PID patients that administrated Intravenous Immunoglobulin (IVIG) , HCV inf Moreover, repeated administration of IVIG antibody caused HBV and markedly prolonged incubation period of this disease in experimentally infected chimpanzees , whereas130 patients that received IVIG therapy in different wards of the Medical Centre i.e. Immunology, Hematology, and Neurology were enrolled in this study. This research project is approved by the Ethics Committee of Mashhad University of Medical Sciences (MUMS), which corresponds to the provisions of the Declaration of Helsinki in 1995. All patients\u2019 documents were kept confidential. Study protocol was expressed for all patients and then the informed consent form was obtained. Five cc blood sample was initially taken from each patient. HTLV-I Ab, HIV Ab, HBsAg, HBc Ab, and HBV Ab were measured using the ELISA technique . Similar immunological tests were repeated three months later. Patients with a negative test for HTLV-I Ab, HBs Ag, HCV-Ab, and HIV- who received IVIG were enrolled in this study. ,s studied exclusion criteria were: 1) Patients with a positive HTLV-I Ab, HBsAg, HCV Ab, and HIV test, 2) Patients receiving other blood preparations with the probability of viral transmission, 3) Cases with high risk factors for HIV, 4) Patients with a positive family history of HBV or HCV, 5) Cases with a sexual partner infected with HTLV-I, HBV, HCV, or HIV, and 6) Patients undergoing any kind of surgery or dental procedure three months before or after receiving IVIG therapy. The study variables included age, sex, serum HTLV-I Ab, HBsAg, HCV Ab, HIV Ab, HBc Ab levels, and type of the IVIG preparation. The study2 test or Mann-Whitney test for non parametric data. A two-tailed P-valve<0.05 was considered statistically significant. The collected data was entered into SPSS software, version 11.05 for all statistical procedures. Differences in proportions of viral infections were analyzed by \u03c7This study included 130 patients aged between 11 to 74 years with a mean age of 29.1\u00b10.92 years old. The studied individuals were 76 (58.56%) female and 54 (41.5%) male. The most common diseases being treated by IVIG were Common Variable Immune Deficiency (CVID) (65.4%), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (31.5%), and Guillain-Barre syndrome (3.1%).HBsAg testing before IVIG injection showed negative results in all cases, whereas after receiving IVIG, it was reported positive and was confirmed by PCR only in one female patient (0.8%) who had CIDP. The test results for HBc Ab before IVIG therapy were all negative, but after receiving this type of treatment, it turned out to be positive in another female patient (0.08%) with CIDP. ELISA serologic test results for HTLV-I Ab, HCV Ab and HIV Ab before and after IVIG treatment were negative in all the studied cases. In this study, 130 patients under IVIG injections were studied for viral infection transmission after IVIG therapy. The results showed only one case of HBV transmission and another with HBC transmission. The previous study on IVIG recipients about anti-HIV antibodies reported the viral infection transmission in only one case, a female drug addict who belonged to a high risk group (AIDS). They concluded that IVIG recipients should not be regarded as a group at risk for AIDS .et al (P=0.05). However, our study showed that there was no HTLV-I viral replication in IVIG products.Cabral et al investigTransmission of HCV via IVIG has been documented before -21. It wet al, patients with non-A, non-B hepatitis following IVIG therapy were studied. They showed that 15 out of 17 (88%) cases that were initially negative for HCV-RNA turned in to positive after receiving IVIG therapy (However, in contrast to these studies, some reported high viral infections transmission of HBV and HCV. In a study by Yap therapy . Healey therapy . In the present study, it is not clear whether the infection was transmitted through IVIG therapy or some other routes. Moreover, there was not any reported evidence on HIV and HCV transmission by plasma products. In the statistical analysis of the current study, no association was revealed between infection transmission and the type of disease being treated with IVIG. However, most common treated patients were CVIDs. Moreover, previous studies were in accordance with the results of the present study as IVIG recipients were especially those with primary immune-deficiency and those treated with IVIG after transplantation -27.This study showed that HTLV-I viral replication and other investigated viral transmissions do not occur in plasma, therefore, the IVIG products are safe. Furthermore, no relationship was found between viral infections especially HBSAg and HBC Ab among IVIG recipients. However examining the common viral antibodies through more sensitive methods, i.e., PCR, among serum donors is highly recommend. Moreover, the authors greatly recommend that plasma units not enter the IVIG production process unless they have been fully examined during a 3-6 month period. Thus, it seems that from the aspect of viral transmission, today\u2019s IVIG is safe."} +{"text": "Thermococcus gammatolerans, the most radioresistant archaeon known to date, is an anaerobic and hyperthermophilic sulfur-reducing organism living in deep-sea hydrothermal vents. Knowledge of mechanisms underlying archaeal metal tolerance in such metal-rich ecosystem is still poorly documented. We showed that T. gammatolerans exhibits high resistance to cadmium (Cd), cobalt (Co) and zinc (Zn), a weaker tolerance to nickel (Ni), copper (Cu) and arsenate (AsO4) and that cells exposed to 1 mM Cd exhibit a cellular Cd concentration of 67 \u00b5M. A time-dependent transcriptomic analysis using microarrays was performed at a non-toxic (100 \u00b5M) and a toxic (1 mM) Cd dose. The reliability of microarray data was strengthened by real time RT-PCR validations. Altogether, 114 Cd responsive genes were revealed and a substantial subset of genes is related to metal homeostasis, drug detoxification, re-oxidization of cofactors and ATP production. This first genome-wide expression profiling study of archaeal cells challenged with Cd showed that T. gammatolerans withstands induced stress through pathways observed in both prokaryotes and eukaryotes but also through new and original strategies. T. gammatolerans cells challenged with 1 mM Cd basically promote: 1) the induction of several transporter/permease encoding genes, probably to detoxify the cell; 2) the upregulation of Fe transporters encoding genes to likely compensate Cd damages in iron-containing proteins; 3) the induction of membrane-bound hydrogenase (Mbh) and membrane-bound hydrogenlyase (Mhy2) subunits encoding genes involved in recycling reduced cofactors and/or in proton translocation for energy production. By contrast to other organisms, redox homeostasis genes appear constitutively expressed and only a few genes encoding DNA repair proteins are regulated. We compared the expression of 27 Cd responsive genes in other stress conditions , and showed that the Cd transcriptional pattern is comparable to other metal stress transcriptional responses but not to a general stress response. While trace amounts of several metals such as iron (Fe), manganese (Mn), copper (Cu), nickel (Ni), cobalt (Co) and zinc (Zn) are essential to support cell growth, elevated amounts induce cell toxicity Arabidopsis thaliana consists of an upregulation of genes involved in sulfur assimilation-reduction and glutathione metabolism in roots, while several genes involved in phenylpropanoid biosynthesis are induced in leaves Saccharomyces cerevisiae exhibit an upregulation of genes involved in glutathione synthesis and sulfur amino acid metabolism, coupled with an upregulation of common stress-response genes Escherichia coli cells downregulate protein biosynthesis, shift to an anaerobic metabolism and enhance several stress response systems Synechocystis PCC6903 produces and repairs Fe-requiring metalloenzymes by a moderate increase of Fe uptake and breakdown of the Fe-rich photosynthesis machinery to release Fe atoms Deinococcus radiodurans induces genes related to iron uptake, cysteine biosynthesis, protein sulfide stress and several DNA repair systems Pseudomonas brassicacearum intraclonal adaptation revealed a reorganization of the cell wall to limit Cd import, a production of polyamines to counteract Cd-induced damages and a downregulation of genes involved in motility During the last decade, transcriptomic analyses performed in Bacteria and Eukarya to investigate Cd toxicity have provided results illustrating the involvement of similar or specific strategies to withstand Cd ions exposure. Human cells exhibit induction of genes encoding metallothioneins, anti-oxidant and heat shock proteins related to cellular protection and damage control mechanisms 2) for several Thermococcus species is higher than 1 mM Thermococcales are largely unknown, in particular for Cd.Metal concentrations in deep-sea hydrothermal chimneys are in the range of 10\u201340 \u00b5M for Cu, 20\u20132000 nM for Co and 40\u20133000 \u00b5M for Zn Thermococcus gammatolerans EJ3T, a hyperthermophilic archaeon isolated from a gamma irradiated enriched culture of microorganisms collected in a North Pacific hydrothermal vent T. gammatolerans to several metals by measuring the MICs for Cd, Co, Zn, Ni and Cu. The global cellular responses following Cd exposure (100 \u00b5M & 1 mM) on T. gammatolerans exponentially-growing cells were analyzed using microarrays containing one 50-mer oligonucleotide probe for each of the 2157 annotated protein-coding genes in contrast to what was observed for several Bacillus strains Pyrococcus furiosus challenged with H2O2et al. T. gammatolerans resistance to Co and Zn, two other metals found in hydrothermal environments T. gammatolerans is rather more tolerant to Co (2 mM) than other Thermococcale species described in T. litoralis remains the most Zn resistant Thermococcale tested that completely inhibits rs as in and alsotrations . A pregrd \u223c5 mM, . In contte AsO4; . T. gamme medium , whereashan 1 mM . The low4 did not modify the growth rate, higher amounts correlated to a concentration-dependent growth decrease compared to an untreated control culture (2S) produced by cellular metabolism. These aggregates were not disrupted even after three thorough washes in a large volume of fresh medium and only traces of Cd were removed from the cell pellet (8 cells/ml). The number of cell aggregates dramatically decreased, and the percentage of Cd retained by cells is more reproducible is found in the CdS precipitate fraction is in average 6.7%, thus 67 \u00b5M and they remain able to grow in a fresh medium with or without Cd (data not shown). Cd chelation seems not to be performed by metallothioneins or polyphosphate or glutathione, since this archaeon does not encode orthologous enzymes involved in their biosynthesis We investigated the impact of a Cd exposure on exponentially growing cells in liquid cultures in ASW-AA-Cyst medium. Whereas the addition of 50 \u00b5M or 0.1 mM CdSO culture . Exposur culture , the amo culture . Howeverl pellet . In ordel pellet , and aftoducible . We quantion F4, . The rem7 cells/mL) were exposed to Cd and were collected after 30 min, 120 min and after 270 min (T. gammatolerans' gene content (Kinetics of gene expression changes induced by Cd were performed at two different concentrations (0.1 mM and 1 mM) and at 3 timepoints . A 0.1mM Cd concentration did not affect the growth rate, whereas 1mM Cd induced a transitory growth arrest for 270 min . Late ex 270 min . For eac 270 min in respo content , most of content . While a content as alreaT. gammatolerans was sensing Cd not only at a toxic dose (1 mM) but also at a non-toxic concentration (0.1 mM) that does not affect growth. Interestingly, both toxic (1 mM) and non-toxic (0.1 mM) concentrations induce a transcriptomic response predominantly 120min after stress induction is not affected by Cd exposure in T. gammatolerans.Three different systems are known to mediate cadmium efflux in archaea and bacteria : P-type ATPases (CadA), resistance-nodulation-cell division (RND)-driven trans-envelope exporters (CzcCBA complex) and cation diffusion facilitators also displays an upregulation following Co treatment T. gammatolerans, encoding CbiQ a putative cobalt transport protein +H+(out)<$>\\raster=\"rg1\"<$>K+(in)+H+(in)) as well as tg1059 coding an osmotically inducible protein C (OsmC) rapidly upregulated after a 30 min exposure to 1 mM Cd. It has been reported that T. kodakaraensis OsmC protein is overexpressed in response to a saline stress but not under oxidative or heat stress However, the transcriptional response after a 120 min treatment with 1 mM Cd reveals that 11 out of the 82 genes encoding putative transporters and permeases protein remains Anabaena is exposed to Cd Several genes encoding predicted transcriptional regulators T. gammatolerans and/or a disruption of iron transporters by an unknown mechanism. At a dose of 1 mM Cd, genes encoding subunits of a putative Fe3+ ABC transporter such as tg1016 and tg1705 are upregulated. Moreover, tg0819 encoding the ATP-binding protein of the Fe3+ dicitrate ABC transporter T. kodakaraensis in low-iron medium D. radiodurans cells challenged with Cd T. kodakaraensis is thought to control the expression of the major iron acquisition effectors T. gammatolerans is upregulated at both doses of Cd. To assess the relationship between iron availability and cadmium tolerance in T. gammatolerans, we analyzed T. gammatolerans growth over several generations, when inoculated at 107 cells/mL and challenged with 1mM Cd either under iron starvation or iron excess (T. gammatolerans under our culture conditions. No growth change was monitored in the presence of 200 \u00b5M DTPA (4)citrate instead of 40 \u00b5M in ASW-AA-Cyst; T. gammatolerans growth is reduced but not impaired in ASW-AA-Cyst medium containing 1 mM Cd since the MIC for Cd is 2 mM enhances the growth rate and the final cell density when exponentially growing cells were exposed to low Cd doses citrate probably because a large amount of Fe remains trapped by DTPA (200 \u00b5M). We added to the culture as controls other transition metals , at the same high iron concentration (100 \u00b5M), and tested if they are able to rescue cell growth in the presence of DTPA and Cd . We also tested cobalt, because of the presence of cobalamin (Vitamin B12) added to our culture medium. The ASW-AA-Cyst culture medium was not supplemented with Ni but contains Zn and Co at a concentration of 3 \u00b5M and 3.8 \u00b5M respectively. However, as shown in The presence of both Cd and DTPA in the culture medium results in a drastic reduction of the growth rate . A lag pA and Cd . Zn and Synechocystis cells exposed to cadmium also enhance Fe uptake and degrade their photosynthetic apparatus, to provide extra Fe atoms required to repair damaged [Fe-S] clusters T. gammatolerans to repair damaged iron containing proteins required for metabolic pathways, energy production and cofactor recycling.At a concentration of 1 mM Cd, a large cluster of genes (tg0035\u2013tg0071) organized in 3 operons, is transiently upregulated at 120 min. Interestingly, several ORFs were also found up-regulated after a 30 min of exposure suggestiThermococcales2 in the absence of sulfur with the reduction of protons (3H+ +2e\u2212 \u200a=\u200a H2+H+). The surplus of protons is exported to generate the proton gradient used by the A0A1-ATPase for ATP synthesis . Indeed, if the transcriptional role of SurR is conserved in T. gammatolerans, the transient loss of sulfur could keep SurR under two forms (oxidized and reduced) that would trigger Mbh genes activation to maintain/enhance re-oxidization of reduced ferredoxins, proton translocation and energy biosynthesis.In the phylogenetically close The second part of the upregulated cluster is composed of the locus (tg0048\u2013tg0054) that codes for a unique membrane-complex among Archaea named Mbc1, composed of proteins that allow Mbh anchorage to the membrane and a MbhH-like subunit whose role in Mbh is unclear . Mbc1 coThermococcus onnurineus and molecular hydrogen coupled with proton translocation that increases ATP synthesis The last part of this cluster (tg0055\u2013tg0065) encodes homologues of formate hydrogenlyase subunits found in us Mhy2, . T. gammThermococcales with Thermococcus sp AM4, and which encodes an AMP-forming acetyl-CoA synthetase , is also upregulated, likely leading to an increased ATP production that governs Ni import T. kodakaraensis, thought to be involved in the expression of the major iron acquisition effectors Thermococcales species.Interestingly, different metal stress induced similar expression patterns although the effects of each metal is more or less pronounced but these patterns clearly differ from that of heat shock and \u03b3-irradiation . Only thThermococcales and closely related to the SpoVT/AbrB family. In Bacillus subtilis, AbrB proteins are transition state regulators that play an essential role in the adaptive capacity and for survival when environmental conditions are deleterious Pyrococcus spOT3 bind specific amino acids Pyrococcus sp OT3 T. gammatolerans FFRPs regulators, the 3 halves FFRPs displayed the same behavior under metal stress condition. Their repression could be associated with a fine-tuning regulation of several metabolic pathways observed here.The most upregulated gene (tg1919) at 0.1 mM Cd was also upregulated at 1 mM Cd as well as with 250 \u00b5M Ni as shown by qRT-PCR . Tg1919 While Cd is known to inhibit base excision repair T. gammatolerans regulates less than 50% of these 27 genes (11 out of 27 for \u03b3-rays) and most of them display a transcriptional downregulation. During the heat shock, T. gammatolerans cells induced tg1688 and downregulated tg1034 that encode a small heat shock protein and a multiantimicrobial extrusion protein respectively as observed in P. furiosus (PF1883 and PF1850) after a 1 hr heat shock treatment at 105\u00b0C T. gammatolerans is grown in sulfur containing medium and cells probably re-oxidize the reduced ferredoxins mainly using the Mbx complexes. Therefore, T. gammatolerans is likely able to develop a set of specific strategies to re-oxidized cofactors and produce energy according to the nature of the stress and its impact on metabolic pathways.Both heat shock and \u03b3-Rays damage cellular components. However, Altogether, these results reveal that Cd transcriptional pattern display close similarities with other metal expression patterns but the Cd transcriptional response is not a general stress response since only few Cd responsive genes were similarly regulated by heat shock or \u03b3-Rays.Thermococcales species thriving in these biotopes are continuously exposed to loads of reduced metals and develop strategies to face such harsh environments. Therefore, T. gammatolerans exhibits elevated resistance to several metals as Cd, Co and Zn, and at a lesser extent to others as Ni, Cu and AsO4. For the first time in Archaea, we performed a time-course transcriptomic analysis to draw a global response to Cd toxicity in growth conditions close to its natural habitat . Several bacterial and eukaryal transcriptomes showed that sulfur compounds play a key role to trap Cd for detoxifying the cells T. gammatolerans is based on amino acid catabolism in the presence of sulfur that continuously produces these compounds and may establish the first efficient barrier of protection against metals T. gammatolerans reprograms, at a sublethal Cd dose, a hundred genes which are predominantly up-regulated 120 min after exposure. Previous archaeal transcriptional analyses also highlighted a regulation of only 50\u2013150 genes following other stresses . Strain EJ3T was grown in serum bottles, 1L Schott bottle or in Hungate tubes, under strictly anaerobic conditions at 85\u00b0C in artificial seawater medium containing amino acids, vitamins and cystine (ASW-AA-Cyst) or in complex organic medium with sulfur (VSM- S\u00b0).2.6H2O 3g; MgSO4.7H2O 6g; (NH4)2 SO4 1g; NaHCO3 0.2g; CaCl2.2H2O 0.3g; KCl 0.5g; KH2PO4 0.42g; NaBr 0.05g; SrCl2.6H2O 0.02g; Fe(NH4)citrate 0.01g; Pipes 3g. This basal ASW medium was supplemented with 0.5 mL per liter of modified 10X Wolfe's trace minerals stock solution 2 0.1g; H3BO3 0.1g and NaMoO4.2H2O 0.1g per liter; The artificial seawater medium (ASW-AA-Cyst) contains reduced calcium and phosphate amount and cystine instead of inorganic sulfur (S\u00b0) as electron acceptor to minimized metal complexation 2.6H2O, 0.5g/l trisodium citrate, 3g/l Pipes, 1g/l yeast extract, 4g/l bactotryptone, 5 ml MgSO4 20%, 1 mL CaCl2 5%, 1 mL KH2PO4 5%, 2g/L inorganic sulfur S\u00b0 . Na2S at a 0.1% final concentration was added to reduce the oxygen dissolved in the medium.The complex organic medium (VSM- S\u00b0) is composed of 20g/l NaCl, 0.25g/l KCl, 0.05g/l NaBr, 0.02g/l boric acid, 0.01g/l SrCl2 . Absence of O2 was followed through disappearance of resazurin sodium salt (1 mg/L) pink color included in the media. Cell culture densities were measured by optical microscopy (Olympus BH-29) using a Thoma counting chamber (Microgravure Precis).For both ASW-AA-Cyst and VSM- S\u00b0 media, NaOH was added to adjust the pH to 6.9 before sterilization. Air contained in the bottles or tubes was first removed using a vacuum and replaced by N4, CoSO4, ZnSO4, NiSO4, CuSO4, ArsSO4 and DTPA (diethylenetriamine-pentaacetic acid) were purchased from Sigma. Stock solutions were prepared in MilliQ water, filter sterilized and stored in the dark.CdSO5 cells/mL with different metal concentrations . To prevent metal precipitation with hydrogen sulfide produced by T. gammatolerans preculture, cells were harvested and washed with sterile basal medium before inoculation. The MIC was defined as the lowest concentration of metal that inhibits growth after incubation at 85\u00b0C on a reciprocal shaker. Cell growth was scored at 24 hrs (as in T. gammatolerans was used as a positive growth control. Growth was measured by direct counts on a Thoma counting chamber. Experiments were repeated in triplicate.The minimum inhibitory concentration (MIC) determinations were performed in ASW-AA-Cyst medium as described above to avoid metal complexation and also in Llannos\u2019 medium treated with Zn or Ni before sampling 120 min after metal addition. Cells were filtered to eliminate cystine and pelleted by centrifugation , immediately frozen and stored at \u221280\u00b0C until further processing. Each culture was repeated twice.5 cells/mL and incubated at 85\u00b0C. When cell density reached \u223c5\u00d7107 cells/mL, 6 serum bottles cultures were rapidly heated at 95\u00b0C (water bath) and incubated during 15 min while the other serum bottles were kept at 85\u00b0C. Cultures (95\u00b0C and 85\u00b0C) were harvested by centrifugation, immediately frozen and stored at \u221280\u00b0C until needed.For the heat shock experiment, a dozen of 50 mL VSM-S\u00b0 medium serum bottles were inoculated at 5\u00d710137Cs \u03b3-Rays source . The same number of non-irradiated cells was kept in ice during irradiation. Irradiated and non-irradiated control cells were then incubated 120 min at 85\u00b0C in fresh VSM-S\u00b0 medium on reciprocal shaker following the manufacturer's instructions. RNA quantity and quality were assessed using a Nanodrop BD-1000 spectrophotometer (Nanodrop Technologies) and Experion Automated Electrophoresis System (Bio-Rad Laboratories), respectively. The reverse transcription reactions were performed with 400 units of Superscript II reverse transcriptase (Invitrogen), RNA (20 \u00b5g), random hexamers (6 \u00b5g), 1.5 mM dATP, dCTP, and dGTP, 1.2 mM dTTP, and 0.3 mM amino allyl-dUTP (Sigma) for 1.5 hrs at 42\u00b0C. RNA was then hydrolyzed during 15 min at 37\u00b0C by 2 units of RNase H. The cDNAs were purified with Microcon-G30 (Millipore), dried and resuspended in 10 \u00b5L water. Indirect labeling of cDNA with either cyanine3 (Cy3) or cyanine5 (Cy5) monofunctional NHS-ester (Amersham Bioscience) occurred after the reverse transcription. cDNAs, mono reactive Cy3 or Cy5 dye and 1\u00b5l of 0.5M pH9 sodium bicarbonate are mixed together and incubated 1 hr at room temperature in the dark for the coupling reaction. The fluorescently labeled cDNAs were purified using a Nucleospin Extract II kit (Macherey-Nagel) and dye incorporation was measured using Nanodrop BD-1000 spectrophotometer (Nanodrop Technologies). The two labeled cDNAs were combined, mixed with 10 \u00b5g polyd(A) and 10 \u00b5g yeast tRNA, precipitated with ammonium acetate/ethanol and resuspended in 50 \u00b5L of hybridization buffer .For microarray experiments, total RNAs were extracted with TriReagent\u2122 solution (Sigma) and contaminating DNA was digested using DNA-After a denaturation step for 2 min at 95\u00b0C, the concentrated Cy3 and Cy5 cDNA were dropped onto glass slide microarrays and incubated in a hybridization chamber (Corning) for 17 h at 50\u00b0C. Four post-hybridization washes of 5 min were carried out at room temperature by incubating slides under agitation in a 2\u00d7 SSC/0.1% SDS solution, in a 1\u00d7 SSC solution, in a 0.2\u00d7 SSC solution and in a 0.05\u00d7 SSC solution, respectively. The slides were dried by centrifugation. Fluorescent signals were detected by a GenePix\u2122 4000B laser microarray scanner (Axon Instruments) with a 10 \u00b5m resolution. All slides were scanned using 100% laser power and PMT voltage auto-adjustment. The resulting 16-bit images were analyzed using GenePix Pro 6.0 software (Axon Instruments). Spots or areas of the array with obvious blemishes, deformation or dust were manually flagged and excluded from subsequent analysis. Raw data overview and preprocessing were processed using MANGO software http://www-archbac.u-psud.fr/genomes/r_tgamma/tgam_Cd_search.html) with visualization tools developed for this project http://www.ncbi.nlm.nih.gov/geo/) under the accession number GSE13546 All the results are available via an integrated database (www.toxnuc-e.org).One 50-mer oligonucleotide probe for each of the 2157 annotated protein-coding genes was designed with Primer3 Software T. gammatolerans as described above. Reverse transcriptions were performed with 5 \u00b5g of total RNA using reverse PCR primer as gene specific primer using the LightCycler System (Roche Diagnostics). The specificity of each PCR reaction was checked by measuring fluorescent signals during melting curve analysis . Gene expression was calculated relative to the transcripts levels of the gene rpoB using the formula 2\u2212\u0394\u0394CtTotal RNA was extracted from c primer and SupeT. gammatolerans culture supernatants (1 mL) were deproteinized using 100 \u00b5L of ice cold 35% perchloric acid leading to protein precipitation after centrifugation (6000g for 2 min). The supernatants were transferred into a new tube and neutralized with 100\u00b5L of ice cold 7N KOH. The sample are then centrifugated at 6000g for 10min, the supernatants are filtered and directly used. Acetate assays were performed according to the manufacturer's instructions with an enzymatic kit based on the monitoring of NADH production at 340nm using acetyl-CoA synthetase, citrate synthase, and L-malate dehydrogenase .T. gammatolerans, cells were resuspended in 3 mL ultra pure HNO3 (69%) purchased from Sigma-Aldrich , and were sonicated in a Branson 1210 bath during 1 hr. The solution was diluted 1000 times in HNO3 2% prior analysis by ICP-MS. The washing supernatants were diluted 10 times in HNO3 2% prior analysis by ICP-MS. Rhodium was used as internal standard and quantifications were performed by external calibration Late exponentially growing cells (3 independent cultures in 50 mL ASW-AA-Cyst medium) were challenged with 1 mM Cd during 30 min, 120 min, 270 min or 24 hrs. Then, cells were filtered and pelleted by centifigation . The pellet was thoroughly resuspended three times in 15 mL of fresh ASW-AA medium to eliminate free Cd ions. After centrifugation , the three washing supernatants were pooled for analysis. To quantify Cd retained by Figure S1Experimental design of microarray approach.T. gammatolerans exponentially growing cultures were exposed to 0.1 or 1 mM Cd. As a control, cultures without Cd (w/o Cd) were grown in parallel. Time course aliquots were collected 30, 120 and 270 min after Cd exposure. RNA was purified and reverse transcribed. Labeled cDNA were hybridized onto microarrays containing oligonucleotide probes for all ORFs printed in duplicate (GEO accession number GSE13546). The Cd transcriptional response was monitored in two independent cultures for each condition and each biological replication was hybridized twice on a microarray in a dye swap (ds) manner leading to a total of 8 data points per condition and per gene.(TIFF)Click here for additional data file.Figure S2Quantification by ICP-MS of Cd.T. gammatolerans exponentially growing cells (50 mL) were challenged at a cell density of 5\u00d7107 cells/mL with 1 mM Cd during 24 hrs. Following Cd treatment, cells were filtered and pelleted by centrifugation . The pellet was resuspended three times in 15 ml of fresh ASW-AA medium to removed soluble Cd. The CdS precipitates fraction was filtered (F4) before Cd quantification. The samples (F1 to F5) were analyzed by ICP-MS as described in the materials and methods section. The sum of Cd quantities found from fractions F1 to F5 is consistent with the total Cd amount added to the culture .(TIFF)Click here for additional data file.Figure S3Effect of Zn, Ni, Co availability on T. gammatolerans Cd tolerance. Cd susceptibility was analyzed in ASW-AA-Cyst medium (black line) or in modified ASW-AA-Cyst media supplemented with: 1 mM Cd (yellow line), 1 mM Cd and 200 \u00b5M DTPA ; 1 mM Cd and 200 \u00b5M DTPA and 100 \u00b5M iron (brown line), 100 \u00b5M Co (clear pink line), 1 mM Cd and 200 \u00b5M DTPA and 100 \u00b5M Co (red line), 100 \u00b5M Zn (clear purple line), 1 mM Cd and 200 \u00b5M DTPA and 100 \u00b5M Zn (purple line), 100 \u00b5M Ni (clear green line), 1 mM Cd and 200 \u00b5M DTPA and 100 \u00b5M Ni (green line). The effect of metals availability on Cd tolerance was investigated in each culture medium inoculated with 107 cells/mL and incubated at 85\u00b0C on a reciprocal shaker. Cell densities were scored using a Thoma counting chamber. The values are the mean of three independent cultures (SD \u226410%).(TIFF)Click here for additional data file.Table S1Quantification of cellular Cd by ICP-MS. The amounts of Cd retained by T. gammatolerans cells after a 1 mM Cd challenge were determined in exponentially growing cells for the timepoints 30 min, 120 min, 270 min and 24 hrs . Following Cd treatment, cells were filtered and pelleted by centrifugation . The pellet was resuspended three times in 15 ml of fresh ASW-AA medium to removed soluble Cd. The supernatants were pooled before analysis. The fractions were analyzed by ICP-MS as described in the materials and methods section.(XLSX)Click here for additional data file.Table S2List of the 114 Cd-responsive genes. Microarray analyses monitored 161 transcriptional changes in response to Cd exposure corresponding to 114 different genes. The expression fold changes and the corresponding p-Value are indicated for each Cd concentration tested (0.1 and 1 mM) and timepoints . Up- and downregulated genes are shown in red and green respectively.(XLS)Click here for additional data file.Table S3List of oligonucleotides used for quantitative real-time RT-PCR. PCR primer pairs were designed using Primer3 software (XLSX)Click here for additional data file."} +{"text": "In November of 2007 a human adenovirus (HAdV) was isolated from a bronchoalveolar lavage (BAL) sample recovered from a biopsy of an AIDS patient who presented with fever, cough, tachycardia, and expiratory wheezes. To better understand the isolated virus, the genome was sequenced and analyzed using bioinformatic and phylogenomic analysis. The results suggest that this novel virus, which is provisionally named HAdV-D59, may have been created from multiple recombination events. Specifically, the penton, hexon, and fiber genes have high nucleotide identity to HAdV-D19C, HAdV-D25, and HAdV-D56, respectively. Serological results demonstrated that HAdV-D59 has a neutralization profile that is similar yet not identical to that of HAdV-D25. Furthermore, we observed a two-fold difference between the ability of HAdV-D15 and HAdV-D25 to be neutralized by reciprocal antiserum indicating that the two hexon proteins may be more similar in epitopic conformation than previously assumed. In contrast, hexon loops 1 and 2 of HAdV-D15 and HAdV-D25 share 79.13 and 92.56 percent nucleotide identity, respectively. These data suggest that serology and genomics do not always correlate. The first human adenoviruses (HAdVs) were isolated in 1953 from a military basic trainee and the adenoid tissue of a pediatric patient as respiratory pathogens In this report, an adenovirus isolated from a bronchoalveolar lavage (BAL) sample that was biopsied from an AIDS patient who presented with fever, cough, tachycardia and expiratory wheezes is examined using genomics and bioinformatics. Based upon the whole genome analysis and supported by limited serological data, this adenovirus belongs to species HAdV-D, and is a \u2018never seen before\u2019 novel virus, to be given the name of HAdV-D59.The work reported herein was performed under United States Air Force Surgeon General-approved Clinical Investigation No. FDG20040024E, by the Institutional Review Board at the David Grant USAF Medical Center. Informed Consent was not required, because we did not use clinical samples.Adenovirus neutralization assays were run as previously described 2 at 37\u00b0C. Thereafter A549 cells were added, mixed, and incubated at 37\u00b0C in 5% CO2 for 7 days. Each assay contained a back titration of the virus used. Living cells were distinguished from dead cells by measuring the amount of Finter's Neutral Red Equal volumes of diluted virus and immune serum were mixed and incubated for one hour in 5% COThe HAdV-D59 genome sequence and its annotation are deposited in GenBank and retrievable as accession number JF799911. In addition, the following HAdV genomes (GenBank accession numbers) were used for comparative computational analyses: HAdV-D8 (AB448767), HAdV-D9 (AJ854486), HAdV-D15 (AB562586), HAdV-D17 (AF108105), HAdV-D19C (EF121005), HAdV-D22 (FJ404771), HAdV-D25 (unpublished), HAdV-D26 (EF153474), HAdV-D28 (FJ824826), HAdV-D36 (GQ384080), HAdV-D37 (DQ900900), HAdV-D46 (AY875648), HAdV-D48 (EF153473), HAdV-D49 (DQ393829), HAdV-D53 (FJ169625), HAdV-D54 (AB333801), HAdV-D56 (HM770721), and HAdV-D58 (HQ883276).Fiber coding sequences used for analysis were as follows: HAdV-D8 (AB448767), HAdV-D9 (AJ854486), HAdV-D10 (AB369368), HAdV-D19C (AB448774), HAdV-D19a (CS301726), HAdV-D22 (FJ619037), HAdV-D26 (EF153474), HAdV-D28 (FJ824826), HAdV-D29 (AB562587), HAdV-D36 (GQ384080), HAdV-D37 (DQ900900), HAdV-D46 (AY875648), HAdV-D48 (EF153473), HAdV-D49 (DQ393829), HAdV-D54 (AB333801), HAdV-D56 (HM770721), and HAdV-D58 (HQ883276). Fiber genes from species HAdV-D genomes were aligned using ClustalW To amplify regions of HAdV-D59 using the polymerase chain reaction (PCR) protocol, conserved adenovirus sequences in species HAdV-D were used to design primers. All amplicons were then sequenced on an ABI 3130xl using a primer walking strategy. The HAdV-D59 genome was sequenced to 8-fold coverage following PCR amplification, with both strands represented.The HAdV-D59 genome was compared against a select number of viral genomes from the HAdV-D group based on its GC content, which is indicative of HAdV species. The selection of which genomes was based on initial overall high nucleotide identity to HAdV-D59. The data presented are final iterations of analyses that initially included all of the sequenced genomes in species HAdV-D.http://www.ebi.ac.uk/Tools/msa/kalign/) for a broad perspective of the genome. SimPlot Whole genome sequences of HAdV-D59 and members of species HAdV-D were first aligned with kalign , via neighbor-joining methods and bootstrap test of phylogeny with replicates set to 1000.Sequence alignments for phylogenomic analysis were generated using the kalign method noted earlier. Phylogenetic trees were constructed from these aligned sequences using Molecular Genetic Analysis Software for a diagnostic specimen (via bronchoscopy). A virus was cultured from the BAL sample and sent to the California Department of Public Health (CDPH) for further analysis and identification. No other pathogens were isolated from this patient.The virus was propagated at the Viral and Rickettsial Disease Laboratory at the California Department of Public Health, and was identified as an unknown adenovirus by serum neutralization assay. Initial sequence analysis of amplicons derived from the hexon and the fiber genes revealed similarity to gene sequences from HAdV-D25 and HAdV-D56, respectively. The possibility that this virus might represent a novel, recombinant pathogen provoked whole genome analysis in order to characterize this isolate more thoroughly.To elucidate the genetic characteristics of this pathogen (HAdV-D59), we sequenced and analyzed the entire genome. The genome length of HAdV-D59 is 35,072 base pairs , with a http://zpicture.dcode.org/). Comparisons of the HAdV-D59 genome with the whole genome sequences of HAdV-D9, -D22, -D19C, -D25, -D28, -D36, -D56 and -D58 were performed. Consistent with other previously reported viruses in species HAdV-D Since initial DNA sequencing suggested evidence of recombination, we analyzed the HAdV-D59 genome using zPicture, a dynamic blastz alignment visualization program designed for comparative analysis in the L1 and L2 domains are greater than 2.5% . Madisch et al stated that percent nucleotide identity differences greater than 2.4% and 2.5% in L1 and L2, respectively, strongly suggests identification of a novel HAdV SimPlot and Bootscan results suggest that a large portion of the E3 transcription region in HAdV-D59 may have originated from a recombination event between either HAdV-D56 or HAdV-D9 and another yet to be described HAdV . InteresPhylogenetic analyses of two genes (CR1\u03b2 and CR1\u03b3 genes) in the E3 region demonstrate that the coding regions for CR1\u03b2 and CR1\u03b3 in HAdV-D59 are closely related to those of HAdV-D9 and HAdV-D56 .SimPlot analyses of the HAdV-D59 fiber was performed on fiber sequences extracted from GenBank. The results suggested that the fiber gene of HAdV-D59 is nearly identical with sequences from both HAdV-D56 and HAdV-D9 . FurtherHAdV-D59 was neutralized by both HAdV-D25 and HAdV-D15 antiserum, yet not by HAdV-D9 antiserum . InteresOur results demonstrated that HAdV-D25 antiserum was more effective at neutralizing HAdV-D59 than HAdV-D25 . Since LEven though HAdV-D15 and HAdV-D25 showed only a two-fold difference via serum neutralization, they were recognized as different serotypes by Rosen et al, because they had different fiber proteins SimPlot analysis of the HAdV-D59 L1 and L2 regions demonstrates high nucleotide identity between the hexons of HAdV-D25 and HAdV-D59 and suggests that they may be derived from a yet undiscovered common ancestor. If L1 and L2 of HAdV-D25 and HAdV-D59 are from a common ancestor, the recombination event may be ancient, as evidenced by 3.52 and 4.81 percent nucleotide differences in the L1 and L2 sequences, respectively. If the recombination events were recent, SimPlot analysis would illustrate near 100% nucleotide identity, which was shown for HAdV-D53 and HAdV-D56 Multiple studies have shown that HAdVs in species HAdV-D recombine with one another in the penton base and hexon genes The section of the HAdV-D59, -D56, and \u2013D9 genomes that encodes for CR1\u03b2, CR1\u03b3, RID\u03b1, RID\u03b2, 14.7K, and fiber show high nucleotide identity . From th"} +{"text": "In February of 1996 a human adenovirus (formerly known as Ad-Cor-96-487) was isolated from the stool of an AIDS patient who presented with severe chronic diarrhea. To characterize this apparently novel pathogen of potential public health significance, the complete genome of this adenovirus was sequenced to elucidate its origin. Bioinformatic and phylogenetic analyses of this genome demonstrate that this virus, heretofore referred to as HAdV-D58, contains a novel hexon gene as well as a recombinant fiber gene. In addition, serological analysis demonstrated that HAdV-D58 has a different neutralization profile than all previously characterized HAdVs. Bootscan analysis of the HAdV-D58 fiber gene strongly suggests one recombination event. Adenoviridae, that are organized into seven species (A\u2013G) Human adenoviruses (HAdVs) were first isolated in 1953 from pediatric adenoid tissue and from a military basic trainee as respiratory pathogens Currently there are three human adenoviruses that are associated with gastroenteritis In this report we examined an adenovirus isolated from the stool of an AIDS patient who presented with severe chronic diarrhea. Based upon whole genomic and bioinformatics analysis, this virus appears to belong to species HAdV-D, with the proposed name HAdV-D58.Cryptosporidium parvum and Giardia lamblia were also found in the fecal matter of the patient; therefore, the clinical symptoms cannot be exclusively linked with the adenovirus infection.In February of 1996 an adenovirus was isolated from the stool of a 31-year-old AIDS patient who presented with severe chronic diarrhea and was subsequently hospitalized. Partial sequencing of HAdV-D58, previously published as the Ad-Cor-96-487 strain human adenovirus D (HAdV-D) (57.0% mean). The organization of the 36 open reading frames (ORFs) that were annotated had a genome organization similar to other mastadenoviruses . The neutralization titer was calculated as the maximum dilution of antiserum that completely inhibited viral growth as evidenced by the lack of cytopathic effects.The isolation of HAdV-D58 (previously known as Ad-Cor-96-487) was previously described http://hadvwg.gmu.edu/.This virus was named HAdV-D58 because the number 57 was already taken in GenBank (HQ003817). For rules of adenovirus nomenclature, see The HAdV-D58 genome and annotation have been deposited in GenBank prior to manuscript submission: accession number HQ883276. The following HAdV genomes (GenBank accession numbers) were used for comparative analysis: HAdV-D8 (AB448767), HAdV-D9 (AJ854486), HAdVD19C (EF121005), HAdV-D22 (FJ404771), HAdV-D26 (EF153474), HAdV-D28 (FJ824826), HAdV-D36 (GQ384080), HAdV-D37 (DQ900900), HAdV-D46 (AY875648), HAdV-D48 (EF153473), HAdV-D49 (DQ393829), HAdV-D53 (FJ169625), HAdV-D54 (AB333801), and HAdV-D56 (HM770721).To amplify regions of HAdV-D58 flanking the sequences previously described by Ferreyra et al. AccuPrep Genomic DNA Extraction Kit (Bioneer Corporation). Finally, the viral DNA was resuspended in deionized water and stored at \u221220\u00b0C until use.HAdV-D58 particles were separated from Hep-2 cells by ultracentrifugation. Genomic DNA was acquired from viral particles using http://www.ebi.ac.uk/Tools/clustalw2/index.html. The default parameters for gap open penalty and gap extension penalty were used.The available genomes from species HAdV-D were aligned using the clustalW Hexon coding sequences used for analysis were: HAdV-D8 (AB448767), HAdV-D9 (AJ854486), HAdV-D10 (AB369368), HAdV-D13 (DQ149616.1),HAdV-D15 (AB330096.1), HAdV-D19C(AB448774), HAdV-D20 (AB330101.1), HAdV-D22 (FJ619037), HAdV-D24 (AB330105.1), HAdV-D25 (AB330106.1|), HAdV-D26 (EF153474), HAdV-D27 (AB330108.1|), HAdV-D28 (FJ824826), HAdV-D29 (AB562587), HAdV-D30 (AB330111.1),HAdV-D32 (AB330113.1), HAdV-D33 (AB330114.1), HAdV-D36 (GQ384080), HAdV-D37 (DQ900900), HAdV-D38 (AB330119.1), HAdV-D39 (AB330120.1), HAdV-D42 (AB330123.1), HAdV-D43 (AB330124.1), HAdV-D44 (AB330125.1), HAdV-D45 (AB330126.1), HAdV-D46 (AY875648), HAdV-D47 (AB330128.1), HAdV-D48 (EF153473), HAdV-D49 (DQ393829), HAdV-D51 (AB330132.1), HAdV-D53 (FJ169625.1), HAdV-D54 (AB333801), and HAdV-D56 (HM770721). SimPlot software was used to complete a bootscan analysis of the aligned hexon genes of the available HAdV-D genomes Fiber coding sequences used for analysis were: HAdV-D8 (AB448767), HAdV-D9 (AJ854486), HAdV-D10 (AB369368), HAdV-D19C (AB448774), HAdV-D19a (CS301726), HAdV-D22 (FJ619037), HAdV-D26 (EF153474), HAdV-D28 (FJ824826), HAdV-D29 (AB562587), HAdV-D36 (GQ384080), HAdV-D37 (DQ900900), HAdV-D46 (AY875648), HAdV-D48 (EF153473), HAdV-D49 (DQ393829), HAdV-D54 (AB333801), and HAdV-D56 (HM770721). Fiber genes from species HAdV-D genomes were aligned using ClustalW To analyze the results by Darr et al http://www.ebi.ac.uk/Tools/mafft/index.html). Phylogenetic distances and trees were generated from these aligned sequences by the Molecular Evolutionary Genetic Analysis software . Distances were obtained with pairwise distance calculation using maximum composite likelihood model. Subsequent phylogenetic trees were obtained using bootstrap tests of phylogeny of 1000 replicates with neighbor-joining method featured in the program.Nucleotide alignment of whole genome, penton, L1 and L2 of hexon, hexon, fiber and fiber knob, ORF2 and ORF3 regions were performed using the multiple alignment software based on a \u201cFast Fourier Transform\u201d algorithm and loop2 (L2) HAdV-D58 coding regions to homologous sequences from other viruses in species HAdV-D.(PDF)Click here for additional data file.Table S2Percent identities of the nucleotide coding sequences of selected E3 HAdV-D58 coding sequences and their homologs.(PDF)Click here for additional data file."} +{"text": "Here, we report that expression of the immune checkpoint (IC) molecules PD-1, LAG-3, and TIM-3 are differentially expressed on CD4+ and CD8+ T cells in the allogeneic response resulting from a mixed lymphocyte reaction. In these studies, PD-1 expression is higher on CD4+ T cells compared to CD8+ T cells. In contrast, TIM-3 is expressed at higher levels on CD8+ T cells compared to CD4+ T cells with an apparent reciprocity in that PD-1+ CD4+ T cells are frequently TIM-3lo/\u2212, while TIM-3-expressing CD8+ T cells are largely PD-1lo/\u2212. In addition, there is a decrease in the frequency of TIM-3+ CD4+ cells producing IFN-\u03b3 and IL-5 compared to TIM-3+ CD8+ cells. Lastly, the memory T cell phenotype within each IC-expressing subset differs between CD4+ and CD8+ T cells. These findings highlight key differences in IC expression patterns between CD4+ and CD8+ T cells and may allow for more effective therapeutic targeting of these molecules in the future.PD-1, TIM-3, and LAG-3 are molecules shown to have immune modulatory properties, and although initially classified as indicators of T cell hyporesponsiveness, it has become clear that they are also associated with the normal course of T cell activation. Functional studies have focused mainly on CD8 Here, we employ a modification of the mixed lymphocyte reaction (MLR) to dissect the differences in IC expression levels and kinetics on CD4+ and CD8+ T cells to define expression patterns during a physiological immune response. We report that expression of PD-1, LAG-3, and TIM-3 coincides with T cell activation and function, but these molecules are differentially expressed on CD4+ and CD8+ T cells. In addition, CD4+ T cells undergoing proliferation that express PD-1 often exhibit lower expression of TIM-3, while TIM-3 expressing CD8+ T cells have reduced PD-1 expression. These differences extend to cytokine production in that IC expression differs between cytokine-producing CD4+ and CD8+ T cells. Lastly, we find that CD4+ and CD8+ T cells exhibit different memory T cell phenotypes depending on which of these molecules are expressed.Immune checkpoint-expressing CD8ral load , 16, 17.ral load , providiral load , 20. Howactivity . These ptivation , which, + by flow cytometry. Human monocyte-derived dendritic cells (DCs) from healthy donors were purchased from Astarte Biologics and confirmed to be >90% CD11c+, and >90% CD83+, CD86+, and HLA-DR+ after activation.Purified human pan T cells from healthy donors were purchased from Biological Specialty Corporation . T cells were confirmed to be >95% CD3T cells and DCs were cultured in complete media consisting of RPMI 1640 with Glutamax , supplemented with 5% heat inactivated human serum . DC were cultured overnight with 500\u2009U/mL each of recombinant IL-4 and GM-CSF and matured with 1000\u2009U/mL recombinant IFN-\u03b3 (Peprotech) and 1\u2009ng/mL LPS (Sigma). Prior to coculture with DC were tested for maturation status by CD83, CD86, and HLA-DR expression by flow cytometry and IL-12 production by ELISA . T cells were labeled with violet proliferation dye 450 (BD) according to the manufacturer\u2019s instructions. T cells were cultured with DC at a 10:1 ratio, incubated at 37\u00b0C for the indicated timepoints, and analyzed for proliferation and activation by flow cytometry. Supernatants were collected and cytokines were measured by multiplex analyses . For ELISPOT analysis, cells were collected on day 6 of MLR and analyzed for IFN-\u03b3 spot production using pre-coated plates . For intracellular detection of cytokines, cells were collected on day 6 of the MLR and treated with PMA (Sigma), ionomycin (Sigma), and GolgiPlug for 6\u2009h prior to addition of antibodies for flow analysis.All cells were labeled with live/dead dye near infra red (Life Technologies) for dead cell exclusion and treated with Fc Block prior to staining with fluorescently labeled antibodies. Anti-human antibodies used for DC staining were anti-CD83 PE , anti-CD86-PE-Cy7 (Biolegend), anti-HLA-DR V450 (BD), and anti-CD11c APC (BD). Antibodies used in the T cell characterization were anti-LAG-3 FITC , anti-PD-1 PerCP-Cy5.5, anti-CD3 Alexa700, anti-CD4 Brilliant Violet 650, anti-CD8 Brilliant Violet 570, anti-IFN-\u03b3 PE, anti-IL-5, anti-CD62L PE, and anti-CD45RA Alexa700 , anti-CD25 PE, and anti-IFN-\u03b3 PE-Cy7, anti-IL-4 PE-Cy7 , and anti-TIM-3 APC (R&D Systems). Surface staining and intracellular staining was performed using Cytofix/Cytoperm\u2122 Plus kit (BD) according to the manufacturer\u2019s instructions. Data acquisition was performed using the LSRFortessa flow cytometer (BD). Data analysis was performed with FlowJo version 9 .t-test (Holm\u2013Sidak) and two-way ANOVA (Dunnet\u2019s). Correlation coefficients were determined using two-tailed paired monotonic analysis (Spearman).For all markers analyzed by flow cytometry, isotype controls were used to establish gates by setting gates between 0.5 and 1% positive events. Gates were drawn around each cell division as determined by violet proliferation dye dilution, and subsequent populations were analyzed for expression of CD25, PD-1, LAG-3, and TIM-3. Quantifications were made based on data generated from FlowJo, and statistical analysis was performed using GraphPad Prism version 6. Statistical significance was determined using two-tailed paired + and CD8+ T cells for analysis. As expected, both CD4+ and CD8+ T cells exhibited progressively increasing proliferation with the majority of T cells divided after 7\u2009days and minimal proliferation by T cells cultured alone. Longitudinal analyses of supernatants collected from these cultures showed levels of TNF-\u03b1, IL-5, and IL-13 increased over time with steady levels of IFN-\u03b3 up to day 7 of MLR, while T cells alone did not produce detectable levels of cytokine , whereas the non-dividing CD4+ and CD8+ populations had a much lower frequency of CD25+ cells and lower overall mean fluorescence intensity (MFI) as shown in Figure + CD4+ T cells was significantly higher than that of CD25+ CD8+ compared to CD8+ T cells (31.0\u2009\u00b1\u20097.2%). Conversely, CD4+ expression of TIM-3 was lower (53.9\u2009\u00b1\u20094.9%) compared to TIM-3 expression on CD8+ T cells (75.9\u2009\u00b1\u20096.2%). LAG-3 expression on CD4+ (38.8\u2009\u00b1\u20093.8%) was lower than PD-1 and TIM-3; however, LAG-3 expression on CD8+ (49.6\u2009\u00b1\u200915.2%) varied between donors with no significant trend observable. Expression levels of each IC on CD4+ and CD8+ T cells across four donors are summarized in Table + and CD8+ T cells was evident even though analysis was restricted to dividing cells that were CD25+ indicating all were activated. To better understand the relationship between cell division and expression of PD-1, LAG-3, and TIM-3 during T cell activation, further analysis of IC molecule expression was performed by gating on iterative population doublings based on proliferation dye dilution over the course of the 6-day culture. As shown in Figure + and CD8+ T cells exhibited MFI of each IC molecule in correlation with the number of cell divisions, i.e., the more a T cell had divided, the higher the expression of PD-1, LAG-3, and TIM-3, coinciding with the same expression kinetics as CD25. Interestingly, the MFI of CD25 and PD-1 was consistently higher on CD4+ T cells compared to CD8+ T cells, whereas the MFI of LAG-3 and TIM-3 was higher on CD8+ T cells compared to CD4+. The broad distribution of IC expression observed on dividing CD4+ and CD8+ T cells prompted us to evaluate co-expression between these molecules. Upon closer examination of CD25+ proliferating cells, PD-1 presented with differential expression between CD4+ and CD8+ T cells. The majority of CD25-expressing CD4+ T cells also expressed PD-1 (66%), whereas of the CD25+ CD8+ T cells, only 30% expressed PD-1 . By 6\u2009days after stimulation, nearly all dividing CD4+ and CD8+ T cells. However, expression of TIM-3 was significantly decreased on cytokine-producing CD4+ T cells compared to cytokine-producing CD8+ T cells in the pair comparison was 0.90, p\u2009<\u20090.0001]. Of note, PD-1hiTIM-3lo expression was largely restricted to CD4+ T cells, whereas CD8+ T cells were predominantly PD-1loTIM-3hi . Taken together, these results show that although PD-1, TIM-3, and LAG-3 are upregulated on activated T cells, the expression pattern of these molecules, in particular PD-1 and TIM-3, differs between CD4+ and CD8+ T cells.Having shown that activated and proliferating T cells expressed IC to varying degrees as well as with differential kinetics, we were then interested in analyzing IC expression in association with cytokine production. Based on the cytokine milieu measured in the MLR Figure A, we foc+ and CD8+ T cells, each subset was analyzed for phenotypic memory T cell markers by flow cytometry. To ensure exclusion of naive/non-responding cells, only proliferating cells were analyzed. Nearly all responding CD4+ and CD8+ T cells exhibited either a CM phenotype (CD62L+ CD45RA\u2212) or effector/EM (CD62L\u2212 CD45RA\u2212) compared to LAG-3-expressing CD4+ (48.2%\u2009\u00b1\u20094.7). LAG-3- and PD-1-expressing CD8+ T cells favored an EM phenotype with less than half the cells exhibiting a CM phenotype . CD8+ T cells expressing TIM-3 had significantly higher frequencies of CM cells compared to the other two IC-expressing CD8+ T cell subsets/populations (52.1%\u2009\u00b1\u20090.9). Distribution of memory subsets on IC-positive cells differed between CD4+ and CD8+ T cells themselves. There were significantly more CD4+ T cells bearing a CM phenotype in LAG-3 and PD-1-expressing populations compared to CD8+ T cells expressing LAG-3 and PD-1 cells. To further understand the difference in IC expression between CD4Over the last decade, several molecules have been shown to be expressed on T cells isolated from patients suffering from chronic viral infection or tumor burden. Poor immune function has been associated with these T cells, thus classifying them as being \u201cexhausted.\u201d Clinical studies evaluating blockade of individual IC molecules, such as PD-1, have shown promising results. In one trial, a response rate of 20\u201325% was reported for patients including those with renal cell carcinoma, melanoma, non-small cell lung carcinoma, and prostate cancer . In a se+ and CD8+ T cells has been reported, it has mainly been in the context of being a phenotypic indicator of T cell exhaustion , the data suggest that activated CD4+ T cells exhibit higher PD-1 expression compared to CD8+ T cells with comparably lower levels of TIM-3 expression, while the inverse expression pattern is observed on activated CD8+ T cells . Although the functional implications of these findings are beyond the scope of this report, results published by others have been mixed regarding expression of IC and T cell function. One study has shown that, in the context of Hepatitis B infection, inhibitory CD4+ T cells maintained high PD-1 expression with low TIM-3 targeting domains could be included in a therapeutic. Another strategy would be to administer different IC blockade (or agonist) to patients depending on their disease state, since kinetics of the immune response can drive upregulation or downregulation of various IC on different cell types. Further studies with different donors could contribute to a more comprehensive understanding of expression patterns and kinetics, which is undoubtedly required for optimal execution of therapeutics targeting IC. Differences in the kinetics and expression levels of these markers must be taken under careful consideration when designing drugs and biologics aimed to target specific ICs as they may favor certain T cell subsets over another, leading to a wide range of therapeutic outcomes.Overall, our NK cells \u201342; thusNS contributed to data generation and analysis and prepared the manuscript. BH, SS, and LB contributed to data generation and analysis. SS-M contributed to data generation and analysis and reviewed the manuscript.The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."} +{"text": "T lymphocytes (T cells) undergo metabolic reprogramming after activation to provide energy and biosynthetic materials for growth, proliferation and differentiation. Distinct T cell subsets, however, adopt metabolic programs specific to support their needs. As CD4 T cells coordinate adaptive immune responses while CD8 T cells become cytotoxic effectors, we compared activation-induced proliferation and metabolic reprogramming of these subsets. Resting CD4 and CD8 T cells were metabolically similar and used a predominantly oxidative metabolism. Following activation CD8 T cells proliferated more rapidly. Stimulation led both CD4 and CD8 T cells to sharply increase glucose metabolism and adopt aerobic glycolysis as a primary metabolic program. Activated CD4 T cells, however, remained more oxidative and had greater maximal respiratory capacity than activated CD8 T cells. CD4 T cells were also associated with greater levels of ROS and increased mitochondrial content, irrespective of the activation context. CD8 cells were better able, however, to oxidize glutamine as an alternative fuel source. The more glycolytic metabolism of activated CD8 T cells correlated with increased capacity for growth and proliferation, along with reduced sensitivity of cell growth to metabolic inhibition. These specific metabolic programs may promote greater growth and proliferation of CD8 T cells and enhance survival in diverse nutrient conditions. In vitro generated Th CD4 T cells are highly glycolytic, performing high rates of glycolysis and minimal fatty acid oxidation. In contrast, inducible CD4 regulatory T cells exhibit low rates of glucose uptake, with high rates of fatty acid oxidation Prior to activation, T lymphocytes (T cells) are quiescent and use only low rates of metabolism to fuel migration and homeostatic proliferation. Once activated by antigen presenting cells, CD4 and CD8 T cells proliferate rapidly and undergo environmentally directed differentiation into diverse effector cell populations. These effector cells optimize the immune response for specific pathogenic challenges. Activated CD4 T cells can differentiate into T helper (Th) subpopulations to combat bacterial or fungal infections, while activated CD8 T cells can differentiate into cytotoxic T cells to combat viral infections. Activation and the transition from na\u00efve to effector lymphocyte greatly alters cellular metabolic demands, as cells require both ATP and biosynthetic components to fuel growth, cell division, migration, and subset differentiation Activation-induced metabolic reprogramming events include elevated expression of metabolite transporters ex vivo and following activation. We demonstrate that activated CD4 lymphocytes have greater mitochondrial mass and are consistently more oxidative, while activated CD8s preferentially adopt a more glycolytic metabolism. This difference is associated with the faster growth and proliferative rates of activated CD8 T cells, along with reduced sensitivity of cell growth to metabolic inhibition.Here, we compare the metabolic programs of CD4 and CD8 lymphocytes both in vivo by stimulation of the TCR by MHC Class II presenting cognate antigen, while the TCR on CD8 T cells binds antigen presented on MHC Class I. These distinct ligands signal through the CD3 components of the TCR complex together with costimulatory molecules such as CD28 to trigger metabolic reprogramming, growth, proliferation, and differentiation in vitro, CD4 and CD8 T cells were isolated from the spleen and lymph nodes of C57BL/6 mice and then stimulated with plate-bound antibodies against CD3 and CD28 in the presence of IL-2. CD4 cells were depleted of CD25+ natural regulatory T cells prior to stimulation. After a 24 h lag period, the viable cell number of CD8 T cells began to rapidly increase. CD4 T cells, however, accumulated more slowly was similar between resting CD4 and CD8 cells; however, following stimulation CD8 T cells showed more rapid expression of CD25 (IL-2R\u03b1: CD25), which pairs with \u03b3c and IL-2R\u03b2 to form a high-affinity heterotrimeric IL-2 receptor The difference in proliferative response between CD4 and CD8 cells could arise from reduced surface expression of CD3, CD28, or IL-2 receptor on na\u00efve CD4 T cells. However, resting CD4 T cells were found to express slightly more CD3 and CD28 on their surface in comparison to CD8 T cells Fig. 2. ex vivo exhibit only a low oxygen consumption rate (OCR) and extra cellular acidification rate (ECAR) Fig. 3C.Oxidative metabolism and metabolic flexibility are constrained by mitochondrial oxidative capacity. The maximal respiratory capacity of stimulated CD4 and CD8 T cells were therefore compared. OCR was measured under basal conditions and following the addition of oligomycin (to reduce OCR to baseline by inhibiting ATP synthase), FCCP (to maximize OCR by uncoupling the electron transport chain (ETC) from ATP synthesis), and rotenone plus antimycin A (to block the ETC by inhibiting ETC complexes I and III). The maximal respiratory capacity after uncoupling by FCCP was significantly higher in activated CD4 T cells than in activated CD8 T cells Fig. 4A.CD4 and CD8 T cells were next examined to determine the ability of cells to utilize distinct metabolic fuels that may reflect differential degrees of metabolic flexibility. Nutrients were provided individually to previously activated CD4 and CD8 T cells and OCR was measured. Strikingly, CD8 T cells responded to glutamine with a higher OCR than CD4 T cells Fig. 4B.). Resting CD8 T cells had higher basal cell surface expression of Glut1. After 48 h activation, however, no differences in total or surface Glut1 levels could be detected between CD4 and CD8 T cells expression in CD4 T cells and an increase in HKI expression in CD8 T cells. In both cell types HKII and HKIII were strongly induced by CD3/CD28 activation, with both activated CD4 and activated CD8 T cells exhibiting similar total levels of HKII and HKIII Fig. 5C. top). CD4 T cells also exhibited higher staining with the potentiometric dye TMRE, both ex vivo and after activation. This suggests that in addition to elevated mitochondrial mass, CD4 cells have a greater mitochondrial membrane potential middle). Mitochondrial activity can lead to production of reactive oxygen species (ROS) and we also found that resting CD4 T cells had higher levels of staining with the ROS-sensitive dye, DCFDA, and that ROS further increased upon activation ( bottom). Together, our data show that while both CD4 and CD8 T cells reprogram their metabolism following activation, CD8 T cells preferentially adopt a highly glycolytic metabolism, while CD4 cells have greater degree of mitochondrial content and activity.To examine the mechanism of preferentially increased OCR and maximal respiratory capacity after CD4 T cell activation, mitochondrial mass and function were next assessed in each T cell lineage. The relative protein expression of cytochrome c and the OXPHOS mitochondrial complexes were examined in na\u00efve and stimulated CD4 and CD8 lymphocytes Fig. 6A.c plus unique accessory chains; however, they activate PI3K/Akt signaling to different extents, stimulate different JAK/STAT cascades and have different immunoregulatory functions When stimulated with a high dose of anti-CD3, anti-CD28 in the presence of IL-2, CD4 T cells have greater mitochondrial mass and produce more ROS than similarly stimulated CD8 T cells Fig. 6B.T cell priming is refined by both co-stimulatory and co-inhibitory signals from co-receptors. To examine if the metabolic differences between CD4 and CD8 T cells were influenced by co-stimulatory receptors beyond CD28, T cells were activated in the presence of anti-CD3, anti-CD28, plus either anti-4-1BB (CD137) or anti-OX40 (CD134). 4-1BB and OX40 are activation-induced co-receptors that can enhance T cell cytokine release, proliferation, and survival. Activated CD4 and CD8 cells express both receptors; however, 4-1BB stimulation acts chiefly on CD8 cells Collectively, these data demonstrate that while activated CD4 and CD8 T cells are metabolically different, activation-induced metabolic reprogramming in each population is fine tuned by both co-stimulatory and cytokine signals. Metabolic rewiring in both CD4 and CD8 T cells is, therefore, in part dictated by the activation environment but is also distinct due to cell-intrinsic differences between these cell populations.The distinct metabolic phenotypes of CD4 and CD8 T cells may promote specific functional responses. In particular, increased emphasis on glycolysis in CD8 cells may provide biosynthetic intermediates to promote rapid cell growth, while higher mitochondrial oxidative capacity of CD4 cells may allow the use of diverse fuels to efficiently generate ATP under metabolic stress. Prior to proliferation, T cell activation leads to a one-day lag phase in which lymphocytes grow in biomass The increased oxidative capacity of CD4 T cells may allow greater metabolic flexibility. The ability of CD4 and CD8 T cells to grow and proliferate was, therefore, tested with inhibition of glycolysis or electron transport. Isolated CD4 and CD8 T cells were cultured in IL-7 alone to maintain viability or stimulated with anti-CD3 and anti-CD28 for 48 h in the presence of increasing concentrations of either the glycolysis inhibitor 2-deoxyglucose (2-DG) or the mitochondrial complex I inhibitor rotenone. The viability of CD4 and CD8 cells was similarly affected by increasing inhibitor dose Fig. 9C,Na\u00efve CD4 and CD8 T cells perform low rates of oxidative metabolism to maintain survival, perform immunosurveillance, and undergo homeostatic proliferation. After activation, both CD4 and CD8 T cells reprogram towards a highly glycolytic metabolic program, generating energy and biosynthetic materials for rapid growth, proliferation and differentiation. Here we show that CD4 and CD8 T cells share many metabolic characteristics but have key differences that may allow CD8 T cells to rapidly proliferate. Importantly, activated CD8 T cells had a more glycolytic metabolism than CD4 T cells, while CD4 T cells had higher rates of mitochondrial oxidative metabolism and a greater maximal respiratory capacity. Functionally, CD8 T cells grew and proliferated faster than CD4 T cells, and activation-induced growth of CD8 T cells was more resistant to glycolytic inhibition.The finding that T cell subsets are metabolically distinct is consistent with a growing literature of metabolic state coordinating cell function and fate. Within the CD4 lineage, it was recently demonstrated that low doses of the mitochondrial ATP synthase inhibitor oligomycin could block activation-induced proliferation in vivo, where T cells are presented with antigens of varied avidity in the presence of varied cytokine milieus, oxygen tensions, and nutrient environments. Recent studies using nutrient transporter knockout T cells in vivo; however, metabolic comparison of in vivo reprogrammed CD4 and CD8 cells has not yet been performed. Metabolic inhibitors have been shown to suppress T cell responses in EAE, asthma, and graft versus host disease in vivo activation environment alters metabolic reprogramming in specific disease states.While there remained differences between CD4 and CD8 T cells irrespective of activation context, mitochondrial mass and ROS production in each population was dependent on both the strength of the activating stimuli and cytokine context. Metabolic reprogramming is therefore partially dictated by the environment and by co-stimulatory signals. This is likely to be important The signaling pathways that lead to distinct metabolic patterns in CD8 and CD4 T cells are unclear. T cell receptor expression and activation is similar in both subsets, suggesting that receptor proximal events are unlikely to lead to divergent metabolic programs. The metabolic reprogramming differences between these two populations may arise in part from subtle changes in the expression of key metabolic enzymes. CD4 T cells expressed more PKM2 than similarly stimulated CD8 cells. Pyruvate kinase is a central gatekeeper in directing the balance between oxidative and glycolytic metabolism in vitro and in vivo comparisons in vitro or in vivo using the pyruvate dehydrogenase kinase inhibitor dichloroacetate Many cell types adopt aerobic glycolysis as a metabolic strategy to fuel proliferation Collectively, the data presented here demonstrate that CD4 and CD8 T cells utilize distinct metabolic strategies to support specific functional demands. Following activation CD8 T cells had a higher glycolytic flux than CD4 cells, correlating with rapid cell growth. CD4 T cells also induced glycolysis upon activation, but had greater mitochondrial content and oxidative metabolism than CD8 T cells. These metabolic differences are likely fundamental to cellular functions and may provide new directions to selectively target or promote specific T cell subsets.All experiments were approved by the Institutional Animal Care and Use Committee at Duke University Medical Center (Protocol A260-11-10) and strictly followed the National Institutes of Health recommendations cited in the Guide for the Care and Use of Laboratory Animals. The Duke University Medical Center animal management program is accredited by the American Association for the Accreditation of Laboratory Animal Care.mycGlut1) have been described previously Mice expressing endogenous levels of myc-epitope tagged Glut1 . Where indicated cells were activated in the presence of 2-deoxyglucose (Sigma) or rotenone (Seahorse Bioscience).CD4+CD25- and CD8+ T cells were isolated from spleen and lymph nodes to \u226590% purity by magnetic bead negative selection (Miltenyi Biotec). Cells were cultured in RPMI 1640 (MediaTech) supplemented with 10% FBS (Gemini BioProducts), penicillin-streptomycin (Gibco), L-glutamine (Gibco), and 50 \u00b5M \u03b2-ME (Sigma). Where indicated, cells were maintained in a quiescent, viable state using 10 ng/ml IL-7 (eBioscience). Alternatively, cells were stimulated on plates coated with 10 \u00b5g/ml anti-CD3 (clone 2C11) and 10 \u00b5g/ml anti-CD28 (both eBioscience) in the presence of 20 ng/ml IL-2 (Novartis), with a starting density of 0.5\u20131.5\u00d710myc was stained with mouse anti-myc followed by rat anti-mouse IgG-PE (eBioscience). Mitochondrial content was determined by labeling cells with mitotracker green or Deep Red FM . Reactive oxygen species were assessed by labeling cells with dichlorodihydrofluorescein . Mitochondrial membrane potential was assessed using tetramethylrhodamine ethyl ester . Cell cycle status was assessed by treating methanol fixed cells with RNAse and then labeling DNA with propidium iodide . Viable cell number was determined flow cytometrically by propidium iodide exclusion (1 \u00b5g/ml PI). Proliferation was assayed by flow cytometry of carboxyfluorescein succinimidyl ester labeled cells. Alternatively, proliferation and viability were assayed simultaneously by co-staining cells with CellTrace Violet and 1 \u00b5g/ml PI. Cell size was determined by assessment of the visible light forward scatter of PI-excluding cells. Data were acquired on a MacsQuant cytometer (Miltenyi Biotec) and analyzed using FlowJo software (TreeStar).To confirm isolation purity cells were labeled with anti-mouse CD4-eFluor 450, CD8- phycoerythrin. Cy5.5, and Thy1.2- fluorescein isothiocyanate (FITC) . Exofacially tagged Glut1Immunoblotting was performed as described previously Oxygen consumption rate (OCR) and extracellular media acidification rate (ECAR) were measured using a XF24 extracellular flux analyzer (Seahorse Bioscience), as described Statistical analyses were performed with Prism software (GraphPad) by student\u2019s T test or two-way ANOVA. Following ANOVA significant differences were identified by \u0160id\u00e1k multiple comparisons test. Expansion index was calculated using FlowJo software (Treestar). Data shown are mean \u00b1 standard deviation, statistically significant results are indicated (* p<0.05)."} +{"text": "The inhibitory receptors programmed cell death-1 (PD-1) and T cell immunoglobulin and mucin domain 3 (Tim-3) are well known inhibitory molecules that play a crucial role in regulating CD8+ T cell activation or tolerance. Here, we demonstrate that the co-expression of PD-1 and Tim-3 on CD8+ T cells is up-regulated in AS patients. PD-1+ Tim-3+ CD8+ T cells are enriched for within the central T (TCM) cell subset, with high proliferative activity and CD127 expression. Co-expression of PD-1 and Tim-3 on CD8+ T cells is associated with increased anti-atherogenic cytokine production as well as decreased pro-atherogenic cytokine production. Blockade of PD-1 and Tim-3 results in a decrease of anti-atherogenic cytokine production by PD-1+ Tim-3+ CD8+ T cells and in an augmentation of TNF-\u03b1 and IFN-\u03b3 production. These findings highlight the important role of the PD-1 and Tim-3 pathways in regulating CD8+ T cells function in human AS.T cell-mediated immunity plays a significant role in the development of atherosclerosis (AS). There is increasing evidence that CD8 Atherosclerosis (AS), a chronic inflammatory disease , is cons+ T cells were the focus of interest because they are the predominant T cell type in mouse atherosclerotic lesions[+ T cells in AS has been less investigated. It was recently shown that advanced human atherosclerotic plaques contain activated CD8+ T cells [+ T cells in AS have shown contradictory results. CD8+ T cells have been shown to be more frequent in early lesions and to have anti-atherogenic effects [+ T cells have also been shown to be important in fully established atherosclerotic plaques [+ T cells have a minor role in the progression of AS [+ T cells have different effects on the development of AS [For many years, CD4c lesions. While t T cells ,8. Howev effects ,10. CD8+ plaques and to h plaques . While son of AS ,14. Recent of AS .+ T responses in a variety of disease conditions. Among these molecules, programmed cell death-1 (PD-1) and T cell immunoglobulin and mucin domain 3 (Tim-3) have attracted the most attention. PD-1 was identified as a marker for T cell exhaustion, and blockade of PD-1 signaling in most cases has shown to revert the dysfunctional state of exhausted CD8+ T cells [+ T cells function, and Tim-3 blockade can restore proliferation and cytokine production of Tim-3+ CD8+ T cells [+ T cells identifies a most severely exhausted CD8+ T cell subset, and combined blockade of PD-1 and Tim-3 pathways has been shown to be the most powerful way to restore the function of exhausted CD8+ T cells [Co-inhibitory molecules are important regulators of CD8 T cells ,17. Tim- T cells ,19. The T cells ,21. Only T cells ,23,24.+ T cells in human AS has not been previously explored. We hypothesized that co-expression of PD-1 and Tim-3 would demarcate particularly regulatory CD8+ T cells associated with AS. To test this hypothesis, we investigated PD-1 and Tim-3 expression on lymphocytes in the context of AS. In particular, we used detailed surface and intracellular phenotype analyses as well as multifunctional assays to study the role of Tim-3 and PD-1 signaling pathways in regulating CD8+ T cell function in AS.To our knowledge, the functional regulation of PD-1 and Tim-3 on CD8The study group comprised 28 healthy people with LS columns following the manufacturer\u2019s instructions. CD8+T purity was 96.8\u00b17.8% as determined by flow cytometry (FCM) with FITC-CD8.Blood mononuclear cells were isolated from samples of the femoral artery and peripheral blood of AS patients and healthy individuals. Whole blood containing acid citrate dextrose anticoagulant was carefully layered over an equal volume of Ficoll density gradient medium. Tubes containing the blood and Ficoll were centrifuged for 20 min at 2000 rpm. Isolated arterial blood mononuclear cells (ABMCs) and peripheral blood mononuclear cells (PBMCs) were washed two times in phosphate-buffered saline (PBS) and centrifuged for 10 min at 1200 rpm, and cultured in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum , 100 U/ml penicillin, 100 \u03bcg/ml streptomycin, and 1\u03bcg/ml amphotericin B at 37\u00b0C in 95% air and 5% CO+ T cells were cultured (5\u00d7105 per well) in the presence of 10 \u03bcg/ml anti-Tim-3 , anti-PD-L1 , anti-Tim-3 plus anti-PD-L1, or isotype control. After 48 h, the culture supernatant was collected and further analyzed by FCM.Arterial CD8For intracellular cytokine analysis, brefeldin A (a Golgi inhibitor) was used for 4h (at the end of the culture) to block the secretion of cytokines into the media after the activation of cells by phorbol 12-myrstate 13-acetate (PMA) and ionomycin . Cells were harvested and analyzed by FCM for intracellular cytokine production.Cell surface molecular expression and intracellular cytokine production were evaluated using FCM. FITC-conjugated anti-human CD8, CD11c, or CD3, PE-conjugated anti-human Tim-3 or GATA-3, PE/CY7-conjugated anti-human CD4, CD14, CD16, CD69, CD45RO, CD62L, IL-10, TNF-\u03b1 or TGF-\u03b2, APC-conjugated anti-human PD-1 or IFN-\u03b3, Brilliant Violet 421-conjugated anti-human CD127, CD44, IL-4, T-bet or Ki67 were used. For intracellular staining, cells were fixed and permeabilized using a Fix/Perm kit . FCM analysis was performed on a Beckman-Coulter CyAN ADP flow cytometer and analyzed with FlowJo software .The significance of differences between two groups was determined by the post hoc Dunnett t test. Multiple groups were analyzed with GraphPad Prism version 5 by one-way or two-way ANOVA with Bonferroni post hoc t tests. For all statistical tests, a p value <0.05 was considered statistically significant.- Tim-3- cells were decreased in AS patients. Among these immune cells, CD8+ T cells demonstrated the most significant up-regulation of Tim-3 and PD-1. We also compared PD-1 and Tim-3 expression on arterial and peripheral blood lymphocytes form the same donors, and found that the PD-1 and Tim-3 expression levels were accordant in blood form local artery and peripheral vein and effector memory [+ Tim-3+, PD-1+ Tim-3-, PD-1- Tim-3+, and PD-1- Tim-3- CD8+ T cells in AS. The PD-1+ Tim-3+ population contained the largest fraction of central memory cells, but the lowest fraction of effector memory cells and memory markers (CD45RO) but higher CD127 than PD-1-Tim-3-T cells . We founry cells . Ki-67 i-T cells . But co-or CD127 .+ T cells in AS exhibited an anti-atherogenic phenotype, fresh isolated ABMCs from local lesional arteries were stimulated with PMA/Ionocymin for 12 h, then stained for CD8 expression, and finally examined for production of pro-atherogenic cytokines (INF-\u03b3 and TNF-\u03b1) and an anti-atherogenic cytokines (IL-10). We found that PD-1+ Tim-3+ CD8+ T cells are associated with decreased pro-atherogenic cytokines but increased anti-atherogenic cytokines [+ T cells following single or combined antibody blockade . We founblockade . We alsoblockade .+ T cells in AS both within the lesional arterial and peripheral venous lymphocytes. Interestingly, the dual expression of PD-1 and Tim-3 on CD8+ T from AS patients was higher than that on CD8+ T cells from healthy individuals both in local arterial and peripheral venous cells, while PD-1- Tim-3- CD8+ T cells were less abundant in AS. Notably, the co-expression of PD-1 and Tim-3 was associated with TCM phenotype and increased anti-atherogenic cytokine production but decreased pro-atherogenic cytokine production by CD8+ T cells from the lesional arterial blood. We further showed that targeting PD-1 and Tim-3 signaling pathways in CD8+ T cells resulted in a decrease in anti-atherogenic cytokine production and in an augmentation in the generation of pro-atherogenic cytokines. These findings, for the first time, highlight the important roles that PD-1 and Tim-3 signaling pathways may play in the regulation of CD8+ T cells function in AS.In the present study, we verified the expression of PD-1 and Tim-3 on CD8+ T cells in AS remains unclear, since contradictory effects of this cell on AS have been reported[+ T cells have different effects on AS may explain this paradox. Although CD8+ effector cytotoxic T lymphocytes promote the development of AS[+ CD25+ T cells has been shown to reduce atherosclerotic lesions[+ CD28high and CD8+ CD25+ T cells can reduce neointima formation after arterial injury [+ Tim-3+ CD8+ T cells are the most severely exhausted CD8+ T cell subset, and combined blockade of ligand-receptor interactions by PD-1 and Tim-3 can restore the function of exhausted CD8+ T cells[+ T cells in human atherosclerotic lesions [+ T cell athero-protective effects, and PD-1+ Tim-3+ CD8+ T cell \u201cexhausted\u201d phenotype, led us to investigate this particular T-lymphocyte subset in human AS.The role of CD8 reported,12,13, ient of AS,12, the c lesions. Furtherl injury ,30. PD-1+ T cells,21. The -/-mice [+ T cells in AS both in lesional arterial and peripheral venous blood. So we wondered whether the Tim-3 and PD-1 signaling pathways are involved in the regulation of CD8+ T cell function in AS. Based on the variable expression of CD44 and CD62L, CD8+ T cells can be divided into two subsets, TCM (CD44+CD62L+) and TEM (CD44+CD62L-)[+ TCM cells but the lowest fraction of CD8+TEM cells were PD-1+ Tim-3+, while the largest fraction of CD8+ TEM cells but the lowest fraction of CD8+ TCM cells were PD-1- Tim-3-. CD8+ TCM cells are less cytolytic and exhibit increased ability of self-renewal compared to CD8+ TEM cells[+ Tim-3+ CD8+ T cells proliferated more than PD-1- Tim-3- CD8+ T cells. This is contrary to what has been observed in chronic viral infection[+ Tim-3+ CD8+ T cells in AS. Further phenotypic profiling demonstrated that these cells expressed less activation and memory markers but higher CD127 than PD-1-Tim-3-CD8+ T cells. CD127 is well known to be lost in exhausted T cells during chronic viral infection[+ Tim-3+ CD8+ T cells, we presume that the co-expression of PD-1 and Tim-3 on CD8+ T cells in AS could not be simply regarded as an \u201cexhausted\u201d marker. Further research in needed to explore the exact mechanism that formation the unique phenotype of PD-1+Tim-3+CD8+T cells in AS.PD-1 is a member of B7 family on T cells . Althoug-/-mice ,32, the 4+CD62L-). We founTEM cells,34,35. Cinfection.We specuinfection. But we + and Tim-3+ CD8+ T cells generate more anti-atherogenic cytokines and less pro-atherogenic cytokines than single or negative CD8+ T cells. Single targeting of the Tim-3 and PD-1 pathways has variable effects on the function of CD8+ T cells from the lesional arterial blood, whereas combined targeting of these pathways is highly effective in enhancing pro-atherogenic cytokine and reducing anti-atherogenic cytokine production by PD-1+ Tim-3+ CD8+ T cells from the lesional arterial blood, as well as their respective transcription factors but not affects cells viability (data not shown). Therefore, we hypothesize that higher expression levels of PD-1 and Tim-3 is a physiological response to the atherosclerotic environment. The expression of Tim-3 and PD-1 by CD8+ T cells may be important, at least in part for preservation of AS from deteriorating. However, whether it is the atherosclerotic microenvironment that shapes the distinct CD8+ T subset and that which differentiates CD8+ T cells in this specific microenvironment still needs to be further determined.Chronic inflammation is an important factor during the development of AS. Pro-inflammatory cytokines such as IFN-\u03b3 and TNF-\u03b1 can enhance lesion development, while anti-inflammatory cytokines such as IL-10 have a protective role in AS. Double-+ Tim-3+ CD8+T cells, and that blockage of Tim-3 and PD-1 pathways can suppress the generation of IL-4. While the exact role of IL-4 in AS is still unclear[+ PD-1+ CD8+ T cells plays a similar role as does IL-10. TGF-\u03b2 is a potent anti-inflammatory and anti-atherogenic cytokine[+ T cells. In addition, interference of PD-1 and Tim-3 signaling also has no effect on its production. It has been reported that TGF-\u03b2 has an opposite effect on PD-1 and Tim-3 expression[We also observed more IL-4 production by PD-1l unclear, given il unclear, we susp cytokine, but we xpression; however+ T is up-regulated in human AS, and that this distinct CD8+ T cell subset cannot be simply regarded as an exhausted subset. PD-1+ Tim-3+ CD8+ T cells from the lesional arterial blood produced more anti-atherogenic cytokines, and blockade of PD-1 and Tim-3 signaling pathways aggravated the pro-inflammatory Th1 responses predominate in AS. This knowledge should be considered to add further information regarding risk of AS since PD-1 and Tim-3 are the targets of new therapies for chronic viral infections. Moreover, since single blockade of PD-1 and Tim-3 has been shown to augment atherosclerotic lesion development in experimental AS[Our data demonstrate, for the first time to our knowledge, that the co-expression of PD-1 and Tim-3 on CD8mental AS,23,24, aS1 Fig+ T cells from healthy individuals (NCD8+T) (n = 10) were stained with antibodies against CD44 and CD62L to determine their differentiation phenotype (see + Tim-3+ and PD-1-Tim-3-cells within each population. (B) Quantification of Ki67 staining in PD-1+ Tim-3+ and PD-1- Tim-3- CD8+ T cells; n = 10. (C) CD8+ T cells from venous blood of healthy individuals were stained with antibodies against PD-1, Tim-3, CD45RO, CD69, and CD127, and the PD-1+ Tim-3+ and PD-1-Tim3-phenotypes were compared (n = 10). Horizontal bars denote means. *P<0.05; *** P<0.001, compared with the PD-1+ Tim-3+ group.(A) CD8type see . Percent(PDF)Click here for additional data file.S2 Fig+ Tim-3+, PD-1+ Tim-3-, PD-1- Tim-3+, and PD-1- Tim-3- CD8+ T cells in AS; n = 18. Data represent mean \u00b1 SEM. * P<0.05; compared with the PD-1+ Tim-3+ group.Quantification of flow cytometric analysis of IL-4 (A) and TGF-\u03b2 (B) in PD-1(PDF)Click here for additional data file.S3 Fig+ T cells cultured for 48 h in the presence or absence of anti-Tim-3 antibody (10 \u03bcg/ml), anti-PD-L1 antibodies (10 \u03bcg/ml), or both anti-Tim-3 and anti-PD-L1. Data represent mean \u00b1 SEM (n = 16). CD8+ T cells from the lesional artery. *P<0.05, compared with the control group.Quantification of flow cytometric analysis of IL-4 (left) and TGF-\u03b2 (right) production by CD8(PDF)Click here for additional data file."} +{"text": "The rate at which HIV-1 infected individuals progress to AIDS is highly variable and impacted by T cell immunity. CD8 T cell inhibitory molecules are up-regulated in HIV-1 infection and associate with immune dysfunction. We evaluated participants (n = 122) recruited to the SPARTAC randomised clinical trial to determine whether CD8 T cell exhaustion markers PD-1, Lag-3 and Tim-3 were associated with immune activation and disease progression. Expression of PD-1, Tim-3, Lag-3 and CD38 on CD8 T cells from the closest pre-therapy time-point to seroconversion was measured by flow cytometry, and correlated with surrogate markers of HIV-1 disease and CD4 T cell count) and the trial endpoint . To explore the functional significance of these markers, co-expression of Eomes, T-bet and CD39 was assessed. Expression of PD-1 on CD8 and CD38 CD8 T cells correlated with pVL and CD4 count at baseline, and predicted time to the trial endpoint. Lag-3 expression was associated with pVL but not CD4 count. For all exhaustion markers, expression of CD38 on CD8 T cells increased the strength of associations. In Cox models, progression to the trial endpoint was most marked for PD-1/CD38 co-expressing cells, with evidence for a stronger effect within 12 weeks from confirmed diagnosis of PHI. The effect of PD-1 and Lag-3 expression on CD8 T cells retained statistical significance in Cox proportional hazards models including antiretroviral therapy and CD4 count, but not pVL as co-variants. Expression of \u2018exhaustion\u2019 or \u2018immune checkpoint\u2019 markers in early HIV-1 infection is associated with clinical progression and is impacted by immune activation and the duration of infection. New markers to identify exhausted T cells and novel interventions to reverse exhaustion may inform the development of novel immunotherapeutic approaches. After being infected with HIV, the pace of disease progression is highly variable between individuals. Some stay well with functioning immune systems for many years, whilst others progress to AIDS quickly. Understanding the factors that underpin these differences is important and may relate to factors such as viral adaptation and immune exhaustion. Recently, there has been interest in certain molecules\u2014called \u2018exhaustion\u2019 or \u2018immune checkpoint\u2019 markers\u2014which reflect how well the immune system functions. Recent trials show that therapies directed against these molecules can improve anti-cancer immunity. It is known from laboratory experiments that these markers are abundant in HIV infection suggesting that the human immune response to HIV is not fully effective. The relevance of these markers in patient cohorts remains unclear. This study measures three exhaustion markers\u2014PD-1, Tim-3, Lag-3 \u2013in individuals with HIV recruited to a randomised controlled trial of therapy in early HIV infection called SPARTAC. We find a complex picture in which these markers alone, together and in combination with other markers that reflect T cell activation (CD38) help predict the speed of clinical progression and immune decline, with differing effects dependent on the duration of infection. We propose that therapies directed against these markers could impact disease progression, vaccine efficacy or even newer curative strategies. Following infection with Human Immunodeficiency Virus Type 1 (HIV-1) the rate at which an individual develops AIDS is highly variable ranging from \u2018progressors\u2019 who, if untreated, experience rapid CD4 T cell decline in months to years to \u2018elite controllers\u2019, who spontaneously maintain undetectable plasma viraemia, often for decades. The tempo of HIV-1-associated disease progression might rest with particular characteristics of HLA class I molecules and the CD8 T cell immune responses which they dictate . When a We sought to determine whether, in primary HIV-1 infection (PHI), these indicators of CD8 T cell exhaustion would correlate with surrogate markers of disease , CD4 T cell count) and actual time to progression within a strictly defined patient population enrolled into a randomized clinical trial of early antiretroviral therapy (ART). In particular, we wanted to study exhaustion in activated CD38 CD8 positive T cell populations, as CD38 expression has also been correlated with disease progression. We found significant associations between ICR expression and both pVL and disease progression, and an enhanced effect when co-expressed on activated T cells.10 RNA copies/ml, respectively, without significant differences in participants enrolled \u2264 or > 12 weeks into PHI.366 participants were enrolled into the SPARTAC trial. Of 156 The expression of PD-1, Tim-3 and Lag-3 on the surface of CD8 T cells and the subset of activated CD8 T cells that co-expressed CD38 was determined by flow cytometry Fig A in and was Correlations between the expression of ICRs on CD8 and CD38 CD8 T cells with CD4 T cell count, pVL and time since seroconversion were assessed . PD-1 anNext we evaluated PD-1, Lag-3 and Tim-3 expression and progression to the SPARTAC trial primary endpoint (either CD4 T cell count <350 cells/\u03bcl or (re)initiation of ART). PD-1 expression at baseline on CD8 and CD38 CD8 T cells predicted clinical progression . This efCox proportional hazards models were used to explore further the association between baseline PD-1 expression on bulk CD8 T cells and clinical progression . The assCox models also demonstrated an effect of bulk CD8 T cell Lag-3 expression on progression when adjusted for ART initiation and CD4 T cell count , but not when including pVL . As for Interestingly, on restricting the Cox models to CD38 CD8 T cells, all three markers were associated with disease progression in unadjusted models or when correcting for ART and CD4 T cell count although, again, not when adjusting for baseline pVL .Having explored the impact of single exhaustion markers on clinical outcome, we next measured whether their co-expression would predict progression Fig D in . In survIn Cox proportional hazards models, there was a strong association with high PD-1/Tim-3 expression on CD8 T cells (above the median) with faster progression (HR 1.64 (95% CI 1.04. 2.60); p = 0.034), after adjusting for baseline CD4 T cell count, ART and pVL. The significant Kaplan-Meier analysis for PD-1/Lag-3 co-expression was not supported by Cox models when adjusting for baseline pVL.CM), effector memory (TEM) and TEMRA constituted 14.1, 4.4, 49.6 and 25.9% of the CD8 T cell population, respectively .Having determined associations between PD-1, Tim-3 and Lag-3 expression and clinical progression, we next identified the CD8 T cell memory subsets on which these markers were present Fig E in . We analectively . PD-1 andim/Eomeshi are associated with an exhausted functional phenotype with reduced polyfunctionality. ,34. 33,3Tim-3 expression showed distinct associations with clinical disease progression and may even be antagonistic to PD-1 early in HIV-1 infection; Tim-3 was associated with delayed progression in participants identified within 12 weeks of seroconversion, but no effect was seen for Tim-3/PD-1 co-expression. This protective Tim-3 effect was not seen for individuals recruited later than 12 weeks after seroconversion, for whom PD-1/Tim-3 co-expression was disadvantageous. The mechanism of the immuno-regulatory effect of Tim-3 is not clear , but thiEM memory subset. Further in depth longitudinal analyses of these responses in HIV-1 specific T cell populations in conjunction with their activation status will be needed to confirm our findings. Secondly, other investigators have suggested that in acute HIV-1 infection PD-1 expression does not necessarily equate to exhaustion , PD-1 APC 0.5 \u03bcg/100\u03bcl (MIH4)[eBioscience], Tim-3 PE 0.05 \u03bcg/100\u03bcl (344823)[R&D], Lag-3 FITC 2 \u03bcg/100\u03bcl (17B4)[LifeSpan Bioscience] and CD38 PE-Cy7 0.4 \u03bcg/100\u03bcl (HIT-2)[Biolegend]. The isotype controls for Lag-3 was IgG2a isotype FITC 0.4 \u03bcg/100\u03bcl (C45)[AdB serotech], for PD-1 was IgG1 isotype APC 0.4 \u03bcg/100\u03bcl (p3)[eBioscience] and for Tim-3 was IgG2a isotype PE 0.4 \u03bcg/100\u03bcl (R35-95)[BD Bioscience]. Cell population gating was performed based on mean fluorescence intensity \u201cminus one\u201d (FMO) and unstAnalyses examining ICR expression on T cell memory subsets used cryopreserved PBMCs from the HEATHER cohort. Cells were stained in BD Horizon Brilliant Stain Buffer (BD) containing all antibodies and Live/Dead Near IR at 1 in 300 dilution (Life Technologies) in 96 well-V bottom plates at 4\u00b0C. PBMCs were stained with the following antibodies: CD3 Brilliant Violet (BV) 570 0.16 \u03bcg/100\u03bcl (UCHT1), CCR7 Pacific Blue 1.8 \u03bcg/100\u03bcl (G043H7)[BioLegend], CD4 BV 605 0.05 \u03bcg/100\u03bcl (RPA-T4), CD8 BV 650 0.012 \u03bcg/100\u03bcl (RPA-T8)[BD], PD-1 PE eFluor 610 0.2 \u03bcg/100\u03bcl (eBioJ105), Lag-3 PE-Cy7 0.024 \u03bcg/100\u03bcl (3D5223H), CD45RA FITC 0.4 \u03bcg/100\u03bcl (HI100)[eBioscience] and Tim-3 PE (as above).CM as CD45RA-/CCR7+, TEM defined as CD45RA-/CCR7- and TEMRA as CD45RA+/CCR7-. and CD38 AlexaFluor 700 0.1 \u03bcg/100\u03bcl (HB-7)[BioLegend]. Fixation and permeabilisation were performed with Foxp3 Buffer Set (BD) as per manufacturer\u2019s instructions in reduced volumes to facilitate staining in 96-well plates. Staining of intracellular epitopes was performed at room temperature in PBS containing 0.5% BSA and 0.1% sodium azide with antibodies to CD3, CD4, CD8 (as above), and T-bet FITC 2 \u03bcg/100\u03bcl (4B10)[BioLegend] and Eomes eFluor660 0.024 \u03bcg/100\u03bcl (WD1928)[eBioscience]. All samples were acquired on a LSR II (BD). Data were analysed using FlowJo Version 10.8.0r1 (Treestar). Na\u00efve T cells were defined as CD45RA+/CCR7+, TAssociations between T cell exhaustion markers on CD8 and CD38 CD8 positive cells and pVL or CD4 T cell count were evaluated using Spearman correlations. The fitted line, superimposed in the relevant scatterplots, was estimated through linear regression. When multiple markers were tested for correlations with other variables (e.g. baseline CD4 T cell count or HIV-1 RNA), the adjusted overall critical p-values were also reported. Adjustments were performed using the method of Simes targetinIn the analyses from the HEATHER cohort, comparison of exhaustion marker expression across three or more groups was performed using Friedman\u2019s test . Where a difference was found, subsequent pairwise comparisons between groups (Dunn\u2019s test) were performed with adjustment for multiple comparisons targeting on overall significance level of 0.05. Expression of exhaustion markers between two T cell subsets was compared using Wilcoxon matched-pairs signed rank test. Statistical analyses were performed using GraphPad Prism 6.0f.S1 TextTable A. Summary of log rank test results from Fig D in Table B. Demographic and clinical characteristics of participants in the HEATHER trial included in the analyses. Table C. Correlations of PD-1, Tim-3, Lag-3, PD1/Tim-3, PD1/Lag-3 and Tim-3/Lag-3. Table D. Cox Model adjusted for Tim-3, PD-1, Lag-3, baseline CD4 and ART. Fig A. Gating strategy: proportion of the total CD8 T cell population that express PD-1, Tim-3, Lag-3 or CD38. Fig B. Expression of PD-1, Tim-3 and Lag-3 on CD8 T cells in healthy controls and Primary HIV Infection. Fig C. Impact of Tim-3 and Lag-3 expression on CD38 CD8 T cells on clinical outcome. Fig D. Impact of co-expression at baseline on CD8 T cells of PD-1, Tim-3 and Lag-3 on clinical outcome. Fig E. Gating strategy used for the characterisation of PD-1, Tim-3 and Lag-3 on memory subsets. Fig F. Correlation of CD39 expression with PD-1, Lag-3 and Tim-3.(DOCX)Click here for additional data file."} +{"text": "The blockade of CD160/CD160-ligand interaction restored CD8 T-cell proliferation capacity, and the extent of restoration directly correlated with the ex vivo proportion of CD160+ CD8 T cells suggesting that CD160 negatively regulates TCR-mediated signaling. Furthermore, CD160 expression was not up-regulated upon T-cell activation or proliferation as compared to PD-1. Taken together, these results provide evidence that CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression.Expression of co-inhibitory molecules is generally associated with T-cell dysfunction in chronic viral infections such as HIV or HCV. However, their relative contribution in the T-cell impairment remains unclear. In the present study, we have evaluated the impact of the expression of co-inhibitory molecules such as 2B4, PD-1 and CD160 on the functions of CD8 T-cells specific to influenza, EBV and CMV. We show that CD8 T-cell populations expressing CD160, but not PD-1, had reduced proliferation capacity and perforin expression, thus indicating that the functional impairment in CD160 T-cell immune response is regulated by a variety of molecules known as co-inhibitory receptors. The over expression of co-inhibitory receptors has been observed in several chronic viral infections such as HIV disease, and is found to be associated with severe T-cell dysfunction. Recent studies have demonstrated that the co-expression of several co-inhibitory receptors correlated with greater impairment of CD8 T cells. However, the relative contribution of individual co-inhibitory receptors to the regulation of T-cell functions remains unclear. In order to shed light on these issues, we have evaluated the influence of the expression of 3 major co-inhibitory receptors such as PD-1, 2B4 and CD160 on CD8 T-cell functions such as proliferation, cytokines production and expression of cytotoxic granules. We demonstrate that CD160-associated CD8 T-cell functional impairment is independent of PD-1 expression and that the blockade of CD160 signaling may partially restore CD8 T-cell functions. Co-stimulatory and co-inhibitory molecules play a major role in the regulation of antigen-specific T-cell responses Co-stimulatory/co-inhibitory molecules are commonly divided into 4 families: 1) the B7 family including CD28, Cytotoxic T-lymphocyte associated protein-4 (CTLA-4), Programmed Death receptor-1 (PD-1), Inducible T-cell Costimulator (ICOS) and B- and T-lymphocyte attenuator (BTLA), 2) TNF-\u03b1 receptor family including CD27, 3) the CD2/SLAM family, including Signaling Lymphocyte Activation Molecule (SLAM), 2B4 and CD48 and 4) the immunoglobulin (Ig) family including T-cell Immunoglobulin mucin-3 (TIM-3), lymphocyte Activation Gene-3 (LAG-3) and CD160 During the past decade, many studies performed in mice and humans have underscored the role of co-inhibitory molecules in the functional impairment of antigen-specific T cells during chronic viral infections such as human immunodeficiency virus-1 (HIV-1) or hepatitis C virus (HCV) Recent studies have demonstrated that HIV-specific CD8 T cells co-expressing several co-inhibitory molecules such as PD-1, CD160 and 2B4 were significantly more functionally impaired than CD8 T cells expressing only one co-inhibitory molecule + CD8 T cells had reduced proliferation capacity, IL-2 production and perforin expression regardless of PD-1 expression thus providing evidence that CD160-associated T-cell impairment is independent of PD-1.In the present study, we evaluated the impact of the expression of co-inhibitory molecules such as 2B4, PD-1 and CD160 on CD8 T-cells specific to influenza (Flu), Epstein Barr virus (EBV) and cytomegalovirus (CMV). We demonstrated that CD160ex vivo using peptide-MHC class I multimer complexes showed that CMV and EBV-specific CD8 T cells expressed significantly higher levels of 2B4 and CD160 as compared to Flu-specific CD8 T cells (+CD160+PD-1+ and 2B4+CD160+PD-1\u2212 cells were significantly higher in CMV and EBV-specific CD8 T cells than in Flu-specific CD8 T cells (P<0.025) .The expression of PD-1, 2B4, and CD160 co-inhibitory molecules was assessed by multiparametric flow cytometry in CMV-, EBV- and Flu-specific CD8 T cells from 22 healthy individuals omplexes . The gatomplexes . The use T cells . Interes T cells . HoweverP<0.025) . Of noteP<0.025) . Flu-speulations . Interesex vivo frequency of virus-specific CD8 T cells (measured by MHC class I multimer staining). The representative flow cytometry profiles and the cumulative data showed that the proliferation index of Flu-specific CD8 T cells was significantly higher than that of EBV and CMV-specific CD8 T cells . We thenctively) . In addiulations . These d+CCR7+) were excluded from the analysis. Cell populations were then stimulated with peptides in the presence of antigen presenting cells (CD8-depleted PBMCs) for 6 days . The representative flow cytometric profiles as well as the cumulative data show that the proliferation capacity of virus-specific 2B4+CD160+PD-1+, 2B4+CD160+PD-1\u2212, 2B4+CD160\u2212PD-1+, 2B4+CD160\u2212PD-1\u2212 CD8 T-cell populations was significantly reduced as compared to 2B4\u2212CD160\u2212PD-1+ and 2B4\u2212CD160\u2212PD-1\u2212 CD8 T-cell populations (P<0.05) (+CD160\u2212PD-1\u2212 and 2B4\u2212CD160+PD-1+ CD8 T cells was not significantly different (P\u200a=\u200a0.0628) . Of note\u200a0.0628) . These d+CCR7+) were excluded from the analysis. Cell populations were then stimulated with coated anti-CD3 and anti-CD28 MAbs for 6 days, and the proliferation capacity was assessed using CFSE flow cytometry based assay (P<0.05) (+CD160+PD-1+ and 2B4+CD160+PD-1\u2212 CD8 T cells was not significantly different (P\u200a=\u200a0.6786), suggesting that CD160-expessing CD8 T cells are endowed with reduced proliferation capacity, independently of PD-1 expression.To determine the intrinsic CD8 T-cell proliferation capacity, CD8 T-cell populations were sorted based on PD-1, 2B4 and CD160 expression. Of note, na\u00efve CD8 T cells (CD45RAed assay . The rep(P<0.05) . Interes+CCR7+) was excluded from this analysis. The representative flow cytometric profiles as well as the cumulative data showed that the frequencies of IL-2 and IFN-\u03b3-producing cells were significantly reduced in CD160+ CD8 T-cell populations as compared to CD160\u2212 CD8 T-cell populations (P<0.05) and between 2B4+CD160\u2212PD-1+ and 2B4+CD160\u2212PD-1\u2212 CD8 T-cell populations (\u2212CD160\u2212PD-1+ CD8 T-cell populations contained higher frequencies of IL-2-producing cells than any other CD8 T-cell population (P<0.05) (In chronic virus infections the loss of CD8 T-cell proliferative capacity is commonly associated with a progressive reduction of IL-2 production (P<0.05) . The frectively) . In addi(P<0.05) , demonst\u2212CCR7+) was significantly enriched in 2B4\u2212CD160\u2212PD-1\u2212 and 2B4\u2212CD160\u2212PD-1+ CD8 T-cell populations, the effector memory compartment was significantly enriched in PD-1+ CD8 T-cell populations and the terminally differentiated effector memory compartment was significantly enriched in the 2B4+CD160+PD-1\u2212 CD8 T-cell population . These d+CD160+PD-1+ and 2B4+CD160+PD-1\u2212 CD8 T-cell populations were enriched in perforin or granzyme B. Indeed, cytotoxic CD8 T cells exert their antiviral activity primarily through the secretion of cytotoxic granules containing perforin and granzymes +CCR7+) was excluded from this analysis. As shown in the representative flow cytometric profiles and the cumulative data perforin and granzyme B were significantly enriched in 2B4+ CD8 T-cell population as compared to 2B4\u2212 CD8 T-cell populations (P<0.05) . However, perforin expression was significantly reduced in 2B4+PD-1+CD160+, 2B4+PD-1\u2212CD160+ and 2B4+PD-1+CD160\u2212 CD8 T-cell populations as compared to the 2B4+PD-1\u2212CD160\u2212 CD8 T-cell population . Interestingly, perforin expression was significantly reduced in 2B4+PD-1+CD160+ as compared to 2B4+PD-1\u2212CD160+ and 2B4+PD-1+CD160\u2212 CD8 T-cell populations . Finally, the potential association between perforin and co-inhibitory molecule expression was assessed within each differentiated CD8 T-cell subset i.e. na\u00efve, central memory, effector memory and terminally differentiated effector memory. The representative flow cytometric profiles and the cumulative data showed that perforin expression was significantly enriched within 2B4-expressing CD8 T cells in both EM (P\u200a=\u200a0.0011) and TDEM (P<0.0001) (P\u200a=\u200a0.0063) and TDEM (P\u200a=\u200a0.026) and in PD-1-expressing CD8 T cells in both EM (P\u200a=\u200a0.0391) and TDEM (P\u200a=\u200a0.00031) (P>0.05) between 2B4+CD160+PD-1\u2212 and 2B4+CD160+PD-1+ CD8 T-cell populations consiste<0.0001) . Interes0.00031) . Taken t0.00031) . Of note0.00031) was not ulations , suggestP<0.0001; and 7.6 fold increase; P<0.0001, respectively) (P<0.05) (P>0.05) (\u2212CD160\u2212PD-1+ and 2B4+CD160+PD-1+ CD8 T-cell populations (+CD160+PD-1\u2212 CD8 T-cell population expressed the highest levels of CD160 (MFI) and 2B4 (MFI) as compared to any other CD8 T-cell population blocking anti-CD160 monoclonal antibodies (mAbs), 2) blocking anti-PD-L1/2 mAbs, 3) combined blocking anti-CD160 and anti-PD-L1/2 mAbs and 4) isotype controls. Of note, anti-CD160 MAbs did not show any agonistic potential either in absence or in presence of TCR signal (data not shown), as assessed by CD69, CD107a and BCL-2 expression or TNF-\u03b1 and IFN-\u03b3 production (data not shown). The representative flow cytometric profiles showed that both anti-CD160 and anti-PD-1 mAb treatments individually increased the proliferation capacity of EBV-specific CD8 T cells . In addictively) . The eff; N\u200a=\u200a5) and 2) c; N\u200a=\u200a6) . The cum(P<0.05) . However(P>0.05) . In addictively) . Of noteulations . Interespulation . Taken tex vivo expression levels of CD160 and PD-1. The representative flow cytometric profiles as well as the cumulative data showed that CD160 signaling blockade was significantly more potent in cells harboring high level of CD160 (percentage of virus-specific CD8 expressing more than 20% of CD160) versus cells harboring low level of CD160 (percentage of virus-specific CD8 expressing less than 20% of CD160) (P<0.0001) . In addictively) . Interesctively) .Previous studies have indicated that PD-1 expression increased following T-cell stimulation and activation Several studies have demonstrated that the increased expression of co-inhibitory molecules including PD-1, 2B4 and CD160 during chronic viral infections is associated with CD8 T-cell dysfunction versus chronic viral infections), the cytokine milieu, the nature of the infected cell population.In the present study, we have evaluated the impact of individual co-inhibitory molecules expression such as 2B4, PD-1 and CD160 on virus-specific CD8 T-cell functions. To address this issue, we have performed both phenotypic and functional characterization of Flu, EBV and CMV-specific CD8 T cells in healthy individuals. We show that EBV and CMV-specific CD8 T cells contained higher frequency of cells co-expressing 2B4, CD160 and PD-1 in different combinations while Flu-specific CD8 T cells had higher frequencies of triple negative, single PD-1 or dual PD-1/2B4 CD8 T-cell populations. In particular, the percentage of CD160 expression was significantly lower in Flu-specific CD8 T cells than in CMV or EBV-specific CD8 T cells. Interestingly, the level of total PD-1 was not significantly different in Flu, EBV or CMV-specific CD8 T cells. These data suggest that CD160 expression in virus-specific CD8 T cells is associated with chronic virus infections such as EBV and CMV. Of note, co-inhibitory molecule expression on virus-specific CD8 T cells are likely influenced by the pathogen characteristics, the type of viral infection i.e. HVEM (member of the TNF receptor superfamily) and MHC class I molecules ex vivo proportion of CD160 expression independently of PD-1 expression. These results suggested that 2B4+CD160+PD-1+ and 2B4+CD160+PD-1\u2212 CD8 T-cell populations were both rescued by CD160/CD160-ligands signaling blockade.The functions of CD160 are complex, and still remain under debate, with potentially various roles +CD160+PD-1+, 2B4+CD160+PD-1\u2212 and 2B4+CD160\u2212PD-1+ CD8 T-cell populations had reduced expression of perforin as compared to 2B4+CD160\u2212PD-1\u2212 CD8 T-cell population, suggesting that the expression of CD160 and/or PD-1 on 2B4+ CD8 T cells is associated with a reduced capacity to express perforin. Interestingly, CD160 signaling is commonly associated with enhanced NK-cell cytotoxic activity i.e. CD160 and CD160 TM, that are modulated following IL-15 stimulation ex vivo nor following IL-15 or TCR stimulation was not significantly different between 2B4\u2212CD160\u2212PD-1+ and 2B4+CD160+PD-1+ CD8 T-cell populations compared to the 2B4+CD160+PD-1+ CD8 T-cell population. The percentage of 2B4\u2212CD160\u2212PD-1+ CD8 T-cell population expressing EOMES, Tbet and CD57 was significantly lower than 2B4+CD160\u2212PD-1+ and 2B4+CD160+PD-1+ CD8 T-cell populations. These data suggest that 2B4\u2212CD160\u2212PD-1+ CD8 T cells may be less functionally impaired than 2B4+CD160\u2212PD-1+ and 2B4+CD160+PD-1+ CD8 T-cell populations.Interestingly, the 2B4In conclusion, while accumulation of different immune check point blockers is clearly associated with progressive dysfunction, the present study demonstrates that CD160-mediated regulation of CD8 T-cell functions is independent of PD-1 expression thus providing evidence that CD160 contributes to the regulation of CD8 T-cell functions.Forty subjects were recruited in this study. Blood samples were obtained at the local blood bank (Centre de transfusion sanguine (CTS), Lausanne, Switzerland). The use of samples used in this study was approved by the Institutional Review Board of the CTS, and all subjects gave written informed consent. Only individuals with no sign of HIV, HAV, HBV and HCV infections were included. Blood mononuclear cells were isolated as previously described The following monoclonal antibodies (mAbs) were used in different combinations. CD8-PB, CD3-APC-H7, PD-1-PECy7, PD-1-PB, IFN-\u03b3-AF700, IL-2-PE, CD4-PB, granzyme B-AF700, perforin-APC were purchased from Becton Dickinson , CD45RA-ECD, CD4-ECD from Beckman Coulter , CCR7-FITC from R&D Systems , 2B4-PECY5.5, CD160-APC, CD160-PE from BioLegend , CD4-eFluor650NC, CD8-eFluor625NC from eBioscience.6) cells were washed, stained for dead cells using the Aqua LIVE/DEAD stain kit (Invitrogen) and, when required, stained with appropriately tittered peptide-MHC class I multimer complexes at 4\u00b0C for 30\u2032 in Ca2+-free media as described Cryo-preserved blood mononuclear cells (1\u20132\u00d7106 in 1 ml of complete medium) were stained with 0.25 \u00b5M 5,6-carboxyfluorescein succinimidyl ester as previously described low CD8 T cells were assessed by flow cytometry.Overnight-rested cryopreserved blood mononuclear cells (106 in 1 ml of complete medium) were stained with 0.25 \u00b5M 5,6-carboxyfluorescein succinimidyl ester as previously described Cryopreserved blood mononuclear cells or left unstimulated (negative control) in the presence of Golgiplug and anti-PD1, anti-CD160 and anti-2B4 mAbs. At the end of the stimulation period, cells were washed, stained for dead cells using the Aqua LIVE/DEAD stain kit (Invitrogen), permeabilized and stained with mAbs to CD3, CD8, CD45RA, CCR7, IFN-\u03b3 and IL-2 PBMC were stimulated overnight in complete media (RPMI (Invitrogen), 10% fetal calf serum , 100 \u00b5g/ml penicillin, 100 unit/ml streptomycin (BioConcept)) with PBMC were washed, stained for dead cells using the Aqua LIVE/DEAD stain kit (Invitrogen). Cells were then washed and stained with the following mAbs: CD3, CD8, PD-1, 2B4, CD160, CCR7 and CD45RA. Cells were then permeabilized and stained with mAbs to perforin and granzyme B PBMC were washed, stained for dead cells using the Aqua LIVE/DEAD stain kit (Invitrogen). Cells were then washed and stained with the following mAbs in different combinations: CD3, CD8, PD-1, 2B4, CD160 and CD57 or CD3, CD8, PD-1, 2B4, CD160, CCR7 and CD45RA. Cells were then permeabilized and stained with mAbs to EOMES and T-bet.6 cells) previously selected by MACS cell separation (Miltenyi kit) were washed, stained for dead cells using the Aqua LIVE/DEAD stain kit (Invitrogen). Cells were then washed and stained with the following mAbs: CD8, PD-1, 2B4, CD160, CD45RA, CCR7. CD8 T-cell populations were sorted by BD FACSAria III on the basis of 2B4, PD-1 and CD160 expression after exclusion of na\u00efve T cells (CD45RA+CCR7+). Sorted populations were labeled with CFSE and stimulated with viral peptides (1 \u00b5g/mL) in the context of irradiated (40 Gy) autologous CD8-depleted PBMCs (ratio CD8/feeder cells 1\u223610) or in anti-CD3 (10 ug/ml) and anti-CD28 (0.5 ug/ml) mAbs coated plate or left unstimulated. Proliferation was assessed at day 6 by flow cytometry. Cells were washed, stained for dead cells using the Aqua LIVE/DEAD stain kit (Invitrogen). Cells were then washed and stained with anti-CD8 and anti-CD3 mAbs.Cryopreserved CD8 T cells for dead cells using the Aqua LIVE/DEAD stain kit (Invitrogen). Cells were then washed and stained with the following mAbs: CD8, CD3, CD56, CD160, CD160-TM (rabbit unconjugated). Cells were then washed and stained with anti-rabbit secondary Ab. To assess their expression after in vitro expansion PBMC were labeled with CFSE and stimulated with IL-15 (50 ng/mL) or with anti-CD3 (10 ug/ml) and anti-CD28 (0.5 ug/ml) mAbs coated plate. CD160 and CD160-TM expression were assessed at day 6 by flow cytometry. Cells were washed, stained for dead cells using the Aqua LIVE/DEAD stain kit (Invitrogen). Cells were then washed and stained with the following mAbs: CD8, CD3, CD56, CD160, CD160-TM (rabbit unconjugated). Cells were then washed and stained with anti-rabbit secondary Ab.CD160 and CD160-TM expression were assessed both http://exon.niaid.nih.gov/spice> 5 and 106 in the flow cytometry experiments.Cells were fixed with CellFix (BD), acquired on an LSRII SORP and analyzed using FlowJo (version 8.8.2) and SPICE 4.2.3. When required, analysis and presentation of distributions was performed using SPICE version 5.1, downloaded from
490\u2009nm), the host switches to the E-form where the structural complementarity with the guest is destroyed as a result of which the C60 is disassembled from the host. The results described herein reveals an actionable roadmap to pursue further advances in component self-assembly particularly light-induced association and dissociation of a guest molecule.Stimuli responsive hosts for C Since C60 is a spherical \u03c0 framework devoid of any functional groups, construction of its receptor has been a challenge for chemists. A number of host molecules for C60 stands as witnesses of ingenuity of molecular architecture4. Complementarity of the spherical shape of the buckyball has been achieved by challenging synthesis of molecular bowls, hoops, peapods and several other flexible structures that undergo induced-fit around the molecule. Cycloparaphenylene acetylenes offer supramolecular complexation with fullerene derivatives5. Platinum-based molecular cages has also been reported to encapsulate the C606. Aromatic molecules such as cycloparaphenylene rings encapsulate C60 as well as other fullerene derivatives8. An aza-buckybowl based system have been reported to act as efficient receptors for C60 and C70 with large association constant9. Larger aromatics such as cyclochrysenylenes form molecular \u201cpeapods\u201d. The complementarity of the convex surface of the buckyball has been achieved by concave bowl-shaped molecules such as corannulenes, sumanenes and even with a expanded rosarin derivative13. Even a nitrogen-containing buckybowl and its assembly with C60 has recently been reported14. Non-planar hydrocarbons such as triptycene also form complexes with fullerenes due to geometrical complementarity of their concave shapes to the spherical surface of the C6015. Fusion of more than one receptor units in a single host molecule displayed enhanced affinity towards the fullerene guest. For instance, a receptor bearing two corannulene units has been reported as a \u201cbucky-catcher\u201d with a high binding constant16.The discovery of fullerene is marked as an epoch in the field of organic nanomaterials21. Light is one of the most extensively used stimuli because of its non-invasive nature and easy regulation by the precise focus of its exposure area, and adjustment of its wavelength and intensity23. Several light-triggered and redox-triggered release of guest molecules have been reported in recent years27. The selective recognition of C60 by a bispyridine ligand with embedded anthracene panels in presence of Ag(I) ion and its light-mediated subsequent release was studied28. Reversible host-guest complexation and decomplexation triggered by light can be achieved by the incorporation of photochromic units in the supramolecular systems29. Azobenzene is a robust photoresponsive molecule which can exhibit significant structural and chemical modification upon exposure of UV and visible light. These photoswitches have been widely used for the rapid and exact modulation of several biological processes45.Stimuli-responsive supramolecular host for fullerenes can open up the possibilities for handling the bucky balls and other carbon-based frameworks with superior controls using the stimuli such as pH, electrical or magnetic fields, electrochemical and photonic signals60 and a photoresponsive group containing nanorings host was investigated and further experimental synthesis of photoresponsive hosts have been predicted46. However, reversible binding and release of C60 still remain a challenge. C60 is known to form stable supramolecular complexes with several compounds having flexible phenyl rings47. Crystal structures showing C60-tetraphenylethene (TPE) bears the witness of the non-covalent van der Waals interactions between the two species48. Recent years, TPE have been widely used due to its abnormal properties i.e. non-luminescent in a solution state and highly emissive upon aggregation and solid state \u2013 so called aggregation induced emission (AIE) active chromophore50.A theoretical study of host-guest interactions between C1, Fig.\u00a060. Binding through supramolecular association is much coveted because it does not perturb the electronic structure of the guest significantly. The azobenzene-TPE photoswitch offers the control of the geometry of the receptor allowed reversible supramolecular interaction with C60.Incorporating a photoswitchable azobenzene unit between two TPE moieties, we have synthesized the azobenzene-TPE , Fig.\u00a01 1 was prepared by reacting 1,2-bis(4-bromophenyl)diazene with 3 equiv. of phenyl)boronic acid in degassed 1,2-dimethoxyethane/2\u2009M Na2CO3 using Pd(PPh3)4 as a catalyst at 100\u2009\u00b0C for 24\u2009h yielded 1 in 69.5% (for details see Supplementary Information).Azobenzene-TPE 1 exhibit E-Z photochromism where the forward and the backward reactions are fully reversible upon exposure to UV and visible light respectively. Upon irradiation with 254\u2009nm light, the n\u2009-\u2009\u03c0* band of the E isomer can be selectively excited leading to the conversion to Z isomer as shown in Fig.\u00a05\u2009M\u22121cm\u22121) becomes broad and the intensity of the band increases with the exposure time. A new broad peak at 550\u2009nm (\u03b5\u2009=\u2009~9.8\u2009\u00d7\u2009103\u2009M\u22121 cm\u22121) arises due to the n\u2009-\u2009\u03c0* transition of the Z isomer which increases in intensity with the 254\u2009nm radiation. The photoisomerization reaction was accompanied by a change in colour that was visually noticeable. The yellow colour of the E isomer was transformed to intense orange under isomerization to the Z isomer and a shoulder at ~550\u2009nm. In the Z isomer, the fluorescence intensity was less intense (\u03a6F\u2009=\u20090.004) with a single band at 480\u2009nm as shown in Fig.\u00a0The molecule mer Fig.\u00a0 The E toE-Z isomerization of 1 under the exposure of 254\u2009nm light was monitored by 1H spectroscopy , 7.58 (Hb), and 7.32 (Hc). Conversion to the Z-isomer upon exposure to 254\u2009nm UV light triggered an upshifted field shift of the 1H resonances and to \u03b4 values (a) and (b) protons appear at 7.34 (Hc\u2019), 7.19 (Hb\u2019) and 6.83 (Ha\u2019). The TPE protons appeared as multiplets and their change in the 1H NMR spectra was not identifying because of the presence of overlapping multiplets. The composition under the irradiation in the NMR tube corresponded to a ca. 3:1 ratio of the Z: E isomer.The opy Fig.\u00a0 using CS60 to Z-1, the formation of Z-1.C60 was apparent from the instant change in the absorption spectra. Apart from the obvious change in the visual appearance of the solution Z-1 with C60 upon mixing monitored at 460\u2009nm clearly revealed an association with 1:1 stoichiometry of the host and the guest C60 the peak of the C60 at 143.0 ppm underwent an upfield shift to 142.9 ppm because of the encapsulation within the aromatic rings of Z-1. The change in the 13C resonance of the host also provided an insight of the binding site within Z-1 and C60 host-guest complex formation, respectively6. Importantly, The MALDI-TOF MS of a sample containing Z-1.C60 indicated the presence of the species that matches well with the expected isotopic pattern takes place in presence of the visible light. The sharp characteristics changes in NMR spectra also prove the encapsulation and release of C60 by the Z form of the molecule. The 1H NMR study was performed with the Z form of the molecule 1 in the presence one equivalent of C60 in CS2. Although the changes in the 1H NMR (Supplementary Fig.\u00a013C NMR was clear. There the peak for the C60 at 143.0 shifted upfield to 142.9 ppm (Fig.\u00a060 upon encapsulation by the host TPE groups in Z form experiences a shielding effect which causes an upfield shift to the C60 nuclei. This change was reversible under exposure to visible light which was also observed earlier with absorption spectroscopy as described earlier.The tra Fig.\u00a0 with theppm Fig.\u00a0. This ch60 molecule fits in perfectly within the aromatic cavity of the Z-1 form. Several phenyl rings of the molecule puckered around to accommodate the C60 with a perfect shape complementarity to form the supramolecular assembly (Fig.\u00a0A three dimensional model of the system obtained from computational simulation using DFT calculation at the B3LYP level displayed clear interactions between the receptor and the fullerene. The Cbly Fig.\u00a0.Figure 5A TPE-linked azobenzene based photoswitchable molecule has been synthesized and characterized by various spectroscopic techniques.E\u2009\u2192\u2009Z isomerisation of the compound 1 offers the possibility of the formation of a complementary pocket for the accommodation of C60 guest molecule.The structural change of the structure upon E and the Z isomers of 1 and the C60 molecule has been investigated by various spectroscopic techniques.Host-guest interaction with both the Z-1.C60 association was pronounced compared to the interaction between the E-1 isomer and C60.It was observed that the Z-1.C60 association can be reversed by the exposure of the system with >490\u2009nm light that converts the Z-1 form to the E-1 form, and thereby weakening the host-guest binding.The To sum-up, our salient findings of this work are as follows.60 molecule51.Thus this work demonstrates the development of the stimuli responsive host system that can be can be used for light-induced association and dissociation of a CSupplementary Information"}
+{"text": "Cytomegalovirus (CMV) infection is common in immunocompetent patients in intensive care units (ICUs). However, whether CMV infection or CMV reactivation contributes to mortality of immunocompetent patients remains unclear.A literature search was conducted for relevant studies published before May 30, 2016. Studies reporting on CMV infection in immunocompetent patients in ICUs and containing 2\u2009\u00d7\u20092 tables on CMV results and all-cause mortality were included.2\u2009=\u200989%, n\u2009=\u20092398) and the CMV reactivation was 31% . The odds ratio (OR) for all-cause mortality among patients with CMV infection, compared with those without infection, was 2.16 . Moreover, upon exclusion of studies in which antiviral treatment was possibly or definitely provided to some patients, the association of mortality rate with CMV infection was also statistically significant . For CMV seropositive patients, the OR for mortality in patients with CMV reactivation as compared with patients without CMV reactivation was 1.72 . Patients with CMV infection required significantly longer mechanical ventilation (mean difference (MD): 9\u00a0days ) and longer duration of ICU stay ) than patients without CMV infection. When analysis was limited to detection in blood, CMV infection without antiviral drug treatment or reactivation was not significantly associated with higher mortality .Eighteen studies involving 2398 immunocompetent patients admitted to ICUs were included in the meta-analysis. The overall rate of CMV infection was 27% contains supplementary material, which is available to authorized users. Human cytomegalovirus (CMV) is a prototypic member of the \u03b2 herpes virus subfamily . The preIt is well known that CMV infection is common in canonical immunodeficiency patients, such as those with human immunodeficiency virus infection, solid organ or stem cell transplantation and patients undergoing chemo- or radiotherapy \u20139. With Whether CMV infection is associated with increased mortality in immunocompetent ICU patients remains controversial \u201316. A prA literature search for relevant publications included within the electronic databases PubMed, EMBASE and the Cochrane Library was performed using combinations of the keywords \u201ccytomegaloviruses\u201d, \u201csalivary gland viruses\u201d, \u201cherpes virus\u201d, \u201ccytomegaloviral infection\u201d, \u201cHHV5\u201d, \u201cintensive care\u201d, \u201ccritical care\u201d, \u201ccritical illness\u201d, \u201cmechanical ventilation\u201d, and \u201cpulmonary ventilator\u201d. All searches were updated on May 30, 2016. No language restriction was enforced. We also consulted relevant reference articles and searched using Google Scholar.Two researchers (LX and HYB) performed data extraction independently, and any discrepancies were addressed by discussion and reevaluation until consensus was achieved. Observational studies were eligible if they reported on CMV infection in immunocompetent patients in the ICU, and if a 2\u2009\u00d7\u20092 table could be constructed based on CMV results and all-cause mortality. All patients were over 18\u00a0years of age. The systematic review included only studies in which all patients were tested for CMV. An episode of CMV infection was defined by one of the examination CMV viral culture, polymerase chain reaction (PCR), CMV antigen (pp65) in blood, tracheal aspirates, urine, or a combination of these. A case was defined by the presence of reactivation, where the patient had CMV infection and was seropositive. Immunocompetent patients were defined as those patients who did not receive a solid organ or hematopoietic stem cell transplant, did not receive immunosuppressive treatment, did not have human immunodeficiency virus infection, did not have primary immunodeficiency, and did not receive chemotherapy or radiotherapy before ICU admission.We obtained information on basic study characteristics , characteristic population, the site and detection method of sample, CMV seropositivity, CMV infection incidence, all-cause mortality, length of ICU/hospital stay, length of mechanical ventilation, and administration of antiviral drugs.The Newcastle\u2013Ottawa scale, developed for evaluating the quality of observational studies . Meta-analytic pooling was performed for outcome variables with a Logit transformation approach, reporting results as summary point estimates . We used the Mantel\u2013Haenszel method to obtain odds ratios (ORs) and 95% CI. When only the median, range, or interquartile range of length of mechanical ventilation and the length of ICU stay were reported, we used simple formulas to estimate the mean and standard deviation .2 measure of inconsistency and the chi-square test of heterogeneity.Between-study heterogeneity was examined using the ITo evaluate publication bias, we constructed a funnel plot and used the Egger test. Sensitivity analyses of the Begg\u2019s test were additionally conducted to ascertain the robustness of our findings. All meta-analyses were performed with R software (version 3.3.3 for Windows) and SPSS 18 .The initial database search identified 1846 potentially relevant studies. Following this, assessment of the full text yielded 17 studies suitable for analysis. Another publication was incorporated after examining references from the extracted articles . ConsequMost studies were conducted in the United States and Europe, except one cohort study in Egypt , and werA total of 2398 patients were included, having been admitted to the ICU for a variety of reasons, with a median age of 59\u00a0years. The median period of prospective studies was 24\u00a0months, ranging broadly from 3 to 78\u00a0months. All studies used CMV blood assays, and 6 studies also assayed sputum samples. Most studies indicated that the frequency of sample collection was once a week. In our analysis, the methods used to assess CMV infection were virus culture, pp65 antigen detection and PCR detection of CMV DNA in ten, three and two studies, respectively, and combinations of two diagnostic methods in the remaining three studies.2\u2009=\u200989%, n\u2009=\u20092398). As compared with patients without CMV infection, the all-cause mortality of patients with CMV infection was significantly higher compared with patients without infection Fig.\u00a0. When an2\u2009=\u200937%, n\u2009=\u2009912) compared with patients without infection as compared with patients without infection and 12\u00a0days , respectively, between patients with and without CMV infection and MD: 9\u00a0days ), respectively in immunocompetent ICU patients Fig. .Fig. 5Th2\u2009=\u200929%, n\u2009=\u2009664) Fig. . But forWe also analyzed the rate of CMV and mortality thought categorized by the detection methods or in the all-cause CMV mortality analysis . We also used Begg\u2019s test to detect sensitivity analysis, and the results showed that the analyses were robust.We used the Egger test to detect publication bias. There was no publication bias either in the overall CMV prevalence analysis . However, when compared with other methods, the association with mortality was marginally less strong using PCR. We may think that viral burden of CMV is determinant of pathogenesis, and higher CMV loads is correlated with progression of some CMV infection disease [We found that the detection rate of CMV by culture, pp65 and PCR was 13, 22 and 34%, respectively. Desachy et al. demonstrated that positive results for CMV infection were obtained in a median of 4\u00a0days by PCR compared with 11\u00a0days by pp65 antigen detection after onset of sepsis . Therefo disease , 40.The presence of CMV seropositivity, representing previous infection, was found in 71% of immunocompetent ICU patients and the incidence of CMV reactivation was high, observed in 31% of seropositive patients in our meta-analysis. There are several factors that might explain the high prevalence. First of all, the rate of CMV seropositivity increases with advancing age and in oWhen the mortality analysis was limited to CMV detection in blood, CMV infection without antiviral drug treatment or reactivation was not significantly associated with higher mortality. This maybe explained that the presence of high peripheral levels of functional CMV-specific CD4+ and CD8+ T cells in immunocompetent patients, which can suppress CMV during episodes of reactivation . It was Patients with sepsis have the highest incidence of CMV infection . Early iThere are five limitations in this study. First, we observed large heterogeneity in many of our analyses. However, little or no heterogeneity was observed in the meta-analysis of mortality outcome. Second, most studies were not blind, thus reducing the reliability of the results. Third, lack of sufficient data on clinical parameters meant that stratified analyses based on such clinical characteristics were not possible. Fourth, the definition of the state of CMV infection was inconsistent and maybe restrictive to capture the dynamics of CMV infection. As such, we could not conduct meta-analysis with outcome data and this is a major limitation of our meta-analysis. Finally, one cannot dOur findings suggests that there is a high incidence of CMV seropositivity and CMV infection in critically ill patients without immunosuppression. This study suggest that CMV infection without antiviral drug treatment or reactivation in critically ill patients is associated with increased mortality, and is not associated with mortality when CMV infection is detected in blood. Further research is necessary to determine the full role of CMV in this vulnerable patient demographic.Additional file 1:Table S1. The Newcastle\u2013Ottawa scale (PDF 17\u00a0kb)Additional file 2:Figure S1. The effect of CMV infection on all-cause mortality in blood (TIFF 276\u00a0kb)Additional file 3:Figure S2. The effect of CMV infection on all-cause mortality in patients without antiviral therapy in blood (TIFF 150\u00a0kb)Additional file 4:Figure S3. The mean difference in mechanical ventilation days in blood between active and non-CMV infection (TIFF 217\u00a0kb)Additional file 5:Figure S4. The mean difference in the length of ICU stay in blood between active and non-CMV infection (TIFF 222\u00a0kb)Additional file 6:Figure S5. The effect of CMV reactivation on mortality in blood (TIFF 133\u00a0kb)Additional file 7:Figure S6. Subgroup analysis of CMV detection rate according to detection method in all trials (TIFF 552\u00a0kb)Additional file 8:Figure S7. Subgroup analysis of CMV detection rate according to detection method in blood (TIFF 393\u00a0kb)Additional file 9:Figure S8. The effect of CMV infection on all-cause mortality in subgroup analysis according to detection method in all trials (TIFF 582\u00a0kb)Additional file 10:Figure S9. The effect of CMV infection on all-cause mortality in subgroup analysis according to detection method in blood (TIFF 420\u00a0kb)"}
+{"text": "This review summarizes the role of PD-1 in (1) modulating ILC development, (2) ILC function, and (3) PD-1 signaling in ILC. Finally, we explore how PD-1 based immunotherapies may be beneficial in boosting ILC responses in cancer, infections, and other immune-related disorders.Programmed cell death-1 (PD-1) is a cell surface receptor that dampens adaptive immune responses. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. This results in the inhibition of T cell proliferation, differentiation, cytokine secretion, and cytolytic function. Although a great deal is known about PD-1 mediated regulation of CD4 Thesels (DCs) ,6. Subsels (DCs) . With thPD-1 is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. Members of this family can be divided into those that predominantly have a positive effect, driving T cell activation, and those that have a negative effect, restraining T cell activation. The inhibitory role of PD-1 was identified in mice that lacked PD-1 expression that developed autoimmune disease relatively late in life . The exp+ and CD4+ T cell activation through T cell receptor results in the upregulation of the PD-1 receptor in in vitro studies. PD-1 is not expressed on resting T cells but can be induced within 24 h post-stimulation [CD8mulation . A similmulation and NKT mulation . PD-1 bimulation ). Emergi+ T cells are known to express inhibitory co-receptors, of which cytotoxic T-lymphocyte associate protein 4 (CTLA4) is the best characterized, as mice that lack this co-receptor die of auto-immune disease within the first few weeks of life [+ T cells that restrain the immune system; these T regulatory (Treg) cells are characterized by the expression of the master transcription factor Foxp3 and high levels of CTLA4 and CD25. Although PD-1 expression is not a characteristic feature of Treg cells, PD-1 activation has been shown to induce Foxp3 expression and maintain induced Treg cell phenotype [Snapshots of PD-1 receptor expression and its relative contribution towards immune tolerance has been confirmed using animal models of autoimmunity and cancer. However, the molecular mechanisms that control PD-1 expression are relatively unclear. Activated CD4 of life . In addihenotype .+ T cells was first described in a chronic murine lymphocyte choriomeningitis virus (LCMV) model whereby PD-1 blockade revived CD8+ T cell function [+ T cells. Consequently, the idea that PD-1 can be expressed on ILCs that lack antigen-specific receptors was not considered. In addition to T cell receptor activation, other stimuli that induce PD-1 expression include NFATc1 [The importance of sustained PD-1 receptor expression in exhausted CD8function . Indeed,function ) has beefunction ,18,19,20e NFATc1 , the inte NFATc1 .PD-1 is a 50\u201355 kDa type I transmembrane glycoprotein composed of an IgV domain which shares 21\u201333% sequence identity with other members of the Ig co-receptor family including CTLA4, CD28, and inducible T-cell costimulatory molecule (ICOS) . The strThe ITSM is essential for the inhibitory function of PD-1, which was initially demonstrated in B cells . SimilarThe recruitment of SHP1/2 to the ITSM has been analyzed by two groups. In both cases, it was shown that SHP2 had a preferentially binding to the ITSM over SHP1 ,24 PD-1 + T cells enhances the induction of Treg phenotype from na\u00efve T cells to form iTreg cells, and participates in human Treg function and in human Th1 to Treg conversion [PD-1 signaling in CD4nversion ,36,37. Enversion , PD-1 innversion ,36. ThesILCs are innate immune cells that play a major role in immune defense and tissue homeostasis. ILCs are classified into three groups: Group 1 ILCs (including NK cells and ILC1s), group 2 ILCs (ILC2s), and group 3 ILCs (including ILC3s and lymphoid tissue inducers (LTi) . Each IL+KLRG1\u2212), inflammatory ILC2s (KLRG1+ST2\u2212), or mature ILC2s (KLRG1+ST2+) in mice [+ ILC3s are positive for NKp46/NKp44 [\u2212 do not express Nkp46/Nkp44 [\u2212 ILC3s are associated under normal physiological conditions within the skin, with the upregulation of NCR+ cells during inflammatory conditions such as psoriasis [+ ILC3s are the prominent ILC3 population within the intestine of healthy individual. These cells are further defined by the expression of the master transcription factor retinoic-acid-receptor-related orphan nuclear receptor \u03b3 (ROR\u03b3t) and are the innate counterpart of IL-17 expressing T helper (Th17) cells. ILC3s are activated by cytokines such as IL-23 and are efficient at inducing anti-bacterial responses through the production of cytokines such as IL-17 and IL-22. LTi cells are classified within group 3 ILCs, as they share these properties [ILC classification is based on their cytokine phenotype, function, and master transcription factors that drive their function. A comprehensive summary of ILC subsets, the activating stimuli, effector cytokine production and co-receptor expression is summarized in in mice ,51,52,5346/NKp44 ,55 where46/Nkp44 . NCR\u2212 ILsoriasis ,57,58. Ooperties . The claIn addition to their helper like function, emerging literature suggests that ILCs can also mimic APC function through expression of MHC class II which in-turn can modulate T cell function ,60,61. A\u2212/\u2212 mice [The expression of CD28 co-receptor family on helper ILCs was not considered until recently, when a study by Maazi et al. demonstr\u2212/\u2212 mice . This ob\u2212/\u2212 mice ,66. Furt\u2212/\u2212 mice . Conside\u2212Flt3lo/\u2212IL7R\u03b1 lo/+\u03b14\u03b27+) and then subjected to single cell RNA-seq. The authors found that within the common helper innate lymphoid progenitors (CHILP) identified as Lin\u2212CD25\u2212IL7R\u03b1+\u03b14\u03b27+ and classified as cluster 6, also expressed PD-1. This PD-1hi population conformed to a progenitor phenotype concurrently expressing Zbtb16, Id2, Tcf7, Tox, and Gata3 and lacRag/\u2212\u2212 mice. We found that blocking PD-1 significantly enhanced the expulsion of worms in Rag/\u2212\u2212 mice. However, this experimental set up included blocking PD-1 in both myeloid and ILC compartments. The function of PD-1 on ILC2 was confirmed as follows: Rag/\u2212\u2212\u03b3c/\u2212\u2212 mice infected with Nippostrongulus brassiliensis were reconstituted with either wildtype(WT) or PD-1\u2212/\u2212 ILC2s. Within this experimental condition, we found that PD-1 deficient ILC2s were significantly superior to WT ILC2s in diminishing worm burden. Blocking PD-1 also enhanced human ILC2 function both in vitro and in vivo suggesting a conserved PD-1 mediated regulatory function in ILC2s. Traditionally associated as a T cell targeting therapy, we describe here a potential novel use of PD-1 blockade to target ILC2s in the context of helminth infection; which was also eluded to by Yu et al. in their model of influenza. Our study also confirmed murine findings in human system where PD-1 blockade enhanced ILC2 function. These combined studies open up a new are of immunotherapy for parasitic helminth disease whereby checkpoint blockade can enhance ILC2-mediated immune responses to parasites. Indeed, one needs to be cautious with such therapies due to their deleterious effects in inducing airway inflammation.PD-1 expression on mature ILCs was also reported by Yu et al. , wherebyRecently, Oldenhove et al. demonstrThe expression of PD-1 on ILC3 and LTi has been recently reported in the human decidua. In this study, the authors sequentially measured PD-1 expression in the maternal ILC compartment during the first and the third trimester. During the first trimester PD-1 was highly expressed on LTi while expression was also noted on ILC3s. In the third trimester, PD-1 expression was significantly downregulated in the LTi cells but this expression was similar to that noticed in ILC3s. Although NK cells lacked PD-1 expression in the first trimester, they were able to significantly upregulate PD-1 in the third trimester. However, PD-1 expression on NK cells did not reach the same frequency as LTi, ILC3, or T cells. The expression of PDL-1 was restricted to the intermediate extravillous trophoblast (iEVT) at the intersection of the feto-maternal interface, suggesting an ILC mediated tolerance mechanism driven by PD-1/PDL-1 in order to prevent fetal rejection in the early phase of pregnancy . FurtherEmerging evidence of PD-1 expression on ILCs indicate that PD-1 signaling can inhibit ILC function. The precise molecular mechanisms that induce PD-1 on ILCs or the signaling pathways that are activated by PD-1 engagement is yet to be fully understood. While our study and the work of others have shown that PD-1 can be induced by ILC2 and \u03b3c cytokines, the precise molecular events that induce PD-1 has not been delineated in ILC2s. In order to elucidate the molecular signaling pathways that are modulated by PD-1 engagement, we explored the T cell literature to identify relevant PD-1 modulating signaling pathways that might be operational in ILC2s. The work by Franceschini et al. on HCV sIn light of the success of PD-1 blocking antibodies in cancer immunotherapy, it remains possible that in addition to enhanced T cell responses, PD-1 may regulate the helper ILC arm of the immune system to modulate anti-tumor responses. The function of helper ILCs in anti-tumor responses has been recently explored whereby ILC1s possess both pro and antiIn summary, ILCs have emerged as an important component of the innate immune system that can influence adaptive immune responses, regulate tissue repair and adipose tissue. The expression of PD-1 on ILCs has identified a new therapeutic window in non-immunogeneic and immunogeneic tumors that needs to be further elucidated. These studies highlight the finding that the role of these receptors is broader than simply modifying the action of antigen receptors. A full comprehensive understanding of ILC modulation by PD-1 will be required in order to fully utilize this signaling pathway in the clinic. Given the number of clinical trials investigating anti-PD-1, PDL-1, and CTLA4 antibodies, it is essential to understand how these interventions affect ILC function within the tumor tissue. With the discovery of ILCs, we have the potential for boosting or dampening tissue-specific immune responses in the context of diseases such as cancer, autoimmunity, and infectious pathogens. Finetuning these responses requires an in-depth understanding of ILC immunobiology and the impact of immune-therapeutics such as jakinib and checkpoint inhibitors in boosting specific ILC responses. Since immunotherapeutic platforms are already well established in cancer and autoimmune diseases such as rheumatoid arthritis, it will be possible to tease out ILC responses to these various therapies in the clinic. Therefore, it is important to include ILCs as a target immune population within these clinical trials in order to fully understand the contribution of these subsets in human disease. In addition, the use of ILCs as a cellular therapy in diseases such as graft-versus-host disease has been recently proposed. The efficacy and clinical feasibility of this process has yet to be fully established . Indeed,"}
+{"text": "Tumor cells experience hypoxia, acidosis, and hypoglycemia. Metabolic adaptation to glucose shortage is essential to maintain tumor cells\u2019 survival because of their high glucose requirement. This study evaluated the hypothesis that acidosis might promote tumor survival during glucose shortage and if so, explored a novel drug targeting metabolic vulnerability to glucose shortage.Cell survival and bioenergetics metabolism were assessed in lung cancer cell lines. Our in-house small-molecule compounds were screened to identify those that kill cancer cells under low-glucose conditions. Cytotoxicity against non-cancerous cells was also assessed. Tumor growth was evaluated in\u00a0vivo using a mouse engraft model.Acidosis limited the cellular consumption of glucose and ATP, causing tumor cells to enter a metabolically dormant but energetically economic state, which promoted tumor cell survival during glucose deficiency. We identified ESI-09, a previously known exchange protein directly activated by cAMP (EAPC) inhibitor, as an anti-cancer compound that inhibited cancer cells under low-glucose conditions even when associated with acidosis. Bioenergetic studies showed that independent of EPAC inhibition, ESI-09 was a safer mitochondrial uncoupler than a classical uncoupler and created a futile cycle of mitochondrial respiration, leading to decreased ATP production, increased ATP dissipation, and fuel scavenging. Accordingly, ESI-09 exhibited more cytotoxic effects under low-glucose conditions than under normal glucose conditions. ESI-09 was also more effective than actively proliferating cells on quiescent glucose-restricted cells. Cisplatin showed opposite effects. ESI-09 inhibited tumor growth in lung cancer engraft mice.This study highlights the acidosis-induced promotion of tumor survival during glucose shortage and demonstrates that ESI-09 is a novel potent anti-cancer mitochondrial uncoupler that targets a metabolic vulnerability to glucose shortage even when associated with acidosis. The higher cytotoxicity under lower-than-normal glucose conditions suggests that ESI-09 is safer than conventional chemotherapy, can target the metabolic vulnerability of tumor cells to low-glucose stress, and is applicable to many cancer cell types. \u2022Tumor cells experience hypoxia, acidosis, and glucose shortage.\u2022Tumor acidosis promotes metabolic adaptation to glucose shortage.\u2022ESI-09, a known EAPC inhibitor, is a novel and safe mitochondrial uncoupler.\u2022ESI-09 kills tumor cells during glucose shortage, even under acidosis conditions.\u2022ES-09 targets metabolically dormant and chemotherapy-resistant tumor cells. The beserfusion , is thouerfusion .The third critical stress in the TME is nutrient deficiency, which is caused by increased nutrient demand for rapid tumor proliferation not met by an adequate supply ,12. AlthAlthough acidosis has been shown to induce a stress response similar to a low nutritional stress response, the role of acidosis in metabolic adaptation to nutrient limitations is not well understood . We hypo22.1The reagents used in this study are listed in 2.22. The H1299, H1975, and PC3 cells were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium containing 10% FBS. Human pulmonary alveolar epithelial cells (#3200) were obtained from ScienCell Research Laboratories, Inc. and grown in AEPiCM medium . Human lung microvascular endothelial cells (cc-2527) were obtained from Cambrex Bio Science Walkersville and grown in a EGM-2MV Bullet kit medium . To assess cell survival, confluent cells were serum-starved for 48\u00a0h in medium containing 0.5% FBS and then incubated in DMEM adjusted to pH 7.4 or pH 6.8 by adding a 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid solution and an HCl solution supplemented with 0.5% FBS and different glucose concentrations in the presence or absence of the tested reagents. When media were not treated with an HCl solution, an equiosmolar amount of NaCl was included to eliminate any potential effect of differences in medium osmolality. The cell number was measured as described to follow. To assess cell proliferation, actively dividing cells in growth medium containing 10% FBS were monitored for cell number.Non-small cell lung cancer cell lines A549 (CCL-185), H1299 (CRL-5803), and H1975 cells (CRL-5908) were obtained from the American Type Culture Collection . PC3 cells (JCRB0077), another non-small cell lung cancer cell line, were obtained from the Japanese Collection of Research Bioresources Cell Bank . The cell lines were authenticated by short tandem repeat profiling using a Promega PowerPlex 16 HS system . Human fetal lung IMR-90 (CCL-186) fibroblasts were obtained from ATCC. The A549 and IMR-90 cells were maintained in Dulbecco's Modified Eagle medium containing 10% fetal bovine serum (FBS) at 37\u00a0\u00b0C in a humidified incubator saturated with a gas mixture containing 5% CO2.3Cell number was evaluated using a Hoechst 33,342 DNA quantification assay. Briefly, cells in a 96-well culture plate were lysed in 100\u00a0\u03bcl of distilled water, followed by a freeze-thaw cycle. The cell lysates then were solubilized in 100\u00a0\u03bcl of TNE buffer containing 10\u00a0\u03bcg/ml of Hoechst 33,342 . The fluorescence intensities were read at an excitation wavelength of 350\u00a0nm and emission wavelength of 460\u00a0nm using a microplate fluorometer .2.4The live, apoptotic, and necrotic cells were distinguished by dual-fluorescence staining with ethidium bromide (2\u00a0\u03bcg/ml) and Hoechst 33,342 (2\u00a0\u03bcg/ml) . Under m2.5LDH activity was evaluated using an enzymatic method with a Cytotoxicity LDH assay WST kit .2.60) were prepared by culturing cells in DMEM supplemented with 10% FBS in the presence of ethidium bromide (50\u00a0ng/ml), sodium pyruvate (1\u00a0mM), and uridine (100\u00a0\u03bcg/ml) for\u00a0>\u00a020 generations. The control parental A549 cells were maintained for the same period in normal culture medium. The successful establishment of the A549 \u03c10 cell line was confirmed by polymerase chain reactions using mitochondrial DNA-specific primers in our previous study [A549 cells devoid of mtDNA according to the manufacturer's instructions. Briefly, 100\u00a0\u03bcl of lysis/assay solution provided by the manufacturer was added to confluent cell cultures in 96-well plates. After the plates were shaken for 1\u00a0min and incubated for 10\u00a0min\u00a0at 23\u00a0\u00b0C, luminescence was measured in a microplate luminometer (PerkinElmer Arvo X2). The ADP/ATP ratio was determined using an EnzyLight ADP/ATP assay kit according to the manufacturer's instructions.2.9Cells were incubated in DMEM containing 10\u00a0mM of glucose and 4\u00a0mM of glutamine at pH 7.4 or 6.8. Intracellular ATP contents were determined before and 10\u00a0min after the addition of glycolysis inhibitor 2-deoxyglucose and mitochondrial ATP synthase inhibitor oligomycin A (2\u00a0\u03bcM). The decrease in intracellular ATP contents following the addition of oligomycin A and 2-DG was referred to as the rate of cellular ATP consumption. The proportion of ATP consumption by protein synthesis and DNA/ribosomal (rRNA) synthesis was determined by measuring the ATP consumption rate in the presence of cycloheximide (2.5\u00a0mM) or actinomycin D (8\u00a0\u03bcM), respectively.2.101F0 ATP hydrolase inhibitor BMS-199264 (2\u00a0\u03bcM). Differences in intracellular ATP contents between the presence and absence of BMS-199264 were referred to as the amount of ATP consumption by mitochondrial F1F0 ATP hydrolase.Intracellular ATP contents were determined before and 10\u00a0min after the addition of 2-DG (30\u00a0mM), and the mitochondrial uncouplers were tested in the presence or absence of selective F2.11(c)\u00a0=\u00a0lactate concentration in the control medium after 6\u00a0h of incubation; Lac(o)\u00a0=\u00a0lactate concentration in the medium after 6\u00a0h of incubation with 2\u00a0\u03bcM of oligomycin; glycolysis %\u00a0=\u00a0Lac(c)\u00a0\u00d7\u00a0100/Lac(o); and OXPHOS %\u00a0=\u00a0100 - glycolysis %. The amount of glucose used for glycolysis was calculated using the following formula based on the assumption that two lactate molecules are produced during glycolysis of one glucose molecule; glucose used for glycolysis (mol)\u00a0=\u00a0amount of lactate production (mol)/2.Confluent cells were incubated in 96-well plates at the indicated pH levels. After 24\u00a0h, a portion of medium from each well was removed and the glucose and lactate concentrations in the culture and original medium (not cultured with cells) were measured using an amperometric blood glucose sensor and an enzymatic method at an outsourcing laboratory , respectively. Glucose consumption and lactate production were calculated based on the difference between the glucose or lactate concentrations in the original medium vs the culture medium. The relative glucose consumption and lactate production rates were calculated by normalizing each treatment to the control group. The amounts of glycolysis and OXPHOS components in the bioenergetic process were calculated using the following formula : Lac(c)\u00a02.12The amino acid content in the culture medium was measured by liquid chromatography-tandem mass spectrometry at SRL, Inc. .2.13Ongoing rRNA synthesis was assessed by fluorouridine (FUrd) incorporation in in situ run-on assays . Briefly2.14Protein synthesis was assessed via the SUnSET technique using an anti-puromycin antibody for the immunological detection of puromycin peptides . Briefly2.15The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured using a Seahorse XFp analyzer . The cellular bioenergetic profiles were measured using an XFp Cell Mito Stress test kit and XFp Mito Fuel Flex test kit (Agilent) according to the manufacturer's instructions .2.162 production in the mitochondrial matrix [2 and glycolysis-derived lactate to extracellular acidification can be separately determined using this kit.TCA cycle activity was assessed using media without glucose but containing 10\u00a0mM of galactose and 4\u00a0mM of glutamine to measure the ECAR . Under tl matrix . The TCA2.172PO4, 5\u00a0mM of MgCl2, 2\u00a0mM of HEPES, 1\u00a0mM of EGTA, and 0.2% fatty acid-free BSA [The A549 cells were permeabilized with Seahorse XF Plasma Membrane Permeabilizer , and the mitochondria were stimulated with substrates for respiratory chain complex I , complex II/III (10\u00a0mM of succinate and 2\u00a0\u03bcM of rotenone), and complex IV in the presence of ADP (4\u00a0mM) in a mitochondrial assay solution for 30\u00a0min\u00a0at 37\u00a0\u00b0C, and fluorescence images were acquired using an Olympus IX71 microscope .2.20Cells were loaded with the plasma membrane potential indicator DiBAC4(3) , and the fluorescence intensities were read using a microplate fluorometer at excitation/emission wavelengths of 485\u2013530\u00a0nm.2.21Intracellular NAD(P)H levels were measured by autofluorescence at excitation/emission wavelengths of 355\u2013460\u00a0nm [2.222 in the medium into the air during the experiment.The oxygen concentration in culture medium was determined using oxygen-sensor microplates according to the manufacturer's instructions. The well in the OxoPlate was overlaid with 300\u00a0\u03bcl of mineral oil to prevent diffusion of O2.23Hypoxia inside the spheroids was detected using a LOX-1 hypoxia probe according to the manufacturer's instructions. The hypoxic regions emitting red phosphorescence were visually detected through an Olympus IX71 microscope .2.246 cells) in 100\u00a0\u03bcl of phosphate-buffered saline were injected into the subcutaneous flanks of nude mice. Once tumors became palpable, the tumor size was measured twice weekly using calipers, and the tumor volume was calculated according to the formula: V\u00a0=\u00a0ab2/2, where a and b are the tumor length and width, respectively. When the tumor volumes reached an average of approximately 100\u2013150\u00a0mm3, the mice were randomly assigned to one of the following six treatment groups: 1) vehicle (n\u00a0=\u00a06), 2) ESI-09 , 3) ESI-09 , 4) bevacizumab , 5) bevacizumab , and ESI-09 (n\u00a0=\u00a07) or 6) bevacizumab and ESI-09 (n\u00a0=\u00a07) for the indicated periods. At the end of the treatment period, blood samples were obtained by vena cava puncture under terminal anesthesia and the tumors were harvested, weighed, fixed in formalin, and embedded in paraffin for further histological analysis. Cell necrosis was evaluated in 3-\u03bcm sections stained with hematoxylin and eosin or DAPI according to the following criteria: cell swelling and lysis, loss of architecture, karyorrhexis, and karyolysis [All of the mice used in the experiments were cared for in accordance with the standards of the Institutional Animal Care and Use Committee under a protocol approved by the Animal Care and Use Committee of the CMIC Pharma Science Co., Ltd., Bioresearch Center . Female BALB/c-nu (nu/nu) mice (5 weeks old) were obtained from Charles River Laboratories Japan, Inc. . The mice were kept in a 12-h light and dark cycle and acclimatized for 1 week before the study. To generate tumor xenografts, A549 cells . The sample size was chosen according to previous empirical experience. The experiments were not randomized and the investigators were not blinded to the allocation. Significant differences were statistically analyzed by performing Student's t test, the Tukey\u2013Kramer test, or Dunnett's test as appropriate. A 33.1To examine the effect of acidosis on lung cancer cell survival under low-glucose conditions, the A549, H1299, PC3, and H1975 cells were grown to confluence in growth medium, then serum-starved and incubated in medium at pH 7.4 or 6.8 containing different glucose concentrations. As shown in 3.2Acidosis decreased intracellular ATP content without increasing the ADP/ATP ratio, showing a reduced ATP pool while maintaining a proper energy balance A. Acidos3.3Upon screening our in-house small-molecule compounds, we identified ESI-09, a previously known inhibitor of exchange protein directly activated by cAMP (EPAC) 1 and 2, for a relevant hit compound that reduced cellular ATP content and cell survival in glucose-free acidic medium . However3.4The Seahorse Mito stress test assay showed that ESI-09 and HJC0197 induced proton leaks that disengaged oxygen consumption from ATP synthesis , indicating that ESI-09 and HJC0197 uncoupled mitochondrial respiration C. Acidos1F0 ATP synthase is presumed to work in reverse mode and hydrolyze ATP to maintain \u0394\u03c8m by pumping protons out of the matrix [1F0 ATP hydrolase inhibitor BMS-199264 [1F0 ATP hydrolase.If mitochondrial respiration is uncoupled , Fe matrix . SupportS-199264 , which iESI-09 and HJC0197 also increased cellular glucose uptake to sustain a compensatory increase in glycolytic ATP production and a futile cycle of OXPHOS . ConsequThese results indicated that ESI-09 and HJC0197 acted as mitochondrial uncouplers that disengaged fuel oxidation and electron transport from ATP synthesis and consequently not only inhibited ATP production but also created a futile cycle of substrate oxidation and electron transport in an effort to maintain mitochondrial membrane potential, leading to wasting of ATP and fuel .3.5Among the tested EPAC inhibitors, only ESI-09 and HJC0197 showed mitochondrial uncoupling activities , indicat0) A549 cells in the low-glucose medium, which verified that the anti-cancer action of ESI-09 is mediated by mitochondrial deterioration , mitochondrial ATP consumption, and hypoxia G. Increa3.8The in\u00a0vivo anti-tumor activity of ESI-09 was evaluated in A549-cell xenograft mice. Because impeding angiogenesis would promote glucose depletion and thus might improve the efficacy of ESI-09, we tested the effects of a monotherapy with ESI-09 , a monotherapy with the anti-vascular endothelial growth factor antibody bevacizumab , and a combination therapy with ESI-09 plus bevacizumab . The mon4We reported two major findings in this study. First, we demonstrated that acidosis limited cellular consumption of glucose and ATP, which caused tumor cells to enter a metabolically dormant but energetically economic state that supported tumor cell survival during glucose starvation. Second, we identified two known EAPC inhibitors, ESI-09 and HJC0197, as compounds that effectively killed tumor cells in the low-glucose medium at either acidic or neutral pH. ESI-09 acted as a mitochondrial uncoupler independent of EPAC inhibition that disengaged fuel oxidation and electron transport from ATP synthesis; as a result, it not only inhibited ATP production but also created a futile cycle of substrate oxidation and electron transport in an effort to maintain mitochondrial membrane potential, leading to wasting of ATP and fuel . Less cytotoxicity of ESI-09 under normal-thlower glucose conditions will be ideal for therapeutic translation in reducing side effects in normal healthy tissue and selectively killing tumor cells in a low-glucose microenvironment. We conclude that ESI-09 is a potent anti-cancer uncoupler that can target metabolic vulnerability to low-glucose conditions, which are often acidic H.We found that the acidosis-induced metabolic reprogramming to save energy (ATP) and fuel (glucose) involved two distinct mechanisms of action by acidosis: first, the inhibition of glycolysis that consumed a large amount of glucose as fuel and second, the inhibition of rRNA/protein synthesis that consumed a large amount of ATP. Our findings are supported by those of several previous studies. For example, acidosis has been shown to inhibit pH-sensitive glycolytic enzyme phosphofructokinase and stim0F1 ATPase to maintain the mitochondrial membrane potential, and scavenging available fuels (glucose and O2) by a futile cycle of substrate oxidation. Using the analogy of energy production from an automobile engine, we propose that acidosis probably shifts engine operation to an economical mode with lower power (ATP) output but less fuel (glucose and O2) consumption. Unlike ETC inhibitors, which just turn off the engine , mitochondrial uncouplers, such as ESI-09 and HJC0197, are just as likely to rev the engine by keeping the gas pedal in neutral, which continues wasteful consumption of fuels (glucose and O2) and energy (ATP) to maintain futile engine rotation without any substantial energy generation . There is a natural scarcity of nutrients and O2 in the TME. If mitochondrial uncouplers force tumor cells to scavenge all available nutrients, such as glucose, glutamine, and fatty acids, or at least both glucose and O2, they would no longer survive that enabled partial and reversible pH-dependent polarization. ESI-09 has several advantages over previous uncouplers. ESI-09 had an effective concentration range of 1\u201310 \u03bcM, which was very close to that of the classical uncoupler FCCP, but did not depolarize the plasma membrane, in contrast to FCCP (ESI-09 and HJC0197 have been identified in high-throughput screening as specific competitive inhibitors that target the cAMP-binding domain of EPAC/cAMP-guanine exchange factor (GEF) Supplem. However to FCCP F, and ex to FCCP . Further to FCCP .2 not only in tumors but also in non-tumorous tissue in poorly vascularized organs. Conversely, however, uncouplers have been reported to prevent ischemia-reperfusion injury by reducing ROS production [However, the clinical application of ESI-09 for cancer therapy may impose several challenges. First, mitochondrial uncouplers generally have a narrow therapeutic window between efficacy and toxicity . For exaoduction . Fourth,oduction .ESI-09 might exert its anti-cancer action not only by mitochondrial uncoupling but also by EPAC inhibition because EPACs, which catalyze the exchange of guanosine 5\u2032-diphosphate and guanosine 5\u2032-triphosphate (GTP) on the small GTPase Rap1 and Rap2, are actively involved in cell adhesion and migration . Recent In conclusion, we identified ESI-09 as a potent uncoupler that can target metabolically vulnerable tumor cells to low-glucose stress even under acidic conditions. The higher cytotoxicity under lower-than-normal glucose conditions suggests that ESI-09 could be safer than conventional chemotherapy for reducing side effects on normal tissue, targeting metabolic dormancy, treating a variety of cancer cell types unlike many drugs specifically targeting genomic alterations, and combating tumor metabolic flexibility and redundancy . Thus, EMinistry of Education, Science, and Culture, Japan .This study was supported by a grant-in-aid for scientific research from the Conceptualization, K.A. Methodology, Y.M., R.K., T.T., and K.A. Investigation, Y.M., R.K., J.K., and K.A. Validation, N.K., K.Y., and H.N. Writing original draft, Y.M. and K.A. Review and editing, K.A., N.K., and H.N."}
+{"text": "The design has several advantages over other traditional closed microfluidic platforms: (1) it enables controlled unidirectional flow of media at physiological rates to support vascular function, (2) it allows for very small volumes which makes the device ideal for studies involving biotherapeutics, (3) it is amenable for multiple high resolution imaging modalities such as transmission electron microscopy (TEM), 3D live fluorescence imaging using traditional spinning disk confocal microscopy, and advanced lattice light sheet microscopy (LLSM). Importantly, we miniaturized the design, so it can fit within the physical constraints of LLSM, with the objective to study physiology in live cells at subcellular level. We validated barrier function of our brain microvessel-on-a-chip by measuring permeability of fluorescent dextran and a human monoclonal antibody. One potential application is to investigate mechanisms of transcytosis across the brain microvessel-like barrier of fluorescently-tagged biologics, viruses or nanoparticles.We describe here the design and implementation of an The blood\u2013brain barrier (BBB) is a unique and highly selective vascular interface that separates the peripheral blood circulation from the neural tissue in order to maintain a homeostatic microenvironment within the central nervous system (CNS) that allows the neuronal network to function properly .The BBB is a complex vascular structure with specialized endothelial cells as its core element, surrounded by extracellular matrix (ECM) and supporting cells, such as astrocytes and pericytes . Brain mHowever, these highly selective barrier properties also extremely limit the therapeutic efficacy of drugs and hinder the treatment of neurological diseases such as Alzheimer\u2019s disease, multiple sclerosis, Parkinson\u2019s disease, HIV infection and brain tumors . Beyond in vivo models are of highest physiological relevance since the BBB is embedded in its natural microenvironment. These models are, however, limited in their throughput. Furthermore, animal models may not predict BBB penetrance and efficacy of drugs in humans due to interspecies differences in the molecular composition of the BBB microvessels and transporters (such as Glut-1 and insulin receptor) . These seceptor) . To overeceptor) . Nevertheceptor) . Hence, in vitro human brain microvessel-on-a-chip consisting of a 3D microfluidic model with a hollow channel in which a continuous monolayer of cells can grow at the interphase between the lumen and the underlying ECM. For our studies, we chose the brain microvascular endothelial cell line TY10 which is a well-established BBB model system . TY10 cells were used between passage 17\u201325 and cultured in ScienCell complete endothelial cell medium . Cell detachment was performed using Accutase\u00ae when cells were \u223c80\u201390% confluent before being seeded into the microfluidic devices. Cells were routinely tested for mycoplasma contamination and found negative.Human brain derived microvascular endothelial cells (TY10 cell line) were isolated from normal brain tissue from a patient with meningioma, and immortalized with retroviral vectors harboring a SV40 large T antigen gene that is engineered to drive proliferation at 33\u00b0C . The TY1A lentiviral vector expressing a plasma membrane targeted eGFP (memGFP) containing a chimera of the N-terminal 41 amino acids of human myristoylated alanine-rich C-kinase substrate (MARCKS) fused to eGFP was made by co-transfection of a plasmid harboring memeGFP and Virapower Packaging Mix into 293T cells. Culture media was harvested 72 h later, cellular debris pelleted by low-speed centrifugation, and further clarified by 0.45 \u03bcm filtration with Millipore steriflip vacuum filters . The supernatant from the viral preparation was added to a flask of TY10 cells during passaging and allowed to incubate for 24 h at 33\u00b0C before switching back to the normal feeding schedule of every other day. The cells were sorted by flow cytometry for eGFP positive cells after 10 days in culture and subsequently expanded and maintained as described above.TM 568 and 647 protein-labeling kits to produce hmAb-AF568 and hmAb-AF647 following the manufacturer\u2019s protocol.The recombinant monoclonal human IgG1 antibody (produced by Biogen) was expressed in CHO cells and purified through Protein-A Affinity Chromatography. The purified protein was fluorescently labeled with Alex Fluor2. The post-exposure baking was the same as for soft baking. The mold was developed for 10 min in 20 ml MicroChem SU-8 developer, rinsed with isopropyl alcohol and blown dry prior silianization by incubating the wafer in a desiccator under reduced pressure in presence of an aluminum cup with 3 drops of trichlorosilane . Hard bake was performed on a hotplate at 150\u00b0C for 15 min.Photomasks with the chip design depicted in Microfluidic devices were subsequently produced by soft lithography; Sylgard 184 elastomer Polydimethylsiloxane (PDMS) was mixed with curing agent , at a 5:1 ratio in a mixer including a 2 min de-foaming step before pouring it onto the master silicon wafer designed by our lab and spin-coating at 400 rpm for 40 s. The utilized speed yielded a PDMS film of 160 \u03bcm thickness that was degassed in a vacuum desiccator for 10 min and cured in an oven at 65\u00b0C for 1 h. The PDMS film was peeled off the master and placed in a plastic petri dish at 65\u00b0C overnight to fully cure. To remove non-crosslinked oligomers within the PDMS that can leach out and contaminate the culture medium , cut PDMTM 30 min epoxy resulted in the sturdiest connection after overnight incubation and further allowed us to remove air bubbles in the epoxy after mixing through centrifugation for 30 s at 14,000 x g in a tabletop centrifuge. The chip was activated by air plasma treatment as above and further cleaned by injecting sequentially 0.5 ml of each acetonitrile, purified water, 0.5 M KOH and again water.To promote bonding, the chips were placed on a hot-plate at 150\u00b0C for 15 min. We tested several glues to fix the Tygon microbore tubing, 0.010\u201d \u00d7 0.030\u201d OD on the chip and SLOW-CURETo functionalize both glass and PDMS surface with primary amine groups, the chips were silanized by pipetting 0.5 ml of a fresh 1% aqueous solution of 3-(Ethoxydimethylsilyl) propylamine on the chip and incubation for 15 min at RT before rinsing with twice with 1 ml pure water. Subsequently, the surfaces were further functionalized by adding 0.3 ml 2.5% glutaraldehyde and incubation for 15 min before the devices were rinsed extensively with pure water. The Schiff bases formed on proteins after glutaraldehyde immobilization are stable without further reduction, as has been demonstrated in surface-protein conjugation . To furtA Pluronic F-127 passivated 100 \u03bcm acupuncture needle was inserted from the outlet toward the inlet of the brain microvessel-on-a-chip to provide the required scaffold for the culturing matrix as indicated in \u00ae . Genipin is a crosslinking agent that covalently attaches to primary amino groups exposed on protein surfaces according to the manufacturer\u2019s protocol. In brief, Cytofix was added to a 1 ml syringe and perfused through the microvessel at a flow rate of 1 \u03bcl/min for 30 min before changing to the Cytoperm buffer (diluted 1:10 in PBS) for 1 h at 1 \u03bcl/min. The flow was then stopped and the brain microvessel-on-a-chip placed on a well of a six well plate in 2 ml of Cytoperm buffer (diluted 1:10 in PBS) overnight. The microvessel was stained with AlexaFluor488 Phalloidin and NucBlue by perfusing the dyes in Cytoperm buffer at 1 \u03bcl/min through the microvessel for 1 h, followed by washing with 0.1% BSA in PBS buffer for 4 h at 1 \u03bcl/min. Images were collected using Zeiss LSM 710 microscope (10x objective) through the bottom glass slide.5 cells per well. Cells were allowed to proliferate for 3 days at 33\u00b0C, 5% CO2 before they were switched to 37\u00b0C, 5% CO2 for 3 days to initiate differentiation of TY10 cells. Cells were fixed with 4% PFA for 10 min at 4\u00b0C and then blocked with 10% normal goat serum serum for 30 min at RT. Staining was performed under permeabilized conditions using BD Perm/Wash Buffer . Primary antibodies were incubated for 3 h at RT. The following primary antibodies were used: anti-CD31 , anti-ZO1 , anti-Occludin , anti-Claudin 5 , anti-Glut-1 , anti-TfR and anti-Laminin . The following secondary antibodies were incubated for 45 min at RT: goat anti-mouse AlexaFluor 488 , goat anti-rabbit AlexaFluor 488 , and goat anti-rabbit AlexaFluor 568 , supplemented with Hoechst 33342 . For imaging, Zeiss LSM 710 Confocal and Leica SP5 Confocal microscopes (40x objective) were used, and image processing was performed in ImageJ (NIH).TY10 cells were seeded in a 24-well glass bottom plate , coated with rat tail collagen type I at 1 \u00d7 10\u00ae FluoroBriteTM DMEM was added. Medium containing 25 \u03bcg/ml of 10 kDa FITC-dextran or hmAb-AF568 was added through the inlet at a flow rate of 1 \u03bcl/min for all the experiments. The inlet was connected to microvessels with and without TY10 cells and image acquisition was started. Leakage of the fluorescent substrate (dextran or hmAb) from the lumen of the microvessel into the adjacent collagen matrix was imaged using a spinning disk confocal microscope with 40x water immersion objective. The fluorescence intensity profiles and ratios between the fluorescent signal in the basal and apical region of the microvessel tube were analyzed using MATLAB . Apparent permeability (Papp) was used for quantifying diffusional permeability as described (0 (r/2), where \u0394I is the increase in total fluorescence intensity upon adding labeled dextran or labeled hmAb to the lumen, (dI/dt)0 is the temporal initial rate of linear increase in intensity as the labeled molecules diffuse out of the microvessel into the surrounding collagen matrix, and (r) is the radius of the microvessel (100 \u03bcm for our brain microvessel-on-a-chip). All experiments were carried out at n = 4\u20136; exact numbers are mentioned per experiment in figure captions. Graphs were plotted using GraphPad Prism 6 .Chips were washed with ECM culture medium (once with 1 ml added to the top of collagen followed by a flow at 1 \u03bcl/min for 15 min) to ensure proper flow profiles during the subsequent barrier integrity assay. Next, all medium was aspirated from the chip and 1 ml of medium without fluorescent compound using Gibcoescribed . In brie2 for 3 days, then switched to 37\u00b0C, 5% CO2 for another 3 days for differentiation, with media changes every other day. Transwell inserts without cells were used as control. On the day of the permeability assay, media was refreshed in both chambers and 1 mg/ml final concentration of 10 kDa FITC-Dextran was added to the top chamber. The plate was incubated for 1 h at 37\u00b0C, 5% CO2 after which samples of 100 \u03bcl were taken from the bottom chamber and transferred to a black/clear bottom 96-well plate. Fluorescence intensity was determined with a plate reader set at excitation 490 nm and emission 535 nm.Transwell inserts were coated with 50 \u03bcg/ml rat tail collagen type I in 1% acetic acid for 1 h and then washed with PBS prior to cell seeding. Per 12-well transwell insert, 125,000 TY10 cells were seeded in 1 ml ECM , and 2 ml ECM was added to the bottom chamber . Cells were allowed to proliferate at 33\u00b0C, 5% COImaging was done using a Marianas spinning disk confocal microscope with the water immersion objective lens LD C-Apochromat 40x/1.1 . The images consisted of 512 x 512 pixels with a pixel size of \u223c333 nm. The EMCCD camera settings and laser power were maintained throughout the imaging experiments. Images were acquired using SlideBook 6 and data analysis carried out using SlideBook 8 and custom-made software using MATLAB 2017A . For the analysis of heat maps and Papp, ROIs were the entire original field of view.\u22175-mm rectangular #1.5 glass coverslip was picked with forceps, and placed in the sample bath of the 3D LLSM. The sample was imaged in a time series in 3D using a dithered multi-Bessel lattice light-sheet by stepping the sample stage at 200 nm intervals in the s-axis equivalent to \u223c104 nm translation in the z-axis. Each 3D stack corresponded to a pre-deskewed volume of \u223c80 \u03bcm x 120 \u03bcm x 47 \u03bcm (800 \u00d7 1200 \u00d7 451 pixels). The sample was excited with a 488-nm laser (\u223c100 mW operating power with an illumination of \u223c77 \u03bcW at the back aperture), a 560 nm laser (\u223c100 mW operating power with an illumination of \u223c176 \u03bcW at the back aperture) and a 642nm laser (\u223c100 mW operating power with an illumination of \u223c121 \u03bcW at the back aperture) to acquire 451 imaging planes, each exposed for \u223c44.1 ms and recorded with two Hamamatsu ORCA-flash 4.0-V2 cameras; thus, each 3D image took \u223c60 s to acquire. The inner and outer numerical apertures (NAs) of excitation were 0.513 and 0.55, respectively. The overall 3D volume of \u223c240 \u03bcm \u00d7 880 \u03bcm \u00d7 180 \u03bcm was obtained by stitching together 165 (3 \u00d7 11 \u00d7 5) 3D stacks, with an overlap of 40 and 9 \u03bcm in the y-axis and z-axis, respectively.A microvessel-on-a-chip fabricated on 82, 2.5 mM CaCl2 in 50 mM Cacodylate buffer pH 7.4) (Sigma) and kept at 4\u00b0C, overnight in the dark. Fixed collagen samples were washed 3 times with a solution containing 50 mM PIPES pH 7.4 kept in ice and then they incubated for 2 h in ice and in the dark in a freshly prepared staining solution (SSI) made of 1% OsO4 , 1.25% potassium hexacyanoferrate (II) and 100 mM PIPES pH 7.4. Samples were rinsed 3 times with ice-cold water and incubated again for a second time for 30 min in ice and in the dark with a freshly prepared staining solution II (SSII). SSII was prepared by 1:100 dilution of SSI in a freshly prepared 1% thiocarbohydrizide . Finally, the samples were washed for 3 times with ice-cold H2O and then incubated overnight in the dark in 1% uranyl acetate at 4\u00b0C.The collagen matrix including the lumen was washed 3 times with PBS and then fixed by immersion in 5 ml of fixing solution . Next day, the samples were washed 3 times with 100% Epon812 and then kept in an oven for 36 h at 60\u00b0C. Sections of 60\u201370 nm in thickness were cut transversally to the long axis of the lumen and imaged with a JEOL JEM 1200 EX TEM microscope with a voltage of 80 KV and a nominal magnification of 15,000.t-test analyses with Bonferroni post-hoc correction. Data were presented as mean \u00b1 standard error of the mean (SEM) where (\u2217\u2217\u2217) denotes a statistically significant difference with p < 0.001 and (ns) indicates a statistically non-significant difference.StatsDirect 3 was used for one-way ANOVA and student\u2019s We engineered an open design microfluidic chip to generate a 3D microphysiological model of the human brain endothelial microvessel readily accessible to optical imaging. The unique characteristics of this novel brain microvessel-on-a-chip are the open design of the cell culture chamber and a cylindrical hollow lumen amenable to continuous unidirectional flow within a casted gel of extracellular matrix (ECM) components. The open system allows direct access of the collagen matrix for efficient exchange of gases and medium in addition to readily access to optical imaging while cells growing with continuous unidirectional flow at the interphase between the casted gel and the lumen mimic the environment of a microvessel.Spinning disk confocal microscopy is performed through the glass slide at the bottom of the microvessel-on-a-chip, while LLSM or AO-LLSM are carried out from the open top as illustrated in The consecutive stages used to generate the cylindrical hollow lumen within the casted gel followed by seeding of endothelial cells on the wall of the lumen are depicted in Cell seeding was performed with two methods. The first one involved use of a cell-concentrator chip designed and operated as indicated in The second, and in our hands preferred cell seeding method , involven = 8) while method 2 had a lower success of 87% (n = 29). Of note, success rate has been defined by a complete cell seeding of the lumen from the first round, resulting in full coverage of the lumen with endothelial cells, without the need for a second round of cell seeding.Extent of seeding was optically monitored with the aid of an inverted microscope by direct inspection of the device placed inside a closed petri dish to ensure sterility. Cellular viability was determined for both cell seeding methods using exclusion of Trypan Blue. These experiments indicate that the two methods have comparable results . In our hands, method 1 was associated with a 100% success rate but at the expense of longer incubation time (24 h vs. 4 h required for method 2) and extra time and cost associated with manufacturing of the cell concentrator microfluidic device. For these reasons, we have mainly opted for method 2 in this study, but intended to offer the reader a second option if cell supply is limiting, for instance.in vitro monolayers of endothelial cells grown on a matrix containing fibronectin, laminin, and collagen type IV exhibit enhanced TEER, suggesting a role for these molecules in promoting the formation of tight junctions derived from control or diseased patients are preferred for in vitro brain microvessels and BBB models. Use of primary cells is restricted to very low passage numbers to prevent down-regulation of the unique features of the BBB . The repin vitro models of the BBB. Use of this approach is not practical for our brain microvessel-on-a-chip model because the geometric constrains prevent us from positioning electrodes on opposite sides of the endothelial monolayer between the cylindrical lumen and the collagen matrix. To circumvent this limitation, we capitalized on our ability to use fluorescence optical imaging with our device as a way to determine permeability coefficient across the endothelial monolayer and hence establish the extent of the barrier function of cells grown in the brain microvessel-on-a-chip. Using spinning disk confocal fluorescence microscopy, we determined the rate of transport of fluorescently tagged humanized monoclonal hmAb-AF568 were also similar , demonstrating that cells formed a functional barrier . It is nl models .Our microfluidic device is the only currently available design that can fit within the physical constraints of LLSM objectives (there is only 170 microns left to fit it the entire microfluidic device). In TM goat anti-human IgG coated polystyrene beads in the collagen matrix, to then capture hmAb-AF647 labeled antibodies perfused through the lumen of the microvessel within the chip; visualization was done using LLSM (+7 \u00b1 1.3+7 (mean \u00b1 SEM in arbitrary units) did not show dependence with distance away from the lumen, consistent with efficient capture of the diffusing antibody.We show our ability to image beads interspersed in the collagen matrix that have captured fluorescently tagged antibodies diffusing from the lumen of the artificial microvessel . In thising LLSM , arrows.In the future, we will capitalize on the recently developed lattice light sheet microscope modified with adaptive optics (AO-LLSM) that has significantly improved optical imaging capabilities to better visualize internal cellular compartments and investigate the transcytosis of antibodies and potentially other biotherapeutics across the endothelial barrier. This system has properties ideal for addressing other biological questions that can benefit from the advantages of LLSM and AO-LLSM because of their high temporal and spatial resolution combined with the very minimal bleaching even when the samples are imaged for prolonged times .Compared to traditional closed platforms, our open design facilitates harvesting of cells for gene expression profiling using RNAseq or quantitative PCR, protein expression by Western Blot or Mass Spectrometry, although the number of cells per microvessel may be limiting for some of these applications. Another advantage of the open chip design is the ease for chemical fixation and sample handling of the biological material located within the collagen associated with TEM, with high resolution volumetric imaging using Focused Ion Beam Scanning Electron Microscopy (FIB-SEM) and also with the newly developed modality of expansion microscopy combined with LLSM (Ex-LLSM) .in vivo BBB. Further, our device is amenable to other barrier-forming cell systems found in vascular beds of peripheral tissues such as kidney or lung, for instance, or systems modeling like the gut epithelium.Our results provide a supporting evidence showing how the open design of our microfluidic brain microvessel-on-a-chip device can be used to facilitate future studies of brain endothelial physiology at a subcellular level, particularly since cells can be grown under controlled unidirectional flow conditions. A next-generation model of the microvessel-on-a-chip could include addition of supporting cells such as astrocytes and pericytes to generate a more complex and physiologically relevant representation of the The readily imaging accessibility of our open design is particularly suited for investigations of molecular transport mechanisms involved in the transcellular transport of biologicals, viruses or nanoparticles with the potential of providing insights at extraordinary level of detail. Although we exemplified here the implementation with the LLSM system, it is also designed to take advantage of AO-LLSM, which enables capture of high-resolution 3D movies of collective behavior of cells in a multicellular environment .All datasets used and/or analyzed during the current study are available from the corresponding author TKi upon reasonable request.MS, MD, GM, and TKi conceived the project. MS and GM were involved in all experiments. MD, MS, GM, SU, and TKi designed the brain microvessel-on-a-chip. RH helped with building the brain microvessel-on-a-chip devices under IK and MS supervision. GM and BO provided advice on all aspects of the cell biology associated with this project. BO performed immunostainings. TG performed dextran permeability assays in transwell. IK and MS performed spinning disk confocal microscopy. KO performed lattice light sheet microscopy under TKi\u2019s supervision. GD helped with data analysis. GN performed electron microscopy. FS, YS, and TKa provided the parental TY10 cells and advised on cell culture procedures. TKi supervised the project. MS, BO, and TKi wrote the manuscript with comments from all authors.GM and BO are employees and shareholders of Biogen. TG was employee and shareholder of Biogen at the time the study was performed. TKi is a visiting scientist at Biogen. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}
+{"text": "IntroductionThe standard of care for early-stage non-small cell lung cancer (NSCLC) is surgery. However, for medical inoperable patients stereotactic body radiation therapy (SBRT) is an alternative method. The aim of the study is to assess the overall survival (OS), progression-free survival (PFS) and local control (LC) of patients diagnosed with NSCLC\u00a0in Manitoba, Canada, between 2013 and 2017 and managed with SBRT.Materials and methodsThis retrospective study included a total of 158 patients that were diagnosed with stage I-II NSCLC and were treated with lung SBRT between 2013 and 2017 in Manitoba. Demographics and clinical data were retrospectively extracted from the electronic patient record. Kaplan-Meier and Cumulative incidence curves were used to describe the OS, PFS, and LC outcomes.ResultsFrom the 158 patients, 32 patients were treated with 60 Gy in eight fractions, while 121 patients were treated with 48 Gy in four fractions. Only 85 patients had biopsy-proven NSCLC. The median OS was 2.87 years . OS rates at one and two years were 85% and 66%, respectively. The median PFS was 2.03 years (95% CI 1.65-2.77). Furthermore, one-year and two-year PFS rates were 77% and 51%, respectively. Only 10 patients progressed locally at one year and 17 at two years, making the LC rate 93% at the one-year and 87% at the two-year mark.ConclusionThese findings add to a growing evidence base supporting SBRT in the treatment of clinically suspected and biopsy-proven early-stage NSCLC patients. The most common malignancy worldwide to date is lung cancer, accounting for 11.6% of all new cancers diagnosed , and it There is no screening program for the early detection of lung cancer in Canada although there are studies investigating the feasibility of low-dose computed tomography (CT) for high-risk populations . Chest CA tissue diagnosis is usually made before commencing radiotherapy; however, some patients may have significant comorbidities that may limit tissue diagnosis by biopsy . In suchFor clinically operable early-stage NSCLC, surgical resection is the best treatment modality to achieve a cure . For thoIn Manitoba, SBRT has been offered to medically inoperable patients in early-stage NSCLC patients since 2013. Not all patients who were treated with SBRT had tissue confirmation for malignancy. Furthermore, in this study, we analyze the clinical outcome of patients who were treated with SBRT, whether they had a biopsy or not confirming malignancy in Manitoba.Study population and data accrualThis retrospective chart review was conducted on\u00a0patients diagnosed with early-stage (stage I-II) non-small cell lung cancer in the province of Manitoba, Canada, between January 2013 and December 2017. Patients were included in the study whether they were diagnosed clinically or through biopsy confirming\u00a0NSCLC. The study was approved by the regulatory local ethics committee. Patients were identified through the radiotherapy treatment record registry.Initial tumor node metastasis staging was determined based on imaging studies, including computed tomography of chest, abdomen, and pelvis, PET-CT scans. The overall staging was determined according to the American Joint Committee on Cancer, Seventh Edition guidelines. Local eligibility criteria to receive SBRT included tumors \u22645 cm with or without chest wall involvement; patients with more than one primary lung tumor were also eligible. Patients\u00a0were deemed medically inoperable or declined surgery. Patients were to be considered N0 if the hilar or mediastinal lymph nodes were \u2264 1 cm and there was no abnormal uptake on FDG PET-CT scan. Patients were excluded from receiving SBRT if organ\u00a0at risk constraints were not met, the patient was unable to lie flat for 60 minutes, or intolerant of the immobilization device. Two SBRT dose regimes were mainly used. A dose of 48 Gy in four fractions (BED = 106 Gy10), with fractions at least 36 hours apart, was used when the tumor was more than 10 mm away from mediastinal or pericardial pleura for added safety. The other regimen used was 60 Gy in four fractions (BED = 105 Gy10). This dose fractionation was considered if the tumor was located between 6 mm and 10 mm away from mediastinal or pericardial pleura, or dose constraints for four fractions were not met, excluding the chest wall and ribs.Data collected included patient demographics, staging, pathological details, disease progression, site of progression, and follow up. Data collection was completed on June 1, 2019.Statistical analysesClinical and demographic characteristics of the cohort were described using frequencies and percent for characteristics measured on a categorical scale, while median and interquartile ranges were used to describe characteristics measured on a continuous scale. Measures of overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method, while measures of LC were estimated using cumulative incidence curves. Differences in OS and PFS between categorical patient characteristics were investigated using Log-rank testing, while differences in LC between categorical patient characteristics were investigated using K-sample tests. P values \u2264 .05 were considered indicative of a significant difference. Univariable Cox regression models fitted with restricted cubic splines were used to investigate the relationship between non-linear continuous patient characteristics and OS and PFS. Likewise, univariable competing risk models fitted with restricted cubic splines were used to investigate the relationship between LC and non-linear continuous patient characteristics. The number of knots in each spline function was determined using Akaike\u2019s information criteria. Knots were placed at fixed quantiles of the predictor variable\u2019s marginal distribution for each .A total of 158 patients were included who met the inclusion criteria with a median age of 76 years and an interquartile range of 13. Two-thirds of the study cohort (n=95) were women and one-third were men (n=63). Eighty-five patients (53.8%) had tissue-confirmed NSCLC diagnosis, while 73 (46.2%) did not have a biopsy and were diagnosed clinically. In biopsy-proven NSCLCs, adenocarcinoma was found in 49 patients, almost double the squamous cell carcinoma pathology, which was found in 25 patients. Three-quarters of the study cohort received 48 Gy in four fractions (BED = 106 Gy10). Eighty percent of the population (n=127) were smokers . One- and two-year OS were found to be 85% and 66%, respectively . At one year, the progression-free survival rate was 77% (95% CI 0.69-0.83) and at two years was 51% (95% CI 0.42-0.60) .Another multi-institutional study across Canada, the USA, and Europe included data on early-stage NSCLC patients treated with SBRT. A total population of 701 patients was assessed, of whom 67% had tissue confirmation of their tumors . They loA population of almost 600 patients with early-stage NSCLC was also studied in the Netherlands, of which 65% of the treated population with SBRT had no biopsy. The outcomes observed showed no difference between biopsied versus non-biopsied patients, with three-year OS and LC rates of 55% and 90%, respectively .An interesting study published by a group from Yale indicated that there is a rising trend observed in the USA in the number of patients undergoing SBRT without biopsy over time.\u00a0This project identified almost 7000 patients within the National Cancer Database in the USA with stage I NSCLC who received SBRT between 2003 and 2011. The majority of the cohort (95%) had a tissue biopsy before SBRT; however, over time, the number of patients treated without tissue biopsy increased. Being medically inoperable, smaller tumor size, and facility type were the only factors in multivariate analysis associated with odds of SBRT without biopsy [Looking at the results presented in the current study, they resemble those discussed previously, with LC of 93% at the one year and 87% at the two-year point. Furthermore, we expected a low median OS that was 2.87 years. OS rates at one and two years were 85% and 66%, respectively; this could be due to the extensive comorbidities found in this frail population.We were not able to report any differences in outcome based on the presence or absence of tissue biopsy, which is comparable to the current literature. Near half of our cohort had no tissue confirmation, which is higher than the Yale study data. One reason could be the higher amount of medically inoperable patients that may have a poor general condition and who are incapable of undergoing certain procedures and investigations. Another reason could be the availability of a multidisciplinary team that discusses thoroughly complex cases in our weekly thoracic disease site conference that have a high comfort level to treat patients empirically based on specific imaging criteria.One of the limitations of this retrospective study is its relatively small sample size. Also, potential selection biases such as poor fitness, personal choice, and other weaknesses were associated with these studies. Looking at the excellent outcomes in the group of patients that had no tissue confirmation and received empiric treatment, we have to question if this was cancer at the time of treatment, especially when we take into consideration that the smaller and less PET avid tumors were more likely present in this group. Moreover, the lack of follow up may influence the OS results. Finally, this work represents a single institutional experience and is retrospective in nature.This study adds to the body of literature that early-stage lung cancer patients treated with SBRT have excellent outcomes, whether they had a biopsy-proven NSCLC or were clinically diagnosed. The authors\u00a0recommend tissue biopsy and pathologic confirmation whenever possible. However, growing literature, including this study, suggests that treating non-pathologically confirmed disease is reasonable. A multidisciplinary team and discussion are crucial and play a remarkable role in the decision making of treating patients without tissue confirmation."}
+{"text": "Efforts to elucidate the function of enhancers in vivo are underway but their vast numbers alongside differing enhancer architectures make it difficult to determine their impact on gene activity. By systematically annotating multiple mouse tissues with super- and typical-enhancers, we have explored their relationship with gene function and phenotype.Though super-enhancers drive high total- and tissue-specific expression of their associated genes, we find that typical-enhancers also contribute heavily to the tissue-specific expression landscape on account of their large numbers in the genome. Unexpectedly, we demonstrate that both enhancer types are preferentially associated with relevant \u2018tissue-type\u2019 phenotypes and exhibit no difference in phenotype effect size or pleiotropy. Modelling regulatory data alongside molecular data, we built a predictive model to infer gene-phenotype associations and use this model to predict potentially novel disease-associated genes.Overall our findings reveal that differing enhancer architectures have a similar impact on mammalian phenotypes whilst harbouring differing cellular and expression effects. Together, our results systematically characterise enhancers with predicted phenotypic traits endorsing the role for both types of enhancers in human disease and disorders. Mammalian gene expression and their parallel gene networks are tightly controlled by non-coding regulatory regions such as enhancers, their accompanying transcription factors (TFs), chromatin re-modellers and non-coding RNAs . Large sBRD4 ), while SEC is depleted .Previous studies have identified SEs to be associated with genes that regulate cell identity and are therefore unlikely to be involved in a housekeeping role , 31. To p\u2009=\u200910\u2212\u20091 and regu mammals ) in browgulation ) in heare marrow ) in bonenscripts , 55) in \u2212\u20098) and abnormal synaptic transmission (q\u2009=\u20092.46\u2009\u00d7\u200910\u2212\u20097), and diseases such as bipolar disorder (q\u2009=\u20098.52\u2009\u00d7\u200910\u2212\u20097) and unipolar disorder (q\u2009=\u20096.26\u2009\u00d7\u200910\u2212\u20095). Similarly, genes related to heart-specific enhancers are enriched for phenotypes like abnormal cardiac muscle contractility (q\u2009=\u20099.05\u2009\u00d7\u200910\u2212\u200916) and diseases like cardiomyopathy (q\u2009=\u20095.45\u2009\u00d7\u200910\u2212\u200914) in CH12 enhancer associated genes is consistent with the idea that oncogenes are placed under the effect of strong enhancers during cancer development leading to over-expression of these genes ) and TEC . Finally, using GTEx data, we compared the number of expression quantitative trait loci (eQTLs) associated with SEC and TEC and observed no significant difference in the number of cis-eQTLs associated with SEC and TEC relative to knockouts of other genes (such as those associated with TEs). We compared several standardised phenotyping procedures within the IMPC and observed a significant difference in severity only for acoustic startle and pre-pulse inhibition Fig.\u00a0. Howeverknockout to examip\u2009\u2264\u20090.016, except thymus p\u2009=\u20090.056) among enhancer-associated genes in each of the 22 tissues, using the STRING database . Then inEnhancer regions contain many binding sites for TFs which contribute to important tissue-specific functions by regulating the target genes . To inveSpi1, with cistrome peaks colocalized with bone marrow enhancers, is implicated in myeloid and B-lymphoid cell development [Gata4, with cistrome peaks colocalized with heart enhancers, is involved in myocardial differentiation and function [Dmrt1, with cistrome peaks colocalized with testis enhancers plays a key role in male sex determination and differentiation [p-value <\u200910\u2212\u20093) and 113 TFs (148 TF-tissue pairs) with SEs across all tissues and cell types and significant colocalisation with corresponding TEs, and 29 TFs with SEs across all tissues and cell types. Examples of such TFs include Hnf6 in liver (\u03c4exp\u2009\u2212\u2009frac\u2009=\u20091), Nkx2\u20135 in heart (\u03c4exp\u2009\u2212\u2009frac\u2009=\u20091), Gata1 in MEL cells (\u03c4exp\u2009\u2212\u2009frac\u2009=\u20090.93) and Neurog2 in brain (\u03c4exp\u2009\u2212\u2009frac\u2009=\u20090.98).First, we found that TFs which have significant colocalisation with enhancer elements include regulators known to be implicated in the corresponding tissue-specific regulation Fig.\u00a0. For exaelopment ; Gata4, function ; and Dmrntiation . OverallOverall, TF cistrome peaks were identified to significantly colocalise with both SEs and TEs, but a greater number of TFs were identified to colocalise with TEs compared to SEs. This could be explained by the relatively large number of TEs in the genome. To investigate this further, for each TF with significant enhancer localization, we computed their transcription factor binding site (TFBS) density in SEs and TEs. The TFBS density could be defined as a measure of TFBS clustering in SEs or TEs see . To summOur findings show mouse enhancer associated genes are correlated to a great extent with tissue-specific gene expression as well as phenotypes. We explored the utilisation of this dataset to infer mammalian gene-phenotype associations as has previously been done for protein-protein interaction (PPI) and gene expression data \u201366. We iBy integrating various features together, 10 combinations were formed, constructing 10 distinct classifiers for each phenotypic domain. The predictive power of each classifier was assessed by generating Receiver Operating Characteristic (ROC) and precision-recall (PR) curves based on 5-fold cross validation, repeated 10 times with different seeds. The classifier trained on all the gene features combined achieved the best performance with a mean AUC-ROC of 0.78 and AUC-PR of 0.27 across all the phenotype domains Fig. . Howeverp\u2009=\u20095.00\u2009\u00d7\u200910\u2212\u20099) based on evidence integrated from a range of data sources by Open Targets platform. Additional\u00a0file\u00a0In order to evaluate the validity of the predictions from the model, we investigated the novel gene-phenotype predictions made by these classifiers. The predictions classified as incorrect are based on the current knowledge of gene-phenotype associations, but it is possible that there are no, or little, prior knowledge about particular gene function, and thus are novel. This also leads to undermining the true predictive power of a classification model. For such reasons, the top false-positive predictions are most interesting as they could provide new hypotheses about gene function. To systematically examine the top false-positive predictions (prediction score\u2009\u2265\u20090.90) in each phenotype domain, we used the Open Targets Platform and the Regulatory elements have been identified as active in a plethora of cell types and tissues, however there is limited understanding about their relationship to overall gene function and the resulting gene-phenotype relationships. To gain insights into the mammalian regulatory landscape and its potential impact on phenotypic outcome, we focused our analysis on tissue-specific enhancers. By generating a catalogue of super, typical and weak enhancers in multiple mouse tissues we systematically investigated their roles in gene function. From multiple aspects such as gene expression, PPI networks and phenotypes, our study now provides evidence that SE and TE associated genes share common phenotypic outcomes even though their expression profiles and overall numbers in the genome differ.SEs are comprised of dense enhancer clusters spanning large genomic regions and are associated with master transcription factors and other key cell identity genes , 31. We Prior research has thoroughly investigated the role of SEs in complex traits, showing that disease-causing SNPs are more enriched in SEs of disease-relevant cell types , 40, 41.Finally, using a machine learning approach, we systematically evaluated the capability of TSREs and other molecular properties to predict gene-phenotype associations in mouse Fig. . By compIn this study, we systematically characterised different enhancer types with the goal of investigating their roles in gene function. We found that super- and typical-enhancers have different effect on gene expression, but both are preferentially associated with relevant tissue-type mammalian phenotypes and human diseases. We show that genes associated with super- and typical-enhancers exhibit no difference in phenotype effect size or pleiotropy suggesting they share common phenotypic outcomes. Our findings in a diverse range of mouse tissues present opportunities for molecular experiments to investigate regulatory mechanisms in mouse models of human diseases.First, the ChIP-Seq data for histone H3 lysine 4 monomethylation (H3K4me1), histone H3 lysine 4 trimethylation (H3K4me3) and histone H3 lysine 27 monoacetylation (H3K27ac) in 22 mouse tissues and cell lines were collected from ENCODE project (LICR lab) in the form of sequence alignments (BAM files mapped to mm9 mouse genome). The 22 epigenomes include 14 adult tissues: BAT (brown adipose tissue), bone marrow, cerebellum, cortex, heart, kidney, liver, lung, olfactory bulb, placenta, small intestine, spleen, testis and thymus; 2 embryonic tissues: limb and whole brain; and 6 cell lines: bone marrow derived macrophage, CH12 , Esb4 (mouse embryonic stem cells), Es-E14 (mouse embryonic stem cell line E14), MEF (mouse embryonic fibroblast), MEL . Next, we used a multivariate hidden Markov model called ChromHMM to integrate all the ChIP-Seq data and summarise into easily illustratable annotations. The chromatin states were jointly learned across 22 mouse tissues using default parameters. Several HMM models were produced consisting of 4\u20138 chromatin states and identified the 6 state model to provide sufficient resolution to isolate biologically meaningful chromatin states. The resulting chromatin states were then annotated based on the biological significance of the frequencies of combined histone marks. Using this approach, potential active promoter , weak promoter , strong enhancer and weak enhancer annotations were mapped across 22 mouse tissues and cell types. To validate our predicted promoter states (states 1 and 2), we compared 217,678 unique non-overlapping promoters to 22,707 known protein coding genes and recovered 81.66% of known promoters. Similarly, to validate the strong enhancer predictions (state 4), we compared 386,222 unique non-overlapping enhancers to 363 experimentally validated VISTA mouse enhancers and recovered 91.18% of VISTA enhancers from our predictions. Chromatin states with <\u20090.95 posterior probability were filtered resulting in 923,791 strong enhancer (state 4); 309,581 active promoter (state 2); 2,531,993 weak enhancer (state 6); and 427,251 weak promoter (state 1) high confidence annotations respectively.n\u2009\u00d7\u2009s, where n is the number of regulatory elements and s is the number of tissues (i.e. 22). Each row of the matrix is a genomic location of the regulatory element (200\u2009bp in length) and columns represents its posterior probability across all the tissues. The matrices were filtered such that only the regulatory elements with a posterior probability \u22650.95 in at least one tissue were retained. The Tau score for each regulatory element was calculated by the following equation:N is the number of tissues and xi is the posterior probability value. Using the thresholds suggested in [\u03c4reg\u2009\u2264\u20090.15), intermediate (0.15\u2009<\u2009\u03c4reg\u2009<\u20090.85), high (0.85\u2009\u2264\u2009\u03c4reg\u2009<\u20091) and absolute tissue-specific (\u03c4reg\u2009=\u20091).To identify tissue-specific regulatory regions across the 22 tissues, we implemented the Tau method which has been previously used to detect tissue-specific expression , 44. Tauested in , the regFor DNasel accessible regions, we collected DNasel hypersensitivity sites (DHS) in 11 tissues from ENCODE (UW lab) in the form of hotspots. The mean of DNaseI signal was computed wherever multiple replicates were available within ENCODE. The genomic coordinates of tissue-specific enhancer and promoter elements were compared with DNaseI hypersensitive hotspots using BEDTools and the To identify SEs in mouse, we implemented an approach similar to previously used by . Using tThe metagene profiles of mean H3K27ac signal across all the SEs and TEs was calculated as the difference in medians of the two groups divided by the pooled median absolute deviation (MAD). The following formula was used:We used GREAT to assocFor investigating the expression of enhancer associated genes, RNA-Seq data for all 22 tissues and cell lines was collected from ENCODE as read alignments (BAM files). Data for cell lines CH12 and Es-E14 was collected from Standford/Yale lab while rest of the data was retrieved from LICR lab. From the BAM files, the read counts over all genes were quantified using HTSeq and exprt\u2009\u00d7\u2009s, where t is the total number of genes and s is the number of tissues/cell lines. Genes not expressed in any tissue were deleted from the matrix leaving genes expressed in at least 1 tissue. The RPKM values were log2 transformed and quantile normalised (QN) to allow easier comparison of gene expression across tissues. Genes were then sorted by ascending QN value and divided into deciles of equal density and placed into 10 bins. The lowest decile was placed in bin 1, the next lowest was placed in bin 2, and so on until the top 10% of QN values were placed in bin 10. The Tau value (\u03c4exp) for each gene was calculated as:N is the total number of tissues, yi is the normalised expression bin profile component of the gene in tissue i. In order to associate \u03c4exp values to tissues, Tau-fraction (\u03c4exp\u2009\u2212\u2009frac) for each gene in every tissue was calculated as ri is the expression of the gene (in RPKM) in tissue i and M is the maximum expression of the gene (in RPKM) across all the tissues. Based on \u03c4exp\u2009\u2212\u2009frac score, the genes were categorised into low (\u03c4exp\u2009\u2212\u2009frac\u2009\u2264\u20090.20), intermediate (0.20\u2009<\u2009\u03c4exp\u2009\u2212\u2009frac\u2009<\u20090.85) or high (\u03c4reg\u2009\u2265\u20090.85) tissue-specific expression in the corresponding tissues. Housekeeping genes were identified based on a strict \u03c4exp threshold. Genes with low \u03c4exp score (\u22640.20) are uniformly expressed across all the tissues and were considered to be housekeeping genes. We identified 1252 housekeeping genes using this threshold out of which 1171 were protein-coding genes.To examine the relationship between enhancers and expression of their target genes, data from all 22 tissues was combined into gene-tissue pairs and grouped into three classes based on their enhancer association: (1) gene-tissue pairs associated with SEs (SEC); (2) gene-tissue pairs associated with TEs (TEC); and (3) gene-tissue pairs associated with weak/poised enhancers (WEC). In order to quantify tissue-specific expression of target genes, we calculated the tissue specificity index for each gene using the Tau method described earlier. We constructed a matrix of expression values with dimensions To visualise the distinct number of enhancer tissue-types calculated for each enhancer-associated gene Fig. f, we genp\u2009=\u20090.012, OR\u2009=\u20090.82) while TEC is enriched .To investigate the molecular functions and biological processes linked with enhancer associated genes, we combined the SE and TE associated genes across the 22 tissues to make two unique lists. This resulted in 3617 genes to be only associated with SEs and 11,437 genes to be only associated with TEs. These gene sets were then used for GO enrichment analysis using ToppGene suite (Additiop\u2009<\u200910\u2212\u20094). To quantify the severity of phenotypes, we used the percentage change value from each procedure. The percentage change is normalised effect size, which is scaled to make it comparable across various procedures and parameters [https://www.mousephenotype.org/impress). All the parameters within a procedure were grouped together for this analysis. For computing the enrichment of mouse essential genes in SEC and TEC, genes producing a lethal homozygous knockout (960 genes out of 2900) were used.The mouse phenotyping data of enhancer associated gene knockouts was extracted from IMPC . All the statistically significant genotype-phenotype associations and their phenotyping data in IMPC release version 5.0 were used. This version compromised of phenotype data for 3323 gene knockouts, with 2900 genes significantly associated with at least one phenotype attribute was collected from MGD on 14th June 2017.p-value was calculated as y is number of permuted random-known edges greater than the observed novel-known edges and N is the total number of items in our distribution (i.e. 1001).The predicted protein-protein interactions among the genes of interest were extracted from the STRING database using thp-value threshold of 5\u2009\u00d7\u200910\u22124 [For the analysis of transcription factor binding sites colocalised with different enhancer sets, we used a cell type independent cistrome, the general genomic map of regions bound by particular TFs in any cell type . The cis5\u2009\u00d7\u200910\u22124 and thenp-values were corrected for multiple testing using Bonferroni correction. Note that the cistrome segments of a TF could significantly colocalise with enhancers in several different cell types, therefore, we counted the number of significant enrichments as TF-tissue pairs. We also performed the analysis with only the cistrome segments that contain high scoring motif hits from HOCOMOCO. The results were very similar to the analysis where all cistrome segments were considered; about 10% of TFs did not have known binding motifs, and for TFs with known motifs, about 90% of significant TF-tissue pairs were independent from whether the motifs were considered or not of length L, one at 100\u2009L upstream and the other at 100\u2009L downstream. This produced a set of control segments of the same lengths and similar global genomic context as the enhancer segment under study. We checked if any control segments overlapped other constituent enhancers, but such cases contributed only 1\u20132% of the total number of control regions and were safely ignored. The extended enhancer segments and control regions were then intersected with the cistrome peaks of each TF and split into two groups; overlapping (if least 1\u2009bp overlapped) and non-overlapping with the cistrome. The Fisher\u2019s exact test on 2\u2009\u00d7\u20092 contingency tables was used to assess the statistical significance of TF cistrome peaks overlapping constituent enhancers (SE or TE) versus control regions divided by the total coverage of enhancer-cistrome intersection (in bp). We calculated densities for only those enhancers (constituent enhancers of SEs or TEs) which had at least one motif occurrence in its intersection with the cistrome. The Wilcoxon Rank Sum Test was then used to compare the TFBS densities of TF-tissue pairs in SEs and TEs . The non-corrected p-values were used to order the TF-tissue pairs by their level of TFBS density disparity between SEs and TEs. The TF-tissue pairs were grouped into bins based on their p-value and the number of TF-tissue cases where its TFBS density was more in SEs compared to TEs, or vice versa, were counted . Then, we calculated the -log10 of HOCOMOCO motif hits within these cistrome regions . The respective values for each TF were taken as the TFBS features. The final set of the TFBS features covered all TFs for which we had the ChIP-Seq cistrome peaks and a binding motif model (n\u2009=\u2009297). For PPIs, all the protein interactions in mouse were collected from STRING database version 10.5. For a gene g, its PPI connectivity with all strong enhancer and active promoter associated genes in tissue t was calculated as N is the total number of enhancer or promoter associated genes in tissue t and Ii is the combined interaction score between gene g and ith gene. Similarly for each gene, its PPI connectivity with all genes known to be associated with the phenotype domain to be predicted was computed as I is the interaction score and M is the total number of known phenotype associated genes from MGD.To predict mammalian gene-phenotype associations, features were extracted from TSREs, expression, transcription factor binding and PPI data for all protein-coding genes. From the TSRE profiles across 22 tissues, strong-enhancers and active promoters associated with each protein-coding gene were extracted. A score representing the tissue-specific enhancers and promoters in each tissue was computed as The random forest classifier was implemented in R using randomForest and caret package . We sougAdditional file 1: Figure S1. Chromatin state segmentation and characterisation across 22 mouse tissues. Figure S2. Overview of tissue-specific regulatory elements in the mouse genome. Figure S3. H3K27ac activity within SEs and TEs. Figure S4. Enrichment of chromatin marks over stitched cohesive enhancer units. Figure S5. Chromatin activity within SE and TE constituent enhancers. Figure S6. Region-gene associations of regulatory elements. Figure S7. Relationship between enhancer activity and their target gene expression. Figure S8. Impact of constituent enhancer density on target gene expression. Figure S9. Enhancer usage switch associated with genes within SEC and TEC with multiple enhancer tissue-types. Figure S10. Genomic view of genes demonstrating enhancer usage switch. Figure S11. Breadth of phenotypes associated with SE and TE gene knockouts in mouse. Figure S12. Number of eQTLs associated with genes within SEC and TEC. Figure S13. Protein-protein interaction maps of enhancer associated genes. Figure S14. Protein-protein interaction simulations. Figure S15. Transcription factor binding within SE and TE constituents. Figure S16. Performance of random forest classifiers to predict mammalian gene-phenotype associations. Figure S17. Precision and recall of classifiers used to predict gene-phenotype associations. Figure S18. Evaluation of top-scoring false-positives using the Open Targets platform. Table S1. Mammalian phenotype and human disease ontology terms enriched in genes associated with weak-enhancers.Additional file 2. List of genes associated with SEs (SEC) and TEs (TEC) in 22 tissues.Additional file 3. Comparison of enhancer-gene pairs with TADs and EPUs.Additional file 4. Enhancer tissue-type association of SEC and TEC.Additional file 5. Enhancer usage switch scores of genes within SEC and TEC.Additional file 6. Gene Ontology enrichment of genes within SEC and TEC.Additional file 7. Mouse phenotype and human disease enrichment of genes within SEC and TEC in 22 tissues.Additional file 8. Enrichment of TF cistrome peaks within SE and TE regions.Additional file 9. Performance metrics of all random forest classifiers.Additional file 10. Exploration of top scoring predictions and the evidence supporting their association with the corresponding diseases."}
+{"text": "The ability of horse chestnut extract (HCE) to induce contraction force in fibroblasts, a process with remarkable significance in skin repair, motivated us to evaluate its wound healing potential in a series of experiments. In the in vitro study of the ability of human dermal fibroblasts to form myofibroblast-like cells was evaluated at the protein level (Western blot and immunofluorescence). The in vivo study was conducted on male Sprague-Dawley rats with inflicted wounds (one open circular and one sutured incision) on their backs. Rats were topically treated with two tested HCE concentrations (0.1% and 1%) or sterile water. The control group remained untreated. The incisions were processed for wound tensile strength (TS) measurement whereas the open wounds were subjected to histological examination. On the in vitro level the HCE extract induced fibronectin-rich extracellular matrix formation, but did not induced \u03b1-smooth muscle actin (SMA) expression in dermal fibroblasts. The animal study revealed that HCE increased wound TS and improved collagen organization. In conclusion, the direct comparison of both basic wound models demonstrated that the healing was significantly increased following HCE, thus this extract may be found useful to improve healing of acute wounds. Nevertheless, the use of an experimental rat model warrants a direct extrapolation to the human clinical situation. Skin wound healing involves four basic steps: hemostasis, inflammation, proliferation, and maturation . EspeciaAesculus hippocastanum L. extracts (horse chestnut extract\u2013HCE) improve the repair of venous ulcers ) and expressed in g/mm2.The measurement technique was described previously . BrieflyWound specimens were routinely processed for light microscopy , and staining with hematoxylin-eosin (HE)).Used semi-quantitative method was described previously . We evalp < 0.05 was considered to be statistically significant. The wound tensile strengths are expressed as mean \u00b1 standard deviation (SD) and were compared by one-way ANOVA, followed by Tukey\u2013Kramer multiple comparison test. The non-parametric data from the semi-quantitative analysis are expressed as median and were compared by Kruskal\u2013Wallis test. Level of In conclusion, the direct comparison of both basic wound models demonstrated that the healing was significantly increased following HCE, thus this extract may be found useful in improving acute skin wound healing. However, we did not observe a direct effect of HCE on fibroblasts to myofibroblast transition, and thus it is essential to perform further experiments aimed at finding the exact underlying mechanism of action and optimal therapeutic protocol. Finally, a direct extrapolation from this experimental model to the human clinical situation presents the third limitation of our study due to inter-species variability. However, general molecular regulation of wound healing should be similar, and thus the present data encourages further respective investigations in other animal models physiologically and evolutionary closer to humans."}
+{"text": "Stocks of yellow fever vaccine are insufficient to cover exceptional demands for outbreak response. Fractional dosing has shown efficacy, but evidence is limited to the 17DD substrain vaccine. We assessed the immunogenicity and safety of one-fifth fractional dose compared with standard dose of four WHO-prequalified yellow fever vaccines produced from three substrains.50). We defined non-inferiority as less than 10% decrease in seroconversion in fractional compared with standard dose groups 28 days after vaccination. The primary outcome was measured in the per-protocol population, and safety analyses included all vaccinated participants. This trial is registered with ClinicalTrials.gov, NCT02991495.We did this randomised, double-blind, non-inferiority trial at research centres in Mbarara, Uganda, and Kilifi, Kenya. Eligible participants were aged 18\u201359 years, had no contraindications for vaccination, were not pregnant or lactating, had no history of yellow fever vaccination or infection, and did not require yellow fever vaccination for travel. Eligible participants were recruited from communities and randomly assigned to one of eight groups, corresponding to the four vaccines at standard or fractional dose. The vaccine was administered subcutaneously by nurses who were not masked to treatment, but participants and other study personnel were masked to vaccine allocation. The primary outcome was proportion of participants with seroconversion 28 days after vaccination. Seroconversion was defined as post-vaccination neutralising antibody titres at least 4 times pre-vaccination measurement measured by 50% plaque reduction neutralisation test for Bio-Manguinhos-Fiocruz, \u22120\u00b790% (\u20134\u00b724 to 3\u00b713) for Chumakov Institute of Poliomyelitis and Viral Encephalitides, 1\u00b782% (\u20132\u00b775 to 5\u00b739) for Institut Pasteur Dakar, and 0\u00b70% (\u20133\u00b732 to 3\u00b729) for Sanofi Pasteur. Fractional doses from all four vaccines met the non-inferiority criterion. The most common treatment-related adverse events were headache (22\u00b72%), fatigue (13\u00b77%), myalgia (13\u00b73%) and self-reported fever (9\u00b70%). There were no study-vaccine related serious adverse events.Between Nov 6, 2017, and Feb 21, 2018, 1029 participants were assessed for inclusion. 69 people were ineligible, and 960 participants were enrolled and randomly assigned to vaccine manufacturer and dose . 49 participants had detectable PRNTFractional doses of all WHO-prequalified yellow fever vaccines were non-inferior to the standard dose in inducing seroconversion 28 days after vaccination, with no major safety concerns. These results support the use of fractional dosage in the general adult population for outbreak response in situations of vaccine shortage.The study was funded by M\u00e9decins Sans Fronti\u00e8res Foundation, Wellcome Trust (grant no. 092654), and the UK Department for International Development. Vaccines were donated in kind. Yellow fever is a mosquito-borne viral disease that is endemic in 44 countries.Evidence before this studyIn July, 2016, after major yellow fever outbreaks in Angola and DR Congo, WHO published a secretariat information paper including a review of studies assessing the immunogenicity of fractional doses of yellow fever vaccines, and recommended consideration of fractional doses to manage a vaccine shortage. Fractional doses of yellow fever vaccine produced by Bio-Manguinhos-Fiocruz (17DD substrain) were given to approximately 7\u00b75 million non-pregnant adults and children aged 2 years or older in Kinshasa, DR Congo. The evidence to support this action was limited to a single vaccine substrain and to a specific context. To broaden and simplify recommendations, WHO called for additional research to be done.Added value of this studyThis is the first randomised controlled trial assessing all four WHO-prequalified yellow fever vaccines, providing information on the immunogenicity and safety of fractional doses of the vaccine substrains at 10 days, 28 days, and 1 year post-vaccination. The results show that, at 28 days post-vaccination, most participants had high neutralising antibodies and that seroconversion rates in the fractional dose groups were non-inferior to standard dose for all vaccines. Seroconversion rates and neutralising antibodies remained high up to 1 year post-vaccination for both fractional and standard doses for all vaccines. These results are aligned with previous studies using the 17DD substrain vaccine but extend the evidence to randomised comparisons of all four vaccines and to sub-Saharan Africa.Implications of all the available evidenceOur study supports the use of one-fifth fractional doses of all four WHO-prequalified yellow fever vaccines for the general adult population and fills a crucial knowledge gap to support WHO policy on the use of fractional dosing of yellow fever vaccine for outbreak response. The immunogenicity and safety of fractional dosing in children and specific populations, such as those living with HIV, is yet to be established. Long-term studies are warranted to substantiate the duration of protection.An outbreak of yellow fever in 2016 in Angola raised major concerns about the adequacy of vaccine supply. Routine vaccination was suspended in some African countries to meet demand,Four studiesWe assessed, for the first time, the immunogenicity and safety of fractional doses of all four WHO-prequalified yellow fever vaccines, to provide evidence to broaden recommendations to include all WHO-prequalified yellow fever vaccines for fractional dosing.We did this double-blind, individually-randomised non-inferiority trial at the Epicentre Mbarara Research Centre in Mbarara, Uganda, and the Kenya Medical Research Institute-Wellcome Trust Research Programme clinical trials facility in Kilifi, Kenya.The study protocolParticipants were recruited from rural communities in the Mbarara municipality, Mbarara district, Uganda, and Kilifi County, Kenya. Communities were informed about the trial using locally adapted strategies. Individuals interested in participating were invited to the study sites. Written informed consent was required to participate. Eligible participants were aged 18\u201359 years, had no contraindications for vaccination, were not pregnant or lactating, had no history of previous yellow fever vaccination or infection, did not require yellow fever vaccination for travel, and were able to comply with study procedures.Participants were randomly assigned to one of eight equal groups corresponding to the four prequalified yellow fever vaccines at standard or fractional dose. Unique allocation numbers were prepared by an independent statistician using a computer-generated random number list with non-disclosed fixed blocks of size 10, with equal allocation to dose within a block and to a given manufacturer by site. The allocation sequence was concealed using pre-prepared, sequentially numbered scratch-off booklets that were stored securely. After enrolment, the vaccination nurse scratched off the randomisation code indicating the allocated vaccine and dose for the participant. Vaccines were reconstituted and administered in a private room not accessible to other study staff.Participants were masked by covering the volume of the syringe with opaque tape. The vaccination nurse and supervisor overseeing vaccination were aware of allocation; personnel assessing outcomes and investigators were masked to vaccine and dose throughout.A batch of standard 10-dose vials of yellow fever vaccine was selected from each manufacturer with potency at time of release closest to internal minimum specification. Vaccine potency was independently measured at the National Institute for Biological Standards and Control UK; . The freParticipants were followed up at 10 days (\u00b11 day), 28 days (\u00b13 days), and 365 days (\u00b114 days) after vaccination. Participants had a medical consultation at each study visit, and a blood sample was obtained at the first visit (before vaccination) and at each scheduled follow-up visit.50 and PRNT90).Serum samples were separated and aliquoted into 3 samples within 4 h after obtention and stored in \u221280\u00b0C freezers at the study sites. Serum samples were analysed at the Institut Pasteur Dakar , where neutralising antibody titres against yellow fever were assessed by 50% and 90% plaque reduction neutralisation tests and geometric mean fold increase . Seroconversion, GMT, and GMFI were also assessed at 10 days and 1 year after vaccination to assess the rapidity of protection and the lasting effect of vaccination. Safety outcomes were also included as secondary outcomes, and included assessment of adverse events (AEs) for 28 days after vaccination, and serious adverse events (SAEs) throughout follow-up. SAEs were defined as any new health-related problem that occurred during follow-up and resulted in death, was life-threatening, necessitated hospital admission or prolongation of existing hospital stay, or resulted in disability or incapacity. AEs included all untoward medical events and were evaluated in the 30 minutes following vaccination and up to 28 days after vaccination. At the visits at 10 and 28 days after vaccination, a clinician asked for the presence of local reaction, headache, fatigue, muscle pain, fever, gastrointestinal problem, and any other symptom since the previous visit. Participants were also asked to report any other symptoms or concerns during and outside scheduled visits. We recorded the nature, relatedness, severity, and outcome of each AE.50 titre \u226510), a sample size of 120 people per unique dose was required (240 per manufacturer). 960 participants were to be recruited (480 per study site).To weigh the public health consequence of loss of protection against an increase in available vaccine doses and coverage, non-inferiority was defined as seroconversion 28 days after vaccination no more than 10% less with the fractional dose than with the standard dose. We assumed 95% seroconversion with standard doses and considered that a loss of protection to 85% seroconversion with fractional doses would still ensure protection above 80%, which is necessary to interrupt local transmission.2 tests for categorical variables and Student's t-test for continuous variables. Any PRNT50 titre reported as seronegative (limit of quantification [LOQ] <10) was converted to LOQ/2. Any PRNT50 titre greater than 20\u2008480 was designated 20\u2008480, as this was the limit of quantification of titres or the last serial dilution.Analysis consisted of pairwise comparisons of fractional versus standard dose of the same manufacturer's vaccine. No comparisons were made between vaccines from different manufacturers. Comparison of baseline characteristics were done using \u03c7The number and percentage of participants who seroconverted are presented by manufacturer and dose with two-sided exact Clopper-Pearson 95% CI. Non-inferiority for the primary outcome was assessed by constructing a two-sided 95% CI using the Wilson score interval of the point difference between seroconversion rates in the fractional and standard dose arms. Fractional doses were considered non-inferior if the lower bound of the CI for difference in seroconversion was greater than \u221210%.t-distribution. Intervals were transformed to show the ratio of GMT and GMFI for the fractional dose compared with standard dose.Two-sided 95% CIs of the mean difference between log GMT and log GMFI between the standard and fractional dose of each vaccine were generated using the 50